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____________________ Summary____________________
Immune stimulating complexes (ISCOMS) are small cage like particles which form 
spontaneously upon agitation of phospholipid, cholesterol and the saponin adjuvant Quil A. It 
is possible to incorporate protein antigen into the ISCOMS structure and ISCOMS have been 
used to stimulate antigen-specific immune responses by both parenteral and mucosal routes. 
However, the mechanisms that underlie these adjuvant effects have not been fully elucidated. 
This project was undertaken in order to expand the knowledge of the adjuvant properties of 
ISCOMS and to identify the influence that these had on the ability of ISCOMS to drive an 
antigen-specific immune response.
My initial experiments concentrated on performing a detailed study of the innate 
effects of ISCOMS in vivo, when given initially as an intraperitoneal injection and later 
orally. The results presented demonstrate that ISCOMS have an ability to stimulate an innate 
inflammatory cascade, comprised of the recruitment and activation of an inflammatory 
infiltrate, secretion of inflammatory cytokines and mediators. Secretion of these factors was 
dependent on the presence of adherent cells indicating the possible role of macrophages in 
their production. A similar pattern of cellular recruitment and activation was measured in gut 
associated lymphoid tissues after oral administration of ISCOMS, but this was much less 
dramatic than had been observed earlier.
I then undertook an examination of the influence that these inflammatory mediators 
had on the generation of antigen-specific immunity as determined by antigen-specific DTH, 
proliferation, cytokine production, CTL activity serum IgG isotype production and intestinal 
IgA production, using gene-targeted knockout mice including IL-12KO, 1L-6KO, IL~18KO, 
IL-4KO, iNOSKO and ylFNRKO. My experiments revealed that most of the components of 
the inflammatory response were not essential for the development of antigen-specific 
immunity to ISCOMS, but it did reveal that IL-12 played a particularly important role in the 
immunogenicity of ISCOMS, as immune responses were severely defective in these mice 
after either parenteral or oral immunisation with OVA ISCOMS.
XX
I then went on to determine if the generation of normal antigen-specific immune 
response, in the absence of inflammatory cytokines, was due to the maintenance of the 
inflammatory cascade induced by ISCOMS. I therefore studied the cellular recruitment and 
inflammatory mediator release from ISCOMS injected gene targeted knockout mice. Despite 
most knockout animals retaining an intact innate cascade, the IL-12KO mice with decreased 
antigen-specific immune responses to ISCOMS also had an ablated innate response. 
However, unusually the ylFNRKO mice which had normal antigen-specific responses to 
ISCOMS also lacked an innate inflammatory cascade. This apparent dichotomy indicated that 
the role of the ISCOMS induced innate immune response for the generation of antigen- 
specific immunity is as complex as it is important and must be better understood if 
efficacious and potent vaccines are to be developed.
XXI
Chapter 1
Introduction
Infection with an invasive pathogen stimulates the development of a protective 
immune response and immunological memory. The purpose of vaccination is to mimic these 
effects of natural infection, without the morbidity and possible mortality associated with 
actual infection. Much time and energy has been invested in the development of vaccination 
strategies and, although there have been successes, such as measles, polio and smallpox, there 
is an ongoing need for effective vaccines that are readily available, easy to administer and 
capable of immunising against all the pathogens that endanger quality of life.
The majority of all antigenic encounters occur at mucosal surfaces such as the gut, 
nasal cavity and respiratory tract, eye and urogenital tract. These tissues have an extensive 
lymphoid system, which is distinct from the peripheral lymphoid system and so parenteral 
immunisations fail to generate protective immune responses in the mucosa, especially the gut. 
Therefore, it is important to generate vaccine strategies that are effective at mucosal sites. 
Subunit vaccines containing purified antigen are being investigated as immunisation 
strategies, as they retain the immunogenicity produced during a natural infection, but do not 
pose the threat of virulence. However, subunit vaccines are not efficacious when 
administered alone, especially by the oral route and therefore effective immunisation requires 
the co-administration of an adjuvant.
It has become clear recently, that the innate immune response has a strong, guiding 
influence over the initiation of adaptive immunity and determines the function of adjuvants. 
The purpose of the work described in this thesis was to explore the role of the innate immune 
response in the efficacy of the parenteral and oral vaccine vector ISCOMS.
1.0 Overview of the Immune Response
The mammalian immune response is a highly complex and delicately balanced 
process that comprises botli innate and adaptive components. These two parts, although 
distinct from each other, are continually interacting.
1.1 Innate Immunity
Innate or natural immunity is considered phylogenetically to be the oldest form of 
host defence and forms of it exist in all species. It provides a rapid response to micro­
organisms which is not dependent on genetically variable, specific recognition elements. 
Instead this network exploits a mixture of highly conserved, invariant soluble factors and cell 
surface receptors, many of which can recognise non-protein structures such as carbohydrates 
or lipids, to monitor the normal environment and detect the presence of potentially harmful 
invading microorganisms.
i) Triggers of the Innate Immune System
The surface receptors on the host form a non-specific surveillance system for 
pathogen associated molecular patterns on invading organisms, a phenomenon that has been 
termed pattern recognition [Medzhitov and Janeway Jr, 1997b, Fearon and Locksley, 1996] 
Three main families of pattern recognition receptors (PRRs) have been identified and 
classified according to their physical and functional properties. Firstly, there are PRRs that 
are plasma proteins and can opsonise microorganisms and therefore aid destruction by the 
complement membrane attack complex (C5-9). These include the collectins such as mannan 
binding lectin, conglutinin and lung surfactant proteins A and D [Sastry and Ezekowitz,
1993], or pentraxins such as C-reactive protein and serum amyloid protein [Gewurz et al., 
1995]. The second family of PRRs comprises endoeytic receptors which are found on the 
surface of cells such as macrophages and dendritic cells and bind directly to molecules 
present on invasive micro-organisms and activate entry into the endoeytic pathway for
antigen processing and presentation, such as the macrophage mannose receptor [Stahl, 1992], 
macrophage scavenger receptor [Krieger and Herz, 1994]. The third family of PRRs is the 
Toll-like-receptors which are involved in both pattern recognition and signal transduction 
[Kopp and Medzhitov, 1999]. These were first identified in Drosophila and recently five 
Toll-like-receptor proteins have been discovered in humans [Rock et ah, 1998]. Each contain 
a leucine rich extracellular domain and a cytoplasmic tail involved in signal transduction 
pathways, which activate NF-kB [Kopp and Medzhitov, 1999]. Although many of the ligands 
for the Toll-like-receptors have yet to be identified, all known ones are involved in expression 
of co-stimulatory molecules and cytokine or soluble mediator secretion, via the induction of 
NF~kB [Stancovski and Baltimore, 1997]. Most important of these is a receptor for LPS on 
monocytes and macrophages, which binds the lipopoiysaccharide binding protein together 
with CD 14 [Yang et ah, 1998].
ii) The Innate Inflammatory Cascade
The ligation of PRRs on host cell surfaces or in serum, initiates a cascade of 
inflammatory events that comprises the release of chemotactic molecules, cellular recruitment 
and mediator release. These not only provide a rapid response to invasion, but also have a far 
reaching influence on subsequent antigen-specific immunity. The initial component is the 
release of chemokines, such as IL-8 or monocyte chemoattractant protein 1 (MCP-1), from 
activated phagocytes or inflamed endothelium, fibroblasts or platelets [Baggiolini, 1998]. 
Chemoattractants recruit neutrophils and monocytes, with neutrophils arriving first and being 
followed quickly by macrophages and dendritic cells, both of which are important for 
clearance of microbes and for processing and presentation of antigen to the lymphocytes 
which are the last of the recruited cells to arrive [Campbell et al., 1998]. The recruited 
neutrophils and macrophages become activated, increase their microbicidal activity, release 
soluble factors and macrophages show increased expression of co-stimulatory molecules, 
adhesion molecules and MHC class II. Mast cells are also involved in this early phase of the 
response. Classically these cells are described as the effector cells of IgE mediated immune 
responses, especially in the context of helminth infestations, but they are also capable of
secreting a number of preformed pro-inflammatory compounds, such as histamine, 
leukotriene B4 (LTB4), macrophage inflammatory protein-la (MIP-la) and MIP-lp as well 
as TNFa [Mekori and Metcalfe, 2000] which can enhance the recruitment of other 
inflammatory phagocytes and lymphocytes, by upregulating the expression of surface 
adhesion molecules and thus providing a suitable site for the extravasation of leukocytes 
[Gallietal., 1999].
iii) Soluble Mediators of the Inflammatory Cascade
Pro-inflammatory mediators released during the acute phase response also induce a 
cascade of events that trigger metabolic processes in the host in an attempt to control 
infection, minimise damage and initiate repair to inflamed tissues. TNFa is released 
immediately as a preformed molecule from mast cells [Gordon and Galli, 1990], or 
synthesised by macrophages after stimulation by LPS or ingestion of bacteria or viruses, and 
after the binding of C5a complement component to the p55 and p75 TNFa receptors which 
are present on a wide variety of target cells and tissues [Adolf et ah, 1994]. TNFa induces the 
synthesis and release of IL-1, which together with TNFa, synergise to induce IL-6 secretion 
[Baumann and Gauldie, 1994]. In association with IL-1, TNFa is also a potent pyrogen and 
appetite suppressant, inducing these effects by binding to receptors present on the cells of the 
hypothalamus [Tracey et ah, 1988, Plata-Salaman et ah, 1988]. TNFa can also stimulate 
ylFN production by NK cells in synergy with IL-12 [Tripp et ah, 1993]. Together with ylFN, 
TNFa acts in an autocrine fashion to amplify the production of inducible nitric oxide (iNOS) 
and thus nitric oxide (NO) release from macrophages, increasing the microbicidal activity of 
these cells and increasing the blood flow to the inflamed site [Oswald and James, 1996].
IL -la and IL-ip are produced by activated macrophages and many other cell types in 
an inactive form that is activated by IL-1 converting enzyme (ICE) which cleaves off a 
regulatory region [Black et ah, 1988]. Active IL-1 binds to the type I and type II IL-1 
receptors which are present on a wide variety of cells including T cells, B cells, endothelium, 
hepatocytes and the hypothalamus [Dinarello, 1998]. Many of the inflammatory effects of IL* 
1 are induced in combination with TNFa, including the stimulation of IL-6, fever and the
secretion of amyloid precursor proteins, as well as the release of chemotactic signals such as 
IL-8 and MCP-1 by mononuclear phagocytes and endothelium [Baumann and Gauldie,
1994]. IL-1 in synergy with IL-6, acts as a growth factor for CD4 T cells, inducing secretion 
of IL-2 production by T cells [Holsti and Raulet, 1989, Houssiau et ah, 1988] and expression 
of the IL-2 receptor a  chain (CD25) [Houssiau etal., 1989].
IL-6 is secreted from as part of the acute phase response by macrophages, fibroblasts 
and mast cells after activation by TNFa and IL-1 [Baumann and Gauldie, 1994]. It induces 
hepatocytes to secrete plasma proteins such as fibrinogen as part of the acute phase response 
and has many effects which overlap with those of TNFa and IL-1, including increasing body 
temperature, the expression of adhesion molecules and chemotactic factors on the surface of 
inflamed endothelium which aids the entry of leukocytes. IL-6 also plays a role in the 
antigen-specific immune response, as it promotes the growth and maturation of B cells and 
stimulates plasma cell differentiation [Kishimoto, 1989]. Recent studies have also implicated 
the direct involvement of IL-6 in the secretion of IgA [Beagley et al., 1989, Kunimoto et al., 
1989], and IL-6 together with IL-10 has also been shown to maintain the secretion of IgA in 
the gut of IL-4KO mice [Okahashi et al., 1996]. IL-6KO mice have been reported to have 
defects in si g A production and the recruitment of neutrophils, as well as being susceptible to 
intracellular organisms such as Candida albicans [Romani et al., 1996] or Listeria 
monocytogenes [Kopf et al., 1994]. However, other studies have disputed the involvement of 
IL-6 in generating antigen-specific mucosal immune responses [Bromander et al., 1996].
IL-12 is a heterodimeric cytokine secreted from macrophages, dendritic cells and B 
cells [Trinchieri, 1995]. The bioactive p70 heterodimer is comprised of disulphide linked 
[Gubler et al., 1991], 35kD and 40kD subunits [Kobayashi et al., 1989, Stem et al., 1990] 
whose genes are found on chromosomes 3 and 5 respectively [Sieburth et a l, 1992]. IL-12 
production is induced directly by bacterial and parasitic products including endotoxins, super- 
antigens and heat shock proteins [Trinchieri, 1995], but also after cognate interactions 
between the CD40 and CD40 ligand (CD40L) [Kennedy et a l, 1996, Stuber et a l, 1996], 
present on APC and activated T cells respectively. The best known effect of IL-12 is to 
induce ylFN production by NK cells and T cells and it is the principal factor controlling the
differentiation of Thl CD4+ T cells [Wenner et af, 1996, Hsieh et al., 1993]. However, IL-12 
also upregulates the expression of IL-8 and thus enhances the recruitment of neutrophils to an 
inflamed site and the establishment of an inflammatory cascade [Nuame et al., 1993]. In 
addition, IL-12 increases the growth and cytotoxic activity of NK cells [Kobayashi et al., 
1989, Robertson etal., 1992] and acts as a growth factor for activated NK cells [Nuame etal.,
1993]. It has similar effects on CD8+ T cells [Gately et al., 1994, Chouaib et al., 1994], 
probably in conjunction with ylFN. IL-12 alone can induce the upregulation of IL-2 and the 
expression of the IL-2 receptor a  chain [Nuame et al., 1993], thus increasing responsiveness
to IL-2 and the ability to clonally expand effector T cells.
The importance of IL-12 in infection has been shown in several models. Addition of 
rIL-12 enhances resistance to Leishmania major [Heinzel et al., 1993], Listeria 
monocytogenes [Hseih et ah, 1993, Tripp et al., 1994] and Toxoplasma gondii [Gazzinelli et 
al., 1993]. In the absence of IL-12, mice had defective protective immunity against 
Mycobacterium tuberculosis [Cooper et al., 1997]. IL-12 also protects against the pathology 
associated with normal granuloma response induced by Schistosoma mansoni eggs in liver 
and spleen [Wynn et al., 1994]. Because of its ability to enhance cytolytic activity, IL-12 has 
also been shown to be involved in the generation of anti-tumour CD8+ T cell activity in 
murine cancer models [Brunda et al., 1993].
IL-18 is a newly characterised cytokine which has several properties similar to IL-12 
including the induction of ylFN production. However IL-18 resembles IL-1 structurally and 
requires enzymatic cleavage by ICE to release the biologically active cytokine [Gu et ah, 
1997, Ghayur et ah, 1997]. First identified as a product of Kupffer cells in the livers of 
Propionibacterium acnes infected mice [Okamura et al., 1995], IL-18 is now known to be 
produced by a number of different cell types, including kératinocytes [Stoll et ah, 1997], 
osteoblasts [Udagawa et ah, 1997], and macrophages [Okamura et ah, 1995]. Like IL-12, IL- 
18 increases the cytolytic activity and induces secretion of ylFN from NK cells and T cells 
[Okamura et ah, 1998a] and enhances the development of Thl cells [Kohno et ah, 1997], and 
IL-12 and IL-18 may act together to generate a number of these effects. There is some recent
evidence that IL-12 may increase the expression of the IL-18Rp2 gene which would also 
increase the pressure to drive a Thl mediated immune response [Xu et ah, 1998].
The gaseous free radical nitric oxide (NO) is produced by the enzymatic action of 
nitric oxide synthase (NOS) on the amino acid arginine [Palmer et al., 1988]. There are three 
isoforms of the NOS enzyme which have two separate functions. Neuronal cell NOS (nNOS) 
and endothelial cell NOS (eNOS) are involved in the Ca^ -'*" dependent, constitutive 
production of small amounts of NO which acts as a signal transduction molecule in the 
nervous system and as a vasodilatory molecule [Meffert et al., 1994, Moncada and Higgs, 
1991]. Inducible NOS (iNOS) on the other hand, is found in macrophages after stimulation 
by inflammatory signals such as the phagocytosis of bacteria or recognition of conserved 
molecules on pathogens such as LPS [Griscavage et al., 1996]. The other major inducer of 
iNOS transcription is ylFN [Kamijo et al., 1994], while TNFa, and IL-1|3 can have similar 
effects [Green and Nacy, 1993]. The high levels of NO produced by activated macrophages 
are toxic to intracellular pathogens or tumour cells. These effects are due to the ability of NO 
to interfere with several intracellular metabolic processes, by targeting iron binding proteins 
including mitochondrial NADPH-ubiquinone, the succinate-ubiquinone oxidoreductases of 
the electron transport chain and the Kxeb’s cycle enzyme aconitase [Oswald and James, 
1996]. NO also targets iron containing molecules of pathogens, forming nitrosyl-Fe 
molecules which disrupt the metabolic and proliferative activity of intracellular pathogens 
and inhibit the superoxide dismutase enzyme (SOD), which is capable of protecting the 
pathogen against the lethal effects of free radicles such as H2O2 and NO [Oswald and James,
1996]. NO has also been implicated in a number of disease conditions, the most important of 
which is septic shock, where it is responsible for dilation of the local and then later the 
systemic vasculature [Green and Nacy, 1993]. Thus the regulation of such a dangerous 
molecule is tightly controlled and NO production is inhibited by TGFp [Ding et al., 1990] 
and IL-10 [Cuncha et ah, 1992] which decrease the stability of iNOS mRNA. Reactive 
oxygen intermediates (ROI) are a group of oxygen species including superoxide (O2"), 
hydroxyl radicals (®OH), and singlet oxygen species (°0) which are formed following 
activation of the NADPH oxidase enzyme present in the lysosomal membrane of phagocytes
[Babior et al., 1988]. These molecules are all toxic and play an important part in the killing of 
intracellular pathogens, which is most clearly demonstrated in individuals with chronic 
granulomatous disease (CGD), who have a genetic defect in the ability to generate oxygen 
radicals. They are deficient in, or have an abnormal form of, one of the protein components 
that makes up the respiratory burst, for example NADPH oxidase [Clark, 1999]. These 
patients suffer recurrent infections of bacteria, parasites and fungal infections and develop 
widespread generation of granulomatous tissue which is formed in an attempt to control these 
infections [Clark, 1999].
1.2 The Role of the Innate Cascade on the Development of Adaptive Immunity
The mediators and cells described above not only play a crucial and often conclusive 
role in the early stages of infection, but also initiate and shape the ensuing antigen-specific 
immune response [Fearon and Locksley, 1996a]. Thus, the ligation of PRRs on resting 
dendritic cells increases the expression of costimulatory molecules, MHC class II and the 
antimicrobial activity of these cells [Medzhitov and Janeway Jr, 1997a, Medzhitov and 
Janeway Jr, 1997b, Janeway Jr, 1989], which enhances the ability to process and present 
antigen [Banchereau and Steinman, 1998]. In addition, these receptors and the pro- 
inflammatory cytokines IL-1, TNFa and IL-12, induces the migration of DC out of tissues 
and into the T cell dependent area of the secondary lymphoid organs where they can interact 
with naive T and B cells.
The nature of these ligand of PRR can also influence the ability of dendritic cells to 
polarise the eventual antigen-specific effector immune response. Recently it has been 
demonstrated that dendritic cells are capable of inducing both a Thl and Th2 response from 
naive T cells, but this mechanism appears to be a consequence of the level of IL-12 
production induced [Kalinski et al., 1999], For example, a number of pathogens secrete IL- 
12 inhibiting factors such as prostanoids from some helminths [Meyer et al, 1996], or IL-10 
induced by Schistosoma mansoni eggs [Velupillai and Harn, 1994], disruption of IL-12
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production is also observed in HIV [Yoo et al,, 1996] and measles virus infection [Karp et a l, 
19961
Depending on the stimulus dendritic cells can also be immunogenic or tolerogenic. 
When resting myeloid derived dendritic cells were pre-cultured with necrotic fibroblasts in 
vitro, the dendritic cells, increased surface expression of costimulatory molecules and were 
capable of inducing proliferation of naive T cell clones [Gallucci et a l, 1999]. In contrast, 
when resting dendritic cells were pre-cultured with apoptotic fibroblasts, no elevation of co­
stimulatory molecules expression or naive T cell proliferation was measured [Gallucci et a l, 
1999], This phenomenon was also detected in vivo, as OVA+apoptotic fibroblast immunised 
mice produced significantly lower OVA-specific DTH responses than OVA+necrotic 
fiboblast immunised mice [Gallucci e ta l ,  1999].
Thus it appears that the nature of the antigen has a profound influence on the outcome 
of the immune response induced, or in fact whether immunity is stimulated at all
1.3 Protective Immunity
There are three arms of the antigen-specific protective immune response, firstly CD4+ 
T lymphocytes which recognise antigen presented by MHC class II molecules and secrete 
cytokines, whose profile determines the nature of the effector immune response that is 
generated. ylFN and IL-2 secretion are associated with Thl CD4+ lymphocytes and the 
establishment of cell mediated immunity, whereas IL-4, IL-5, IL-10 and IL-13 are secreted 
by Th2 cells and promote humoral immune responses [Mosmann and Coffman, 1989, 
Mosmann, 1996]. Secondly, antigen-specific antibodies recognise structural patterns within 
the infecting agent, with CD4+ T cells assisting in the differentiation and antibody production 
by B cells [Parker, 1993]. Thirdly, antigen-specific CD8+ CTL, recognise and kill infected 
cells bearing processed antigenic peptides within MHC class I [Griffiths, 1995], by release of 
pore forming agents such as perforin and granzyme serine esterases that disrupt metabolic 
processes and induce apoptosis of the infected cell [Kagi et a l, 1994]. CTL also induce 
apoptosis following ligation of the Fas ligand (FasL) expressed on CTL with Fas on the target
cell [Kagi et al., 1994]. The exact nature of the protective immune response depends on the 
infecting agent and thus if any vaccine immunotherapy is to be successful in generating a 
protective immune response it is vital that we understand and can mimic different immune 
mechanisms induced by various infecting organisms or disease processes. Viral infections 
generally involve the ability of MHC class I restricted CTL to kill infected cells, but also 
induce the production of neutralising antibodies to limit the dissemination of the viral 
pathogen. Intracellular pathogens other than viruses are either bacteria, protozoal parasites or 
fungi. Most of these organisms rely on active uptake into host cells following ligation of PRR 
and induction of phagocytosis and thus these pathogens generally target macrophages 
[Aderem and Underhill, 1999]. Because these organisms reside within the cell, they are 
concealed from immune surveillance, and most have evolved evasion strategies which not 
only prevents killing by normal antimicrobial processes of the cell but also prevents their 
discovery by the immune system [Brodsky et al., 1999]. However, after recognition by CD4+ 
T cells, the infected cells are activated by ylFN, with enhancement of microbicidal activity of 
the macrophage and clearance of the pathogen. In addition, there may be secretion of TNFa 
and IL-1 as well as activation of CD8+ CTL [Orme et al., 1993]. Extracellular pathogens are 
continuously exposed to potential attack by the adaptive immune response and Th2 
dependent humoral immune responses are the major mechanism for the elimination of such 
organisms. Small extracellular pathogens such as bacteria can be opsonised and cleared by 
macrophage phagocytosis, while larger multicellular organisms such as helminths or 
nematodes which have been opsonised by antigen-specific antibody can be cleared by 
antibody dependent complement or cell mediated cytotoxicity. Extracellular organisms may 
also secrete toxins that are harmful, and thus neutralising antibodies are also a powerful 
mechanism for the capture and clearance of these soluble molecules, by immune complex 
formation and clearance in the liver [Schfferli etal., 1986].
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2.0 The Common Mucosal System
The tissues of the mucosae encounter the majority of antigens that enters the host and 
infections of mucosal surfaces such as the digestive tract, nasal cavity, respiratory tract, eye 
and urogenital tract and breast are the most common cause of morbidity and mortality in 
humans [Bloom, 1989]. These infections are caused by viruses such as rhinoviruses, 
influenza virus, polioviras, and human immunodeficiency virus (HIV), bacteria such as E. 
coli, S. typhi, V. cholerae, Bordetella pertussis and Mycobacterium tuberculosis’, protozoal 
parasites such as Giardia lamblia and Cryptosporidium parvum, as well as helminthic 
parasites such as Trichuris trichura. Ascaris lumbricoides, and Haematobium solis. The 
mucosal surfaces contain considerable amounts of mucosa-associated lymphoid tissue 
(MALT) that are anatomically and functionally distinct from the peripheral immune system 
[Mowat and Viney, 1997]. Of these, the gut associated lymphoid tissues (GALT) are the most 
intricate and specialised, containing organised lymphoid structures such as the Peyer’s 
patches (PP) and mesenteric lymph nodes (MLN), as well as large numbers of scattered 
lymphocytes both in the epithelium (intraepithélial lymphocytes (lEL)) and in the lamina 
propria (LP).
2.1 Immune Mechanisms of the GALT
The induction of intestinal immune responses is believed to occur first in the PP, 
which are submucosal nodules of organised lymphoid tissue in the small intestine, containing 
defined T and B cell areas including germinal centres (GC) [McGhee et al., 1992]. Above the 
T and B cell areas is the dome area of the PP which contains T and B cells, macrophages and 
dendritic cells, and bulges into the lumen of the small intestine, being covered by a single 
layer of follicular associated epithelium (FAE). This contains specialised epithelial cells (M 
cells), that have microfolds on their luminal surface and which are able to take up particulate 
materials such as bacteria and viruses from the intestinal lumen [Neutra et ah, 1996]. M cells 
do not process antigen, but appear to transfer it to professional APC [Wolf and Bye, 1984],
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which reside in an epithelial pocket created by the M cell, or in the dome area immediately 
below the FAE [Keren, 1992, Mowat and Viney, 1997]. The majority of these cells are 
dendritic cells, but they differ from those found in other tissues [Kelsall and Strober, 1996]. 
Most dendritic cells found beneath the M cells are immature and have been shown to capture 
antigenic peptides in vivo [Kelsall and Strober, 1996, Ruedl et al., 1996], These cells are 
then Ihought to migrate to the MLN where they are able to present antigen to naive T and B 
cells [MacPherson et al., 1995]. Although the initial encounter with antigen is thought to 
occur in the PP, cells migrate away to other mucosal sites before becoming effector cells. For 
example B cells primed in the PP show preferential class switching to IgA production 
[McGhee et ah, 1992], but before full differentiation, these leave the PP via the efferent 
lymphatics and recirculate to mucosal effector sites such as the LP, by which time they have 
differentiated into high affinity IgA secreting plasma cells [Brandtzaeg et ah, 1999]. The 
production of IgA secreting cells occurs because of the influence of the local cytokine 
environment in the PP, with TGFp being a crucial switch factor for IgA production 
[Brandtzaeg et ah, 1999].
T cells are also primed in the PP and like B cells, migrate from the PP to the 
mesenteric lymph node (MLN) via the afferent lymphatics before differentiating fully 
[McGhee et ah, 1992]. The MLN has a normal secondary lymphoid architecture and appears 
to form an interface between the mucosal and peripheral immune systems [Mowat and Viney,
1997]. After a few days, these T and B cells leave the MLN and gain access to the thoracic 
duct (TD), from where they enter the blood stream and exit preferentially in the mucosal 
surfaces because of expression of the a4^7 integrin which associates with the mucosal 
addressin adhesion molecule-1 (MADCAM-1), found predominantly only on mucosal 
vasculature [Mowat and Viney, 1997]. In addition to access via M cells, some soluble antigen 
may also cross the villus epithelium directly and be transported to the MLN in the lymphatics 
or carried on an APC such as dendritic cells, which can lead to the priming of T cells in the 
MLN itself [Mowat and Viney, 1997].
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2.2 Effector Immune Responses in the Mucosa
The effector phase of the mucosal immune response occurs in the wall of the gut 
itself. Here are found B cells, T cells, macrophages, dendritic cells and mast cells, which are 
scattered within the LP or as dispersed T cells within the epithelium (lEL). These cells are 
capable of making a wide range of immune responses, which are able to combat the variety of 
pathogens encountered at this site.
i) Humoral Immune Responses in the Mucosa
The principal humoral immune defence in the gut is mediated by secretory IgA (sIgA) 
antibodies [Brandzaeg, 1989]. Over 90% of all antibody in the gut is sIgA, which is produced 
by plasma cells in the LP as a dimer linked by a joining (J) chain. This dimer binds to the 
poly Ig receptor (pIgR) on the basal surface of the enterocytes in the crypt, triggering 
endocytosis and then transport through the epithelial cell in a transport vesicle [Mostov,
1994]. This vesicle ultimately fuses with the luminal surface of the epithelial cell, where the 
pIgR is partially cleaved and releases si g A that contains a small fragment of the pIgR still 
attached (secretory component) [Mostov, 1994]. sIgA is found only in mucosal secretions and 
because of its multivalent binding sites, is ideally suited to interfering with binding and entry 
of pathogens into mucosal tissues [Czinn et al., 1993, Mazanec et al., 1995]. si g A bound to 
luminal antigen can either be excreted or taken back up through the epithelium, where it can 
enter the liver via the portal bloodstream and be cleared through phagocytosis by hepatic 
macrophages (Kupffer cells) or excreted in the bile. As IgA does not bind complement, sIgA 
mediated clearance of pathogens does not cause inflammation in the delicate tissues of the 
gut mucosa [Russell-Jones et al., 1981, Lamm et al., 1995].
Despite the predominance of si g A in mucosal secretions, the absence of sIgA is a 
relatively common immunodeficiency and usually does not incur major complications or 
infection [Mbawuike et al., 1999]. In this situation the function of sIgA may be replaced by 
IgM, which also contains a J chain, and thus can bind to the pIgR and undergo transcytosis 
across the epithelium. IgG is found in secretions only under conditions of inflammation.
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while IgE production may contribute to protective responses against helminth infection, by 
binding to FceR on eosinophils and mast cells elevated at times of expulsion and releasing 
toxic granule contents into the lumen of the gut [Galli, 1997].
ii) Cellular Immune Responses in the Mucosa
Effector T cells are localised throughout the organised and diffuse compartments of 
the GALT. The CD4+ T cells that are found within these tissues all show an activated 
memory phenotype [Mowat and Viney, 1997] and they normally secrete cytokines such as 
ylFN, IL-4, IL-5 and TGPp [Mowat and Viney, 1997] which are thought to directly influence 
the isotype switching of antibodies from B cells. IL-5 is a required cytokine if an augmented 
sIgA response is to be generated [Harriman et ah, 1988], and TGFj? also directs the class 
switching to IgA [Brandtzaeg et ah, 1999].
The T cells in the lEL are very different to those found in the periphery. Up to 80% of 
these cells are CD8+, and conventional CD4ap+ T cells are rare [Guy-Grand and Vassalli, 
1993]. There are many different subsets of lEL and of the lEL, only a small subset are 
classical CD8aP+ aj3 TCR+ CTL, with another population of lEL being CD8aa+ [Guy- 
Grand and Vassalli, 1993]. Of these cells some are «P TCR+ but some are also yô TCR+ 
[Lefrancois, 1991]. These yô TCR+ cells are thought to have developed extrathymically 
[Rocha et ah, 1994] and some yô TCR+ lEL exhibit NK cell like lytic activity but this is not 
generated to MHC class I restricted antigens [McGhee et ah, 1992]. The role, if any, that 
these cells have in protective mucosal immune responses is yet to be fully defined as they 
normally do not exhibit classical CTL activity and do not proliferate well to mitogens or 
antigen [Mowat and Viney, 1997], even though a large expansion of CD8oca+ yô TCR+ cells 
is found in coeliac patients [Halstensen et ah, 1989, Savilahti et ah, 1990]. There is some 
recent evidence that these yô TCR+ lEL may play some regulatory role in maintaining gut 
homeostasis and tolerance to intestinal antigens [Mowat and Viney, 1997], in addition to a 
possible role in providing help for mucosal IgA secretion [Fujihashi et ah, 1996]. Many of the 
lEL have been identified as containing cytoplasmic granules and perforin [Guy-Grand et ah,
1991] and some CD8ap+ I EL have been shown to have antigen-specific cytotoxic activities
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against Toxoplasma gondii [Charles et ah, 1994b]. Nearly all subsets of ÏEL express the 
aEp7 integrin, which associates with E-cadherin on enterocytes and so is thought to be 
responsible for the accumulation and maintenance of lEL in the villus epithelium [Cepek et 
ah, 1994].
2.3 Immune Regulation in the GALT
Although the immune apparatus of the gut must generate strong protective immune 
responses against pathogens, the majority of antigen encountered by the GALT is harmless, 
such as dietary proteins and commensal bacteria. Active immune responses against these 
materials would be dangerous as it can lead to chronic inflammatory diseases such as Crohn’s 
disease, ulcerative colitis and coeliac disease [Mowat, 1987]. For these reasons, the default 
response to harmless antigen is the induction of systemic immunological unresponsiveness, 
known as oral tolerance [Mowat, 1987]. This long lasting phenomenon can affect all aspects 
of the systemic immune response and in addition to being of physiological importance, it is a 
potential obstacle to the development of orally active vaccines containing purified protein 
antigens [Mowat, 1987].
Several mechanisms have been implicated in mediating oral tolerance, but these may 
be dependent on the feeding regime used to induce tolerance. Thus it is proposed that single 
or continuous feeds of high doses of antigen may lead to clonal anergy or perhaps deletion of 
antigen-specific T cells, whereas multiple feeds of low doses of antigen may induce the 
generation of regulatory T cells such as the CD4+ Th3 subset o rT rl subsets of T cells, which 
may suppress other T cell responses by secretion of TGFp, IL-4 or IL-10 [Faria and Weiner, 
1999]. In all cases, CD4+ T cells appear to be the most important targets and mediators of 
oral tolerance [Mowat and Viney, 1997]. The induction of tolerance is preceded by limited 
activation of these cells in tissues of the GALT such as the MLN, and it appears that orally 
administered soluble antigens may be presented by APC lacking the appropriate 
costimulatory molecules such as B7.1 and B7.2, which leads to partial activation of the CD4+ 
T cells, followed by unresponsiveness (anergy) upon subsequent restimulation with antigen in
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an immunogenic form [Mueller et al., 1989], Of the APC that might be involved, recent 
attention has focused on the resting dendritic cells present in the gut. Administration of the 
dendritic cell growth factor flt3 ligand (FLtSL) increases the numbers of dendritic cells in the 
GALT and other lymphoid organs and dramatically enhances the development of oral 
tolerance [Viney et ah, 1998]. These FLtSL induced dendritic cells express low levels of B7 
and CD40 costimulatory molecules, which may indicate dendritic cells in the gut are 
normally in a resting state and present antigen in a tolerogenic fashion [Viney et ah, 1998]. In 
addition, recent evidence suggests that the gut is rich in immunomodulatory cytokines, such 
as IL-10, TGFp and PGE2, which may inhibit the activation of APC and thus suppress T cell 
induction [Khoury et ah, 1992]. Overcoming or modulating these mechanisms is an important 
consideration for designing oral vaccines.
2.4 Compartmentalisation of the GALT
One of the most important features of the mucosal immune system is its 
compartmentalisation and isolation from the peripheral immune system. T and B cells primed 
in the GALT recirculate preferentially to mucosal surfaces, whereas T and B cells stimulated 
in other peripheral lymphoid tissues are unable to enter mucosal tissues [Phillips-Quagliata 
and Lamme, 1988]. This phenomenon is due to the fact that lymphocytes primed in the 
MALT lose L-selectin, and increase their expression of oAi^l which interacts with the 
mucosal addressin adhesion molecule-1 (MAdCAM-1), found mainly on endothelium of 
mucosal vasculature [Bargatze et ah, 1995]. This provides the molecular basis of why a 
mucosally delivered vaccine is necessary to generate protective immune responses in these 
tissues. Despite this separation from the peripheral immune system, there is dissemination of 
lymphocytes between the different mucosal tissues, which all express MADCAM-1. This is 
termed the common mucosal immune system and its existence is important for the 
development of mucosal vaccines as it implies that lymphocytes can be primed at an easily 
accessible mucosal site, such as the gut or nasal cavity, and then disseminate to other distant 
mucosal tissues as effector cells [Mestecky et ah, 1994].
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3.0 Mucosal Vaccination Strategies
It is important that a successful vaccine is able to prime all the arms of the immune 
response that would normally be stimulated by natural infection, as well as inducing effective 
memory. The majority of current vaccines are administered parenterally, but these are 
generally ineffective against mucosal pathogens, due to the inability of primed lymphocytes 
to enter the mucosal compartment [Phillips-Quagliata and Lamme, 1988]. Therefore there is a 
pressing need for the development of vaccines which are active at mucosal sites and it is 
widely accepted that a single, orally administered recombinant vaccine inducing long lasting 
mucosal and systemic immunity is a principal goal of vaccine research.
3.1 Oral Vaccination Vectors
i) Live Attenuated Oral Vaccines
The simplest means of generating an appropriate, long lasting immune response to a 
pathogen is by pre-exposure to the living organism. However, as the principle of vaccination 
is to protect the host without inducing disease, it is vital that the infecting micro-organism is 
made harmless before administration. Therefore, the first vaccines consisted of whole 
organisms which were killed, one of the most successful being the Salk polio vaccine [Smith,
1992]. However, although killed vaccines share most antigens with the live pathogen, they 
often do not induce the same range of innate and specific immune responses due to their 
inability to invade. Therefore several attenuated vectors have been investigated to induce 
protective responses. Of these, attenuated Salmonella strains, with mutations in growth genes 
such as surA have been very successful at generating protective immune responses 
[Sydenham et al., 2000], as have Shigella strains with mutated genes aroA and virG genes 
[Kotloff et ah, 1996, Noriega et al., 1996].
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ii) Attenuated Organisms as Oral Vectors
Attenuated bacteria and viruses have also been used as deliveiy vectors for the 
generation of immune responses against incorporated DNA of other pathogens. For example, 
Salmonella [VanCott et a l, 1996, Steger and Pauza, 1997], Shigella [Fennelly et al., 1999], 
Listeria [Ikonomidis et a l, 1997] and BCG bacteria [Fennelly et a l, 1995] have been studied 
as potential mucosal vaccine vectors, after incorporation of genes from a number of different 
pathogens including influenza [Ikonomidis et a l, 1997], measles [Fennelly et a l, 1995], 
simian immunodeficiency virus (SIV) [Steger and Pauza, 1997], andletanus Toxiod [VanCott 
et a l, 1996], Viruses have also been used as vaccine vectors, for example attenuated vaccinia 
virus [Moss et a l, 1984] and Venezuelan equine encephalitis virus [Caley et a l, 1997] have 
been studied for their ability to deliver in the most part other viral genes. This strategy is 
particularly appropriate in the defence against viral pathogens as it is capable of generating 
CTL responses. However, there are several problems that have hindered the development of 
such recombinant bacterial and viral vectors. The bacterial carrier itself can induce an 
immune response in the GALT, which if a booster regime is required means that the second 
immunisation may be blocked by an anti-vector response [McGhee et a l, 1992]. Also the 
expression of the foreign gene may be unstable and therefore lost and there is a possibility of 
a reversal of the attenuating processes of the carrier organism [McGhee et a l, 1992]. These 
types of vaccines are also not particularly stable at fluctuating temperatures and so limit the 
potential market to that of more temperate climates. Finally, the use of the inactivated carrier 
limits the immune response generated to that normally induced to the carrier and so may not 
stimulate a response relevant for clearance of the pathogen [McGhee et a l, 1992]. Thus 
research has been undertaken to search for non living mucosal vaccine carriers that generate 
all of the required protective immune responses, both mucosally and systemically, but which 
also avoid the problems associated with using attenuated organisms.
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3.2 Oral Adjuvants
i) Soluble Toxins as Adjuvants
A number of non-viable mucosal adjuvants have been described, of which cholera 
toxin (CT) produced from Vibrio cholerae and the homologous heat labile enterotoxin from 
E, coli (LT) are the most widely studied. These toxins are comprised of five attachment units 
or B subunits surrounding the enzymatically active A subunit, which is divided into A1 and 
A2 [Spangler, 1992]. The B subunits bind to the GMl ganglioside receptor found on the 
surface of many cells, including intestinal enterocytes and following binding, the A subunit 
can translocate into the cell [Holmgren, 1981]. The CTAl and LTAl subunits have ADP- 
ribosyl transferase activity, which activates GTP binding proteins and Gs proteins, thus 
increasing adenylate cyclase activity and cAMP levels [Holmgren, 1981]. In addition to being 
responsible for the massive fluid and electrolyte loss seen in the relevant infections, the ADP- 
ribosylase activity is crucial for the adjuvant activity of CT, although it may not be required 
for that of LT [Lycke, 1997].
CT was first recognised as a potential adjuvant when it was found that the holotoxin 
stimulated active mucosal and systemic immune responses, both to itself and to co­
administered unrelated protein antigen when given orally [Lycke and Holmgren, 1986]. Since 
this discovery, the use of CT as an adjuvant has become more refined and it has been shown 
that CT is capable of increasing both humoral and cell mediated immunity mediated by both 
CD4 and CD8 T cells. For example, feeding of low doses of CT together with keyhole limpet 
haemecyanin (KLH), could induce both KLH-specific antibody and cell mediated immune 
responses . Feeding OVA+CT generates antigen-specific DTH, proliferation, Thl and Th2 
cytokine secretion as well as high levels of mucosal si g A and IgG [Grdic et al., 1999].
There are several ways in which in which CT or LT may act as adjuvants, including 
increasing the uptake of luminal antigen via epithelial cells, increasing expression of B7.2 on 
APC [Cong et al., 1997] and stimulation of high levels of inflammatory cytokines such as IL- 
1 and IL-6 [Grdic et al., 1999]. However, the mucosal adjuvant effects of CT are dependent 
on the presence of IL-4 [Vajdy et al., 1995]. These results have been interpreted as showing
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that the local adjuvant effects of CT require presentation of antigen in a manner which 
involves intimate cell-cell contacts in the follicular areas of Peyer's Patches (PP), which are 
defective in IL-4KO mice [Vajdy et al., 1995]. Despite the potent adjuvant effects of CT and 
LT, their practical use as vaccine vectors has been limited by their high toxicity in man. In 
addition, they also carry the same potential risk of inducing immune responses to themselves 
as with live vectors. Recent work has attempted to develop a variety of non toxic forms of CT 
and LT and these may prove useful in the future [Agren et ah, 1997].
ii) Particulate Oral Adjuvants
A large number of orally active adjuvant systems are particulate in form. This may be 
because these are targeted preferentially to M cells, or because they protect protein antigen in 
the hostile environment of the gut. One such example are microspheres constructed from 
biodegradable polymers such as poly(lactide-co-glycosides) (PLG). These can be made to 
many different sizes, from >lpm  up to 3 mm in diameter and can be formulated to degrade at 
different rates, releasing antigen in a constant flow over a few days to up to 2 years [Morris et 
ah, 1994], which could eliminate the need for booster immunisations. Oral administration of 
microparticles induces a wide range of antigen-specific systemic and mucosal immune 
responses, including si g A responses and systemic CTL and serum IgG responses [Maloy et 
al., 1994]. However, this approach has proved difficult as large amounts of antigen are 
required and the microencapsulation process may alter the antigenicity and stability of the 
incorporated antigen [Gupta and Siber, 1995].
Simple liposomes are another particulate vaccine carrier. Like PLG, their size can be 
varied and it is possible to incorporate protein antigen. Although preliminary studies have 
shown that si g A responses can be stimulated by oral immunisation with liposomes containing 
antigen [Michalek et al., 1989], liposomes are fairly unstable in the intestine and thus it 
would be desirable to have other stable, non-living mucosal adjuvant systems that induce a 
wide range of immune responses by the oral route. This prompted the investigation of 
lipophilic immune stimulating complexes (ISCOMS) containing Quil A.
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4.0 Immune Stimulating Complexes (ISCOMS) as Oral Vaccine Vectors
4.1 Structure of ISCOMS
ISCOMS were first described by Morein and colleagues in 1984. An ISCOM is a 
hydrophobically bonded micelle that forms spontaneously on mixing cholesterol, a lipid such 
as phosphatidyl choline and the mixture of saponins which comprise Quil A [Lovgren and 
Morein, 1988] . Each ISCOM particle consists of identical 12nm subunits which combine to 
form rigid icosahedral matrices of about 40nm diameter [Morein, 1988] (Figure 1.1) During 
formation of the ISCOMS, it is also possible to incorporate other hydrophobic molecules 
such as glycoproteins from cell membranes. The first ISCOMS to be described used crude 
mixtures of glycoproteins found in the membranes of viruses and bacteria. These included 
membrane glycoproteins of viruses such as parainfluenza-3 virus [Morein et al., 1984], 
influenza A virus [Sundquist et ah, 1988] measles virus [Varsanyi et ah, 1987], feline 
leukaemia virus [Osterhaus et al., 1985] and some bacterial antigens for example, Neisseria 
gonorrhoeae [Kersten et ah, 1988a]. However, it was difficult to incorporate purified 
hydrophilic protein antigens, thus limiting the potential usefulness of the approach. This can 
be overcome by chemical modification of proteins by acidification to reveal hydrophobic 
groups [Morein et al., 1990], or by addition of hydrophobic regions by chemical linkage of 
palmitic acid tails [Mowat and Reid, 1992]. Using the latter approach, a variety of proteins 
have been incorporated into ISCOMS including ovalbumin (OVA) [Reid, 1992], cytochrome 
c [Reid, 1992] gpl20 from HIV [Browning et ah, 1992] and somatostatin-avidin complexes 
[Estrada et ah, 1995].
4.2 ISCOMS as Parenteral Adjuvants
Initial experiments showed that parenteral immunisation with ISCOMS containing 
viral and bacterial membrane glycoproteins induced antigen-specific immune responses, but 
these were assessed mainly by the levels of serum antibody [Morein et ah, 1984, Ertiirk et ah.
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1989, Lovgren et al., 1988, Kersten et al., 1988b, Nagy et al., 1990] The antibody levels 
stimulated by ISCOMS were at least equivalent to those found after immunisation with 
conventional adjuvants such as Complete Freund’s Adjuvant (CFA) or alum, and parenteral 
immunisation with ISCOMS induced all subclasses of IgG [Lovgren, 1988], Later studies 
investigated the effect of ISCOMS on other immunological parameters and found that cell 
mediated immune responses were also induced. These included delayed type hypersensitivity 
(DTH) reactions in vivo [Mowat et al., 1991a, Grdic et al, 1999], antigen-specific 
proliferative responses [Mowat et al., 1991a, Fossum et al., 1990, Maloy et al., 1995, Grdic et 
al., 1999] and cytokine production in vitro [Maloy et ah, 1995, Sjolander et ah, 1997] These 
responses are characteristically CD4+ T cell dependent and the profile of IgG isotypes 
secreted after immunisation with ISCOMS, indicated that both Thl and Th2 subsets of CD4+ 
T cells were primed by parenteral immunisation [Maloy et ah, 1995, Sjolander et ah, 1997]. 
This finding was confirmed by the pattern of antigen-specific cytokine production which 
encompassed a Thl and Th2 profile, including IL-2 [Fossum et ah, 1990, Villacres-Eriksson 
et ah, 1992, Maloy et ah, 1995, Villacres-Eriksson, 1995], IL-4 [Maloy et ah, 1995, 
Villacres-Eriksson, 1995, Sjolander et ah, 1997], IL-5 [Maloy et ah, 1995], IL-10[Sjolander 
et ah, 1997, Villacres-Eriksson, 1995] and ylFN [Villacres-Eriksson et ah, 1992, Maloy et ah, 
1995, Sjolander et ah, 1997, Villacres-Eriksson, 1995]. A surprising and important additional 
property of ISCOMS was the finding that antigen entrapped within the ISCOMS structure 
was able to enter the endogenous antigen processing pathway and hence prime class I MHC- 
restricted CTL. CTL activity has been shown with a number of antigens [Mowat et ah, 1991a, 
Heeg et ah, 1991, Jones et al., 1988, Trudel et ah, 1992, Mowat et ah, 1993], and the OVA- 
specific CTL have been identified as CD8+ lymphocytes that recognise the immunodominant 
epitope OVA 257-264 expressed from endogenously synthesised protein in H-2K^ cells 
[Heeg et ah, 1991] The basis for this capacity of ISCOMS to prime for CTL activity is 
unknown, but could reflect the detergent effect of Quil A allowing direct entry of protein into 
the cytoplasm through the cell membrane or after ingestion into an endosomal compartment 
[Campbell and Peerbaye, 1992]. Previous studies have shown that the induction of CTL by 
ISCOMS requires functionally active macrophages, as CTL generation can be inhibited by
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the lysosomal toxin dichloromethylene diphosphate (CtyMDP), or with silica, both of which 
paralyse the function, of macrophages [Maloy, 1996]. This is consistent with recent findings 
that the phagocytic pathway in macrophages is highly efficient at driving class I processing in 
other systems [Debrick et ah, 1991, Kovacsovics-Bankowski and Rock, 1995, Harding and 
Song, 1994].
4.3 Induction of Protective Immunity bv ISCOMS
The essential property of any vaccine is that it can generate a highly specific 
protective response to subsequent challenge infections. Although the primary response to 
ISCOMS peaks 2-3 weeks after immunisation, memory T cell responses can be recalled for 
up to 8 months after a single subcutaneous immunisation with OVA ISCOMS [Maloy, 1996] 
indicating their potential to generate long-lasting memory.
The ability of parenteral administration of antigen loaded ISCOMS to confer 
resistance to a challenge with a pathogen has been tested in a number of animal models of 
infection including influenza A [Lovgren et ah, 1990], canine distemper virus [Visser et ah, 
1992, de Vries et ah, 1988], pseudorabies virus [Tiilman and Garmendia, 1994], rabies virus 
[Fekadu et ah, 1992], simian immunodeficiency virus (SIV) [de Vries et ah, 1994] and 
respiratory syncytial virus [Trudel et al., 1992], Salmonella [Charles et ah, 1994a], Yersinia 
enterocolitica [Noll and Autenreith, 1996], Trypanosoma cruzi [Araujo and Morein, 1991], 
Leishmania major [Papadopoulou et ah, 1998] and Toxoplasma gondii [Ovemes et ah, 
1991]. Most encouraging is an ISCOMS based parenteral vaccine against equine influenza 
virus which is currently being used in Sweden. Trials of a human flu vaccine using ISCOMS 
technology have also been initiated. These findings have recently been published and indicate 
that a single intramuscular injection of an ISCOM based influenza vaccine was tolerated well 
and induced an increased level of influenza-specific CTL activity in 50-60% of the 
volunteers, as compared to those who received the standard influenza vaccine [Ennis et ah, 
1999]. Such positive outcomes of early human trials indicates that ISCOMS which retain 
immunogenicity can been formulated for human use.
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4.4 ISCOMS as Mucosal Adjuvants
Early studies showed that intranasal administration of ISCOMS containing influenza 
A virus envelope glycoproteins stimulated serum antibody titres equivalent to those found 
after subcutaneous administration of ISCOMS [Lovgren, 1988]. Subsequent work using the 
same vector demonstrated local cellular and humoral immune responses in the lung after 
intranasal immunisation [Jones et al., 1988], as well as immunity to challenge with live 
influenza A virus [Lovgren et al., 1988]. By using a fusion peptide of paramyxovirus linked 
to a measles virus derived CTL epitope from measles nucleoprotein, ISCOMS were also 
shown to prime nucleoprotein-specific CTL after an intranasal immunisation [Hsu et ah, 
1996]. Although initial studies suggested that ISCOMS containing influenza proteins were 
ineffective when given by the oral route [Lovgren, 1988], ISCOMS are exceptionally stable 
structures, and can resist degradation by exposure to low pH and bile salts [Kersten, 1990]. 
Furthermore, it has been known for many years that the saponins themselves are effective 
adjuvants when given orally, inducing serum antibodies, antigen-specific proliferation and 
CTL activity [Chavali and Campbell, 1987b, Chavali and Campbell, 1987a]. These 
indications that ISCOMS could be an effective oral vaccine were confirmed by initial 
findings from this laboratory that a single feed of ISCOMS containing OVA could induce 
primary OVA-specific IgG, DTH and class I MHC-restricted CTL responses in mice [Mowat 
et al., 1991a]. In addition, feeding OVA ISCOMS did not induce the systemic tolerance to 
subsequent challenge which is the normal consequence of feeding equivalent amounts of 
soluble OVA. Thus ISCOMS appear to bypass the regulatory mechanisms which normally 
inhibit responses to orally administered proteins. Although the dose of OVA ISCOMS 
needed to induce primary systemic responses orally was ten fold greater than that given 
parenterally [Mowat et al., 1991a], as little as 50pg OVA could induce detectable DTH 
responses [Mowat et ah, 1991a]. However, it was more difficult to prime serum antibody 
responses in this way and six feeds of 50pg - lOOpg OVA ISCOMS were found to be optimal 
for inducing serum IgG antibody responses and CTL activity in the spleen. This protocol also
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stimulates local immune responses, as shown by the fact that CTL could be demonstrated in 
draining mesenteric lymph node (MLN) and by the presence of high levels of secretory IgA 
antibodies in gut lavage fluid [Mowat et ah, 1993], Interestingly, optimal IgA production was 
dependent more on the frequency of oral immunisation, rather that the amount of antigen, as 
IgA levels increased progressively after 1, 3 or 6 feeds, but lOpg OVA/dose was as effective 
as lOOpg [Mowat et ah, 1993]. No IgA antibodies could be found in serum after oral 
immunisation alone, but these could be stimulated by combined oral and parenteral 
immunisation with OVA ISCOMS (Personal Communication A.M. Donachie). Later studies 
showed that repeated oral immunisation with OVA ISCOMS resulted in both Thl and Th2 
dependent immune responses, with OVA-specific proliferative responses and the production 
of IL-2, ylFN and IL-5 in the MLN and spleen [Maloy et ah, 1995]. Oral OVA ISCOMS also 
primed for both IgGl and IgG2a serum antibody production after challenge with OVA 
parenterally [Maloy et ah, 1995]. Thus, orally administered ISCOMS are strong inducers of 
both local and systemic immunity, prime both MHC class I and MHC class II restricted 
responses, induce cellular and humoral responses and do not bias towards either the Thl or 
Th2 cells. Subsequent work has shown that the oral immunogenicity of ISCOMS is not 
confined to the model antigen OVA. Local and systemic immune responses which protected 
against challenge were seen after oral administration of ISCOMS containing subunit antigens 
derived from influenza virus [Ghazi et ah, 1995, Scheepers and Becht, 1994], and surface 
sporozoite antigens from Eimeriafalciformis [Kazanji et ah, 1994] .
These studies also have important practical implications for the use of ISCOMS as 
vaccine vectors. Firstly, the toxicity often found due to the Quil A component of ISCOMS 
given by other routes is reduced when given orally [Phillips et ah, 1979]. Secondly, oral 
immunisation with OVA ISCOMS does not induce susceptibility to immunopathology in the 
intestine upon subsequent oral exposure to antigen [Mowat et ah, 1993], as is found in other 
circumstances when oral tolerance is broken. Together these results suggest that ISCOMS 
will be safe and effective when given as an oral or nasal vaccine.
There have been few studies of the immunogenicity of ISCOMS given by other 
mucosal routes. However it has been shown that local antigen-specific antibody responses
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can be generated when ISCOMS containing antigens from sheep erythrocytes are 
administered into the vagina or the upper reproductive tracts of female mice. [Thapar et al., 
1991].
Thus, especially after the encouraging start to human trials of an intramuscular 
ISCOMS based influenza vaccine, the development of oral human ISCOMS based vaccines 
is a second priority.
4.5 Mechanisms for ISCOMS Adiuvantieitv
Little is known currently of how ISCOMS act. However, previous work in our 
laboratory had suggested that Quil A and the particulate nature of ISCOMS played an 
important role [Maloy, 1996]. Quil A itself is capable of inducing similar antigen-specific 
immune responses by both parenteral and oral routes, with the same range of CD4+ and 
CD8+ T cell responses, as well as local and systemic antibody production [Campbell and 
Peerbaye, 1992]. However, much larger amounts of both Quil A and antigen are required to 
generate immune responses equivalent to those induced by ISCOMS themselves [Maloy, 
1996]. Thus it seems that delivery of the Quil A adjuvant in the particulate form of the 
ISCOMS is central to their adjuvant effects. Other work has suggested that ISCOMS may 
influence the innate immune response, with reports of increased recruitment of neutrophils 
[Watson et a l, 1989] and the production of IL-1 [Villacres-Eriksson et a l, 1993] IL-6 
[Behboudi et a l, 1997] and IL-12 [Villacres-Eriksson et a l, 1997] after parenteral 
administration. In addition recent evidence has indicated that ISCOMS induce an 
upregulation of the expression of B7.2 [Sambhara et a l, 1998]. However, these properties 
have not been studied in detail, nor is it known if they are essential for the adjuvant effects of 
ISCOMS on specific immune responses. Finally no studies have been undertaken in the 
mucosa. These were the aims of the current work.
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5.0 Specific Aims of Study
In the first part of this thesis, I assessed the innate responses induced by a single 
administration of ISCOMS. To do this, I studied the effects of injecting ISCOMS into the 
peritoneum, as this provided an easily accessible and discrete compartment from which 
inflammatory cells could be removed. I monitored the number and phenotypic populations of 
cells that were recruited and determined their functional activity by measuring the production 
of inllammatory cytokines and mediators. Having obtained data from this site, Ï then 
performed equivalent studies on the innate immune responses induced in the secondary 
lymphoid tissues of the small intestine following a single oral dose of ISCOMS. The results 
of these studies are described in Chapter 3.
As these experiments showed that ISCOMS stimulated a large range of innate 
immune responses, I then went on to determine how some of these factors influenced the 
induction of antigen-specific immune responses to ISCOMS using gene-targeted knock out 
mice. The results of this work are described in Chapter 4.
As these studies indicated that only certain components of the innate immune 
response were required for the immunogenicity of ISCOMS, finally, I examined how defects 
in these factors correlated with differences in the early inflammatory responses induced by 
ISCOMS. These results are presented in Chapter 5.
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Figure 1.1 Ultrastructural appearance of OVA ISCOMS.
A transmission electron micrograph (magnification x73 (XX)) of ISCOMS after negative 
staining, with 3% phosphotungstic acid, showing the characteristic cage-like structure.
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Chapter 2
Materials and Methods
2.1 Animals
Female C57B1/6 (B6) mice were purchased from Harlan Olac (Bicester, Oxon, UK.) 
while female BALB/c mice were bred at the University of Glasgow. 129/Sv ylFN-type II- 
receptor knockout (ylFNRKO) [Huang et al., 1993] mice and (B6xl29) F2 IL-4 knockout 
(IL-4KO) [Kopf et al., 1993] mice were originally obtained from Dr H. Bluethmann 
(Hoffmann-La Roche, Basal, CH). p40 IL-12 deficient (IL-12KO) BALB/c and C57BL/6 
[Magram et al., 1996] mice were obtained from Dr. J. Magram, Roche Pharmaceuticals, 
Piscataway, NJ, USA. Inducible nitric oxide synthase deficient (iNOSKO) MFl mice [Wei et 
al., 1995] and IL-18 deficient (MF 1x129) mice were a gift from Prof, F.Y. Liew, Department 
of Immunology, University of Glasgow. All these mice were bred and maintained at the 
University of Glasgow under SPF conditions and first used at 6-8 weeks of age.
Female IL-6 deficient (IL-6KO) SV mice [Kopf et al., 1994] were obtained from Prof. 
J. Alexander, Department of Immunology, University of Strathclyde, Glasgow and were bred 
and maintained at the University of Strathclyde.
2.2 Anaesthesia
For some procedures, animals were anaesthetised using 5% halothane BP (Rhone 
Merieux, Harlow, Essex, U.K.)
2.3 Antigens
Ovalbumin (OVA, Grade V) was obtained from Sigma (Poole, Dorset , U.K.) as a 
lyophilised powder and stored at 4“C until required.
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Heat-aggregated OVA (HAO) was prepared by heating a 2% (w/v) solution of OVA 
in sterile saline (Baxter Healthcare Ltd, Thetford, Norfolk, U.K.) at 70°<C for 60 minutes in a 
waterbath. The precipitated OVA was then centrifuged for 10 minutes at 450g at 4"C and the 
supernatant removed. The pellet was then resuspended and washed with cold saline and re­
centrifuged. The pelleted HAO was resuspended in sterile saline at a concentration of 
20mg/ml and stored in aliquots at -20°C until required. For use as an in vivo challenge, HAO 
was resuspended at a concentration of 2mg/ml in sterile saline and sonicated for 20 minutes 
until a colloidal suspension was obtained.
2.4 Adiuvants
Quil A (Spikoside) produced by Iscotec AB, Lulea, Sweden, was kindly provided by 
Dr. K. Lovgren (Department of Veterinary Medical Microbiology, Swedish University of 
Agricultural Sciences, Uppsala, Sweden.) and whole cholera toxin (CT) derived from Vibrio 
cholerae was purchased from Sigma, resuspended in sterile saline to a concentration of 
Img/ml and stored at 4°C until required.
2.5 Production of OVA ISCOMS
OVA ISCOMS were prepared using a modified protocol of that described previously 
[Mowat and Reid, 1992]. In order to incorporate the non-hydrophobic OVA protein into the 
lipophilic ISCOMS matrix, OVA was chemically modified by attachment of hydrophobic 
palmitic acid groups via a succinimide estérification reaction. Paimitified OVA was then 
mixed with cholesterol and phosphatidyl choline in the presence of Quil A and the ISCOMS 
formed spontaneously.
i) Palmitification of OVA
20mg OVA was dissolved in 2.5ml of 0.05M carbonate buffer (pH 9.2) and passed 
through a Sephadex PDIO column (Pharmacia, Uppsala, Sweden.) to remove low molecular
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weight peptides. Whole OVA was eluted from the column with 0.05M carbonate buffer and 
200[xl fractions collected in a Falcon flexible 96 well assay plate (Becton Dickinson Labware, 
Oxnard, CA, USA.). Protein content was assessed by the Bradford assay and the protein 
containing fractions pooled. The concentration of protein was adjusted to Img/ml by addition 
of 0.05M carbonate buffer containing 5% sodium deoxycholate (BDH Ltd, Poole, Dorset, 
U.K.) and 10% dimethyl sulfoxide (DMSO) (Sigma).
Palmitification of the resulting purified OVA was achieved by dropwise addition of 
314fxl of a lOmg/ml N-(palmitoyloxy) succinimide (NPS) (Sigma) solution dissolved in 
DMSO giving a 20:1 molar ratio of palmitic acid to OVA. Both NPS and OVA were 
prewarmed to 37"C and the reaction performed with constant shaking to prevent precipitation 
of NPS. The mixture was then incubated overnight at 37°C in a shaking incubator with a 
stroke rate of 100/minute. The palmitification reaction was stopped by addition of 1ml Tris 
(hydroxymethyl methylamine (TrisHCI, pH 8.5), followed by a further incubation for 30 
minutes at 37“C. Excess TrisHCI prevents palmitification by providing free amino groups.
Free palmitic acid was separated from paimitified OVA by ultracentrifugation. A 40% 
(w/v) solution of sucrose (BDH) was prepared in phosphate buffered saline (PBS) and 8ml 
pipetted into six Ultraclear tubes (Beckman Ltd, High Wycombe, Bucks, U.K.). Ig sucrose 
was added to the protein/NPS mixture so as to give a 5% w/v solution, and 4ml of this was 
overlaid on to the 40% sucrose layer in each tube. 1ml of a 2% (w/v) solution of decanoyl N- 
methylglucamide (Mega-10) (Sigma) in PBS was added carefully to the top of each tube, 
which were then centrifuged at 40,000 rpm for 4 hours at 4“C using a SW41.14 rotor (Sorvall 
(UK) Ltd, Stevenage, Herts, U.K.) in an ultracentrifuge (Sorvall). Following 
ultracentrifugation, the top layer of PBS containing the free palmitic acid was discarded and 
the paimitified OVA harvested from the 5% sucrose layer.
ii) Preparation of OVA ISCOMS
A mixture of cholesterol and phosphatidyl choline (both Sigma) was prepared by 
adding 50mg of each to 1ml chloroform (Aldrich Chemical Co., Poole, Dorset, U.K.) and 
adding this to 5 ml of distilled H2O containing 20% (w/v) Mega-10, The chloroform was
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evaporated under a stream of nitrogen until the mixture was completely clear, leaving a 
solution containing lOmg/ml of each lipid. The lipid mixture was dispensed in 1ml aliquots 
and stored at -20°C until required.
To prepare OVA ISCOMS, 1ml of the lipid mixture (giving a final concentration of 
0.5mg/mi) and 50mg Quil A (giving a final concentration of 0.1% (w/v)) was added to the 
paimitified OVA solution. The solution was sonicated for 20 minutes, transferred into 
dialysis tubing (Visking, Medicell International Ltd, London, U.K.) and dialysed for 4-5 days 
at 20°C against 4 litres of 50mM TrisHCI or PBS which was changed every 12 hours. The 
formation of ISCOMS was observed by a cloudiness of the dialysate.
The ISCOMS were separated from free reaction products by ultracentrifugation over a 
discontinuous sucrose gradient prepared in Ultraclear tubes. The sucrose gradient was 
produced by pipetting 4mls of 40% sucrose (w/v) solution in PBS into Ultraclear tubes 
(Beckman) and overlaying 4mls of 10% sucrose (w/v) solution in PBS. 5mls of the ISCOMS 
mixture was carefully layered on to the top of each tube and these were then centrifuged at 
40,000 rpm for 16 hours at 4°C using the SW41.14 rotor (Sorvall) and a Sorvall 
ultracentrifuge. The ISCOMS were visualised as a white band at the interface between the 
10% and 40% sucrose layers and were harvested and dialysed for 24 hours against 4 litres of 
PBS to remove excess sucrose.
ISCOMS were then sterilised by filtration through a 0.2pm filter (Acrodisc, Gelman 
Sciences, Ann Arbor, MI, U.S.A.), aiiquoted and stored at -20“C until required. The 
formation of intact ISCOMS was confirmed by negatively staining with 3% phosphotungstic 
acid (pH 6.6) and analysis on a Philips CM 10 transmission electron microscope (TEM) at a 
final magnification of 73000x (Mrs Jane Hare, Department of Pathology, Western Infirmary, 
Glasgow).
iii) Quantification of OVA ISCOMS Protein Content
The concentration of OVA in samples of purified protein and in OVA ISCOMS was 
measured using Bradford's Assay. Briefly, 20pl of test sample were added to ISOpl of a 20% 
(v/v) solution of Bradford's reagent (Coomassie Blue Dye in 55% phosphoric acid with 15%
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methanol) (Bio-Rad, Hemel Hempstead, Bucks. U.K.) in dH20. After an incubation for 20 
minutes at room temperature, the O.D. 570nm of the samples was read using a MR5000 
automatic plate reader (Dynatech Laboratories Ltd., Billingshurst, West Sussex, U.K.) and 
the concentration of OVA calculated by comparison with a standard curve generated from 
dilutions of OVA in PBS.
iv) Quantification of Endotoxin Content in OVA ISCOMS
The content of lipopolysaccharide (LPS) in OVA ISCOMS was quantified using the 
Limulus lysate assay (Sigma) and was found to be very low (<0.5pg/ml), equivalent to 
0.5ng/dose of ISCOMS.
2.6 Administration of OVA ISCOMS in vivo
ISCOMS were administered parenterally either as a subcutaneous (s.c.) injection in a 
volume of 50pl sterile saline into the hind footpad under light halothane anaesthesia or as an 
(i.p.) injection in a total volume of 200pl sterile saline.
Oral immunisation of ISCOMS was performed by feeding 200pl volumes using a 
rigid steel gavage needle placed in the oesophagus. CowV-<tiL Wjui
Ç,oXs.vA.«a^ cvvj^A. ^
2.7 Isolation of Peritoneal Exudate Cells
Peritoneal exudate cells (PEC) were removed by lavage. Mice were injected i.p. with 
6mls of RPMl 1640 (Gibco BRL, Paisley, U.K.), the abdomen gently massaged and fluid 
withdrawn using a 19 gauge needle. The cells were washed by centrifuging in RPMI 1640 at 
450g for 5 minutes, resuspended in fresh RPMI 1640 and viable cell counts performed in a 
Neubauer haemocytometer (Weber Scientific, Middlesex, U.K.) using a phase contrast 
microscope at x400 magnification (Nikon Labophot, UK). The cells were then centrifuged 
again at 450g and the pellet resuspended at a concentration of 1x10^ PEC/ml in the 
appropriate medium and stored on ice until required.
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2.8 Histological Analysis of PEC bv Cvtospin
Aliquots of 5x10^ cells were spun onto glass microscope slides at 200 rpm for 5 
minutes using a cyto-centrifuge (Shandon, Runcorn, UK) and fixed in a 50:50 methanol in 
acetone solution for 2 minutes. The slides were allowed to air dry and washed in PBS before 
being immersed in Geimsa stain (Sigma) for 30 minutes. The slides were rinsed in distilled 
water, allowed to air dry and then mounted in Histamount (Sigma) under glass.
The cells were then assessed histologically at x400 magnification using a Nikon 
Labophot microscope. To perform qualitative analysis of cell numbers, 10 fields/cytospin 
were assessed and the average calculated.
2.9 Isolation of Lymohoid Cells
Popliteal lymph nodes (PLN), spleens (SP), Peyer's patches (PP) and mesenteric 
lymph nodes (MLN) were removed after sacrifice and cleaned of any surrounding tissue. The 
lymphoid organs were then gently crushed using a sterile 2ml syringe plunger (Plastipak, 
Becton Dickinson, Mountain View, CA, USA) in a Petri dish (Costar, Northumbria 
Biologicals, Cramlington, U.K.) containing RPMI 1640 medium. The cells were then pipetted 
several times through a sterile glass pipette to obtain a single cell suspension which was then 
passed through sterile nylon mesh (Nitex, Cadich and Sons Ltd. London, U.K.) to remove 
debris. The cells were washed by centrifuging at 450g for 5 minutes, resuspended in fresh 
RPMI 1640, counted, resuspended at an appropriate concentration and stored on ice until use.
2.10 Flow Cvtometrv
Lymphoid cells and PEC were analysed phenotypically by flow cytometry using the 
surface markers listed in Table I. Aliquots of 10^ cells were washed twice in FACS Buffer 
(PBS containing 2% PCS (Gibco BRL) and 0.02% sodium azide) and all staining reactions
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performed for 45 minutes on ice in a total volume of 50pl FACS Buffer containing antibodies 
at 1:25 dilutions. Between staining steps, cells were washed twice in cold FACS Buffer and 
finally resuspended in 500pi of FACSflow (Becton Dickinson). For analysis, a Becton 
Dickinson FACScan® flow cytometer (Becton Dickinson) was used which consisted of 
single argon laser of 488nm wavelength. Data from 10,000 cells were acquired and analysed 
using Lysis II software.
2.11 Stimulation of Cvtokine Production in vitro
For the assessment of cytokine production, 4x10^ cells were cultured in vitro in 24 
well plates (Costar) in I ml of RPMI 1640 containing 10% heat inactivated FCS, lOOU/ml 
penicillin, lOOpg/ml streptomycin, 50pg/ml Fungizone (all Gibco BRL) and 0.05pM 2- 
mercaptoethanol (Sigma) (culture medium) in the presence or absence of lOpg/ml LPS (5". 
enteritidis. Sigma) plus 20ng/ml recombinant murine ylFN (Pharmingen) or with lOpg/ml 
concanavalin A (Con A). For the measurement of antigen-specific cytokine secretion, similar 
aliquots of 4x10*  ^cells were cultured with or without lOpg/ml Con A or Img/ml OVA. After 
culture at 3TC  in 5% CO2 in air, the supernatants were removed and centrifuged for 5 
minutes at 13000g before being frozen at -20°C until required.
2.12 Removal of Adherent Cells in vitro
Adherent cells were removed from PEC populations by adding 4x10^ PEC in 1ml 
culture medium to 24 well plates (Costar) and incubating at 37°C in a humidified incubator 
containing 5% CO2 in air for 3 hours. Non-adherent cells were then gently aspirated using a 
sterile glass pipette and transferred into fresh wells.
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2.13 Measurement of Reactive Oxygen Intermediate Production
Reactive oxygen intermediates (ROI) released during the respiratory burst were 
measured by a chemiluminescence assay [Easmon et al., 1980]. Briefly, cells were washed in 
Hank's Balanced Salts Solution (HBSS) (Gibco BRL) without phenol red, and wanned to 
37°C in a water bath. lOOpl of O.lmM 5-amino-2,3-dihydro-l,4-phthaiazinedione solution 
(Luminol) (Sigma) was added to 2x10^ cells in 400pl of the warmed HBSS and these were 
then stimulated by addition of Ipg/ml phorbol 12-myristate 13-acetate (PMA) (Sigma). The 
suspensions were mixed at 37“C and the chemiluminescence measured using a 1250 
Luminometer (LKB Wallac, Turku, Finland) every 10 seconds for a total of 10 minutes. All 
measurements were expressed as mV and the background chemiluminescence was assessed 
by incubating cells in the absence of PMA.
2.14 Measurement of Nitric Oxide Production
The concentration of nitric oxide (NO) present in culture supernatants was deteimined 
by detection of nitrite, a stable metabolite of NO, using the Griess reaction. Briefly, the 
Griess reagent was made by mixing equal volumes of 5% orthophosphoric acid containing 
1% sulphanilamide (Sigma) and 0.1% napthylethylenediamine (Sigma) and kept at 4°C until 
required. 50pi culture supernatant or standard dilutions of sodium nitrite in RPMI 1640 
containing 10% FCS were added to 96 well Immulon 4 microtitre plates (Dynatech) in 
triplicate and 50pl of the Griess reagent was then added. The colour generated by the reaction 
was measured spectrophotometrically at 570nm using a MR5000 microtitre plate reader 
(Dynatech).
2.15 Measurement of Systemic Delaved Tvoe Hvpersensitivitv (DTHI Responses
Systemic OVA-specific DTH responses were assessed 7 days after immunisation with 
OVA ISCOMS by measuring the increment in footpad thickness 24 hours after a
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subcutaneous challenge with lOOpg HAO, using callipers (Kroplin Ltd, Kingston-upon- 
Thames, Surrey, U.K.) . Background responses were determined by challenging naive mice 
with HAO and were subtracted to obtain antigen-specific DTH levels.
2.16 Measurement of OVA"Specific Antibodies in Serum
Blood was obtained from the retro-orbital plexus using heparinised capillary tubes 
(Hawksley & Sons Ltd, Lancing, Sussex, U.K.) under light halothane anaesthesia and the 
serum was separated by centrifugation at 500g for 10 minutes. Samples were stored at -20°C 
until required and the levels of serum antibody were then analysed by ELISA, [Garside et al., 
1995].
i) Quantification of Total IgG Antibodies
Immulon 4 ELISA plates (Dynatech) were coated overnight at 4“C with 50pl of a 
lOpg/ml solution of OVA in 50mM carbonate buffer. The plates were then washed three 
times with PBS containing 0.05% polyoxyethylenesorbitan monolaurate (Tween 20) (Sigma) 
(PBST). lOOpl of samples diluted 1:400 in PB ST were added to the plate in triplicate and 
incubated for 2.5 hours at room temperature in a humid environment. The plates were then 
washed three times with PBST and lOOpl of a 1:1000 dilution of alkaline phosphotase 
conjugated goat-anti-mouse IgG (Sigma) was added and the plates left for a further 3 hours at 
room temperature in a humid environment. Plates were then washed three times with PBST 
and lOOpl of a Img/ml solution of phosphotase substrate (p-nitrophenyl phosphate) (Sigma) 
dissolved in dH20 containing 10% diethanolamine (DEA) (Aldrich) was added to each well. 
The O.D. 450nm of the samples was read using an MR5000 automatic microplate reader 
(Dynatech) after an incubation for 10-30 minutes at room temperature. The results from 
individual mice were expressed either as an O.D. 450nm, or as the dilution that gave an 
equivalent O.D. 450nm of a 5% concentration of an hyperimmune standard of ammonium 
sulphate-purified anti-OVA IgG which had been obtained from mice immunised twice with 
lOOpg OVA in CFA.
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ii) Quantitation of OVA-Specific Serum IgG Antibody Isotypes
Immulon 4 plates were coated overnight at 4°C with 50pl of a lOjxg/ml OVA solution, 
then washed three times with PBST. The plates were blocked with 3% (w/v) bovine serum 
albumin (BSA) (Sigma) in PBST for 1 hour at room temperature and then washed again three 
times with PBST. A 1:400 dilution of hyperimmune OVA-specific serum as standard or 
serum samples were diluted either 1:400 in PBST for IgGl or 1:20 in PBST for IgG2a and 
added to the plates in a volume of 50pl and then serially diluted 1:1 in PBST. The plates were 
incubated for 2.5 hours at room temperature and then washed three times with PBST. IgGl 
was detected by adding 50pl of a 1:16,000 dilution of biotinylated rat-anti-mouse IgGl 
antibody (Serotec) in PBST and IgG2a by the addition of 50pl of a 1:500 dilution of 
biotinylated rat-anti-mouse IgG2a (Serotec) in PBST. The plates were then incubated at room 
temperature for 1 hour and then washed three times with PBST. lOOpl of a 1:1000 dilution of 
extravidin peroxidase (Sigma) in PBST was added to each well and incubated for 1 hour at 
room temperature. The plates were washed several times with PBST and lOOpl of the 
chromophore 3, 3, 5, 5' - tetramethylbenzidine (TMB) and H2O2 (Dynatech) added to each 
well. After an incubation of 10 minutes at room temperature the plates were read at 630nm on 
a MR5000 microtitre plate reader (Dynatech). The level of IgG isotypes present in test wells 
was calculated the dilution that gave an equivalent O.D. 450nm ^ 5% of the hyperimmune 
standard.
2.17 Measurement of Intestinal Secretory IgA Antibodies
Intestinal secretions were collected using a lavage technique modified from that 
published previously [Elson et al., 1984]. Mice were given four feeds of 200pl 16% 
polyethylene glycol (PEG) (Sigma) solution in PBS within an hour. The small intestine and 
caecum were then removed and rinsed through with 6ml of ice cold PBS containing 
0.Img/ml soyabean trypsin inhibitor and 50mM ethylendiametetraacetic acid (EDTA) (both 
Sigma). The fluid was clarified by centrifugation at 1500g for 10 minutes and 3ml of the
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supernatant was removed. Then 30pl of lOOmM phenylmethylsulfonyl (PMSF) (Sigma) in 
95% ethanol (Aldrich) was added to each aliquot, which were then centrifuged in Eppendorf 
tubes at 27000g for 15 minutes at 4°C. lOpl of PMSF solution, lOpl of a 1% (w/v) solution of 
sodium azide (Sigma) in PBS and 50pl of FCS were then added to 1ml of the resulting
supernatants which were then stored at ~20°C until required.
OVA-specific intestinal IgA responses were also assessed by ELISA. Immulon 4
ELISA plates (Dynatech) were coated overnight at 4°C with 50pl of a lOpg/ml solution of 
OVA in 50mM carbonate buffer. The plates were then washed thoroughly with PBST and 
lOOpl of undiluted sample added in triplicate, incubated for 2.5 hours at room temperature in 
a humid environment and then washed three times with PBST. lOOpl of a 1:1000 dilution of 
alkaline phosphotase conjugated goat-anti-mouse IgA (Sigma) was added and the plates left 
for a further 3 hours at room temperature in a humid environment. The plates were then 
washed three times with PBST and 100pi of a Img/ml solution of phosphotase substrate 
(Sigma) dissolved in dH20 containing 10% DEA (Aldrich) was added to each well. The O.D. 
450nm of the samples was read using an MR5000 automatic microplate reader (Dynatech) 
after an incubation of 10-30 minutes at room temperature. The results from individual mice 
were expressed as an O.D. 450nm.
2.18 Measurement of OVA-Specific Proliferative Responses
Single cell suspensions from spleen or popliteal lymph node (PLN) were cultured in 
flat bottomed 96 well microtitre plates (Costar) in quadruplicate. Cells were cultured at a 
concentration of 2.5xl0^/well in culture medium with or without Img/ml OVA or lOpg/ml 
Con A at 37°C in 5% CO% and humidified air. Eighteen hours prior to harvesting, the cells 
were pulsed with IpCi ^H-thymidine (West of Scotland Radionucleotide Dispensary, 
Western Infirmary, Glasgow) and harvested onto glass fibre filter mats using a Betaplate 96 
well harvester (LKB Wallac, Turku, Finland). DNA bound ^H-thymidine was then counted 
using a Betaplate scintillation counter (LKB Wallac).
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2.19 Measurement of Cvtokines bv ELISA
Culture supernatants were assayed for cytokine levels by sandwich ELIS As, already 
established in the laboratory [Garside et al., 1995]. Immulon 4 plates (Dynatech) were coated 
with an appropriate concentration of rat-anti-cytokine antibody (See Table II) diluted in 0.1 M 
carbonate buffer and incubated overnight at 4^C. The plates were then washed three times 
with PBST and blocked for 1 hour with 200pl of 10% FCS in PBS. The plates were then 
washed twice with PBST and 50pl of samples, or serial dilutions of recombinant murine 
cytokines as standards, added in triplicate to the plate (See Table III). The plates were then 
incubated at 37®C for three hours before being washed three times with PBST. 50pi of the 
appropriate biotinylated-detection antibody was added to the plate and incubated for 1 hour at 
370c  (See Table IV). The plates were then washed three times with PBST before lOOpl of a 
1:1000 dilution of extravidin peroxidase (Sigma) in PBS + 10% FCS was added to each well 
and incubated for 1 hour at 37°C. The plates were washed several times with PBST and lOOpl 
of the chromophore TMB and H2O2 (Dynatech) added to each well. After an incubation of 
10 minutes at room temperature, the plates were read at 630nm on a MR5000 microtitre plate 
reader (Dynatech). The level of cytokine present in test wells was calculated from the 
standard curve.
2.20 Measurement of OVA-Specific Cvtotoxic T Cell Responses
OVA-specific CTL activity was measured in spleens of mice 7 days after i.p. 
immunisation or 7 days after the final feed of OVA ISCOMS as described previously [Mowat 
et al., 1991b]. 3x10^ spleen cells from immunised animals were restimulated in vitro with 
1.5x10^ OVA transfected EG7.0VA cells which had been treated for 60 minutes at 37°C 
with 50pg of mitomycin c per 1x10^ cells in a volume of 1 ml of culture medium containing 
5% NCTC-135 medium (Gibco) (CTL medium). The cells were co-cultured in 25cm^ culture 
flasks (Costar) for 5 days at 37°C in 5% CO2 and humidified air. After culture, the effector 
cells were washed three times and assayed for CTL activity using EG7.0VA cells that had
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been labelled with by incubating 2.5x10^ EG7.0VA cells in 1ml of RPMI 1640 
containing 5% newborn calf senim (NCS)(Gibco) and 2MBq Na2^^CrOq (West of Scotland 
Radionucleotide Dispensary) for 60 minutes at 3TC  in 5% CO2 and humidified air. The 
target cells were then washed five times to remove excess Na2^^Cr0 4  by centrifugation at 
450g for 5 minutes and added to V-bottomed 96 well microtitre plates (Costar) in RPMI 
1640+5% NCS at a concentration of 2x10^ cells/well. Effector cells were added to target 
cells in quadruplicate at various concentrations so as to give effector:target (E;T) ratios of 
100:1, 50:1 and 25:1 in a total volume of 200pl. The cultures were then incubated at 37°C in 
5% CO2 for 4 hours before lOOpl of supernatant was removed from the top of each well and 
^^Cr release counted on a Compugamma counter (LKB Wallac). The percentage of OVA- 
specific CTL lysis of target EG7 cells was calculated by using the following formula:
^  . . (Experimental Release - Spontaneous Release) ,Cytotoxicity = -— -------------------------   x 100%(Total Release - Spontaneous Release)
In all experiments, 10% Triton X (BDH Laboratory Supplies, Poole, UK) was used to 
obtain the maximum release and medium or naive spleen cells restimulated with EG7.0VA 
cells was used to obtain the spontaneous release. ^ICr-labelled EL4 cells were used as non- 
OVA expressing negative control target cells,
2.21 Statistics
Unless otherwise stated, all results are expressed as means ± 1 standard deviation 
(ISD) and were compared using Student’s t-test.
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Table I. Phenotypic marker antibodies used for flow cytometry
MARKER CLONE ISOTYPE HOST CONJUGATE DILUTION COMPANY
CD4 RM4-5 IgG2aK Rat PE 1:25 Pharmingen
CD8 53-6.7 IgG2aK Rat HTC 1:25 Pharmingen
B220 RA3-6.B2 IgG2aK Rat Biotin 1:50 Pharmingen
Whole 5120- IgG2a Rat Biotin 1:10 Serotec
Neutrophils
F4/80
26.1/11
C1;A3-1 IgG2b Rat Biotin 1:10 Serotec
CD 11c HL3 IgGl Hamster PE 1:25 Pharmingen
I_Abd 25-9-17 IgG2aK Mouse FITC 1:25 Pharmingen
CD25 7D4 IglVÎK Rat FITC 1:25 Pharmingen
CD 16/ 2.4G2 IgG2bK Rat - 1:25 Pharmingen
CD32
Streptavidin - - - PE 1:10 Vector
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Table II. Capture antibodies used for sandwich ELISA
CYTOKINE CLONE ISOTYPE HOST CONCENTRATION
(ng/ml)
COMPANY
IL -la ALF16L1 IgG Hamster lOpg/ml Genzyme
IL-5 TRFK5 IgGl Rat 4fxg/ml Pharmingen
IL-6 MP5-
20F3
IgGl Rat Ipg/ml Pharmingen
IL-12 C17.15 IgG2a Rat 5pg/ml Genzyme
ylFN XMG1.2 IgGl Rat 2fxg/ml Pharmingen
Table III. Recombinant cytokine used in sandwich ELISA
CYTOKINE TOP
STANDARD
BOTTOM
STANDARD
COMPANY
IL -la 20.000 ng/ml 31.250 pg/ml Genzyme
IL-5 200.000 U/ml 0.313 U/ml Genzyme
IL-6 10.000 ng/ml 15.625pg/ml Genzyme
IL-12 10.000 ng/ml 15.625 pg/ml Genzyme
ylFN 40.000 ng/ml 62.500 ng/ml Genzyme
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Table IV. Detection antibodies used in sandwich ELISA
CYTOKINE CLONE ISOTYPE CONJUGATE HOST CONCENTRATION
(ng/ml)
COMPANY
IL -la Polyclonal - Biotin Rabbit 5[xg/ml Genzyme
IL-5 TRFK4 IgG2a Biotin Rat 4pg/ml Pharmingen
IL-6 MP5-
32C11
IgG2a Biotin Rat 1 pg/ml Pharmingen
IL-12 Polyclonal - Biotin Rabbit 5pg/ml -
ylFN XMG1.2 IgGl Biotin Rat 2pg/ml Pharmingen
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Chapter 3
Parenteral and Oral Administration of ISCOMS induces an Inflammatory 
___________________________ Cascade in vivo^___________________________
Introduction
Although ISCOMS are well known to induce a wide range of antigen-specific 
immune responses in vivo by both parenteral and mucosal routes, the basis for their adjuvant 
properties has not been studied in any detail. As it is now clear that an ability to stimulate the 
innate immune response exerts a powerful influence over the type of acquired immunity 
generated to an antigen [Medzhitov and Janeway Jr, 1997a, Fearon and Locksley, 1996], it 
seemed appropriate to explore the effects of ISCOMS on the early non-specific immune 
response. Therefore, in the experiments described in this chapter, I investigated if ISCOMS 
were capable of inducing an innate response after parenteral or oral administration.
Experimental Protocol
In the first experiments, mice were injected i.p. with 5pg OVA ISCOMS in saline. 
The peritoneum was chosen as it provided a discrete, relatively localised compartment for 
sampling, that was also easily accessible. In addition, previous studies in our laboratory had 
shown that ISCOMS were immunogenic by this route [Mowat et al., 1991a, Maloy et al., 
1995]. At various times after injection, PEC were removed by lavage, counted and examined 
by cytospins and flow cytometry. The release of ROI was determined by PMA induced 
chemiluminescence of Luminol and the production of nitric oxide was measured by the 
Greiss reaction after in vitro culture in the presence or absence of ylFN+LPS, Inflammatory 
cytokines were assessed by ELISA analysis of supernatants in response to ylFN+LPS. After 
studying the responses to i.p. ISCOMS, I went on to perform similar experiments using 
Peyer’s patches and mesenteric lymph nodes taken from mice fed 200pg OVA ISCOMS. In 
all experiments, control mice received saline alone.
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Results
3.1 Recruitment of Local Inflammatory Cells after Intraperitoneal Administration of 
ISCOMS.
Intraperitoneal administration of ISCOMS induced recruitment of an inflammatory 
infiltrate as determined by the total number of PEC obtained in peritoneal lavage. This was 
preceded by an early reduction in the number of PEC, with a 50% decrease in the total 
number of PEC being observed at 3.5 hours after administration of ISCOMS as compared 
with saline injected controls. The numbers of PEC remained depressed until 48 hours after 
ISCOMS injection, by which time there was a marked and significant increase in the number 
of PEC to levels three times that of control mice. The number of PEC was still significantly 
elevated at 72 hours (Figure 3.1).
3.2 Histological Examination of PEC after i.p. ISCOMS
I next explored the nature of the inflammatory infiltrate by histological analysis of 
cytospins prepared of PEC isolates. PEC from control mice consisted mostly of small resting 
lymphocytes and macrophages, together with a small number of mast cells which were 
identified by the presence of multiple dense granules (Figure 3.2a). The decrease in total PEC 
early after injection of ISCOMS was accompanied by an increase in the absolute number of 
polymorphonuclear leukocytes at 3.5 hours (Figure 3.2b) and 7 hours (Figure 3.2c). 
Polymorphonuclear cells were still present at 24 hours, although in much lower numbers, 
(Figure 3.2d), and by 48 and 72 hours, polymorphonuclear cell numbers had returned to 
control levels (Figures 3.2e and f). Mast cell numbers also increased soon after injection of 
ISCOMS and showed evidence of degranulation. This was seen as early as 3.5 hours (Figure 
3.2b), when a substantial number of these cells had degranulated. There was a second rise in 
mast cell numbers at 48 hours, although no degranulation was seen at this time (Figure 3.3).
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Mast cell numbers then returned to control levels at 72 Hours (Figure 3.3). There was no 
change in the numbers of macrophages from PEC isolated at early timepoints after injecting 
ISCOMS, but at 48 hours, there was an influx of large mononuclear cells, many with a foamy 
appearance consistent with activated macrophages (Figure 3.2e). In parallel, there was a 
steady increase in the numbers of lymphoid cells from control levels to a peak at 48 hours, 
when many were lymphoblastoid in appearance (Figure 3.2e). At 72 hours after ISCOMS 
injection, lymphocyte morphology was returning to that observed in control cytospins (Figure 
3.2f).
3.3 Phenotypic Analysis of PEC Recruited by Parenteral Administration of ISCOMS.
To analyse the inflammatory infiltrate in more detail, I used flow cytometry to assess 
the expression of cell surface markers specific for neutrophils, macrophages, dendritic cells 
and T and B lymphocytes. In addition, I determined the activation status of these cells by 
assessing the levels of MHC class II on macrophages and dendritic cells and the IL-2Ra 
chain (CD25) on CD4+ and CD8^ T cells. Unfortunately, no statistical analysis of these 
results were feasible as I had to pool the PEC cells from injected mice.
Consistent with the histological appearances I had observed previously, the decrease 
in PEC numbers early after injection of ISCOMS was accompanied by a large increase in the 
absolute numbers and proportions of neutrophils which peaked at 3.5 hours and declined 
rapidly thereafter. The number of F4/80 expressing macrophages began to increase by 7 
hours, reached a peak at 48 hours and then declined (Figure 3.4a), again confirming the 
microscopic analysis of cytospins.
The numbers of dendritic cells, as determined by expression of the CD 11c surface 
marker, were low in control PEC but, after a further drop at early timepoints, these increased 
to a peak at 72 hours. These CDllc+ cells were observed to be virtually all MHC class 11+, 
consistent with them being mature dendritic cells (Figure 3.4d).
The numbers of CD4+ and CD8+ T cells declined rapidly over the first 7 hours after 
ISCOMS injection (Figure 3.4b). Thereafter, the numbers of CD4+ T cells returned toward
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control levels, whereas CD8+ T cells remained low until 72 hours, before rising to a level that 
was twice that of control mice (Figure 3.4b). The numbers of B220+ B cells followed a 
similar pattern, with a rapid early decrease followed by recovery to levels which were 
eventually double that of control values at 48 hours after administration of ISCOMS (Figure 
3.4c).
I next determined the activation status of the inflammatory infiltrate by examining the 
expression of CD25 and MHC class II antigens and their co-expression on T cells and 
macrophages respectively. MHC class 11+ F4/80+ macrophages were not found in control 
PEC, but their numbers increased dramatically from 7 hours until 48 hours, when 25% of 
macrophages were MHC class 1I+. By 72 hours, few MHC class 11+ macrophages remained 
(Figure 3.4e). There were also virtually no CD4+ T cells coexpressing CD25 in control PEC. 
Although the rise in the absolute numbers of CD4+ T cells was not dramatic after injection of 
ISCOMS, these CD4+ T cells were clearly becoming activated, as evidenced by their 
expression of CD25, with 26% of CD4+ T cells being CD25+ by 48 hours (Figure 3.4e). As 
the numbers were much smaller, I was unable to assess the level of CD25+ CD8+ T cells .
Thus i.p. injection of ISCOMS induced a rapid, local recruitment of inflammatory 
cells, consisting initially of neutrophils and mast cells, followed by macrophages and DC and 
later by both T and B lymphocytes. Once recruited, many of these cells become activated as 
indicated by their increased expression of MHC class II and CD25.
3,4 Parenteral Administration of ISCOMS Induces Production of Local Inflammatory 
Cytokines and Mediators
I next assessed the functional consequences of the cellular recruitment observed after 
an i.p. injection of ISCOMS by measuring IL-1, TNFa, IL-6 and IL-12 as products of 
activated macrophages and dendritic cells and ylFN as a lymphocyte product.
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i) IL - la
PEC from control mice showed very low levels of spontaneous production of IL-la, 
but spontaneous IL -la production was significantly enhanced AS hours after ISCOMS 
injection, when PEC produced more than 20 times that of controls, before decreasing to 
undetectable levels (Figure 3.5a). An almost identical pattern of increased IL -la  production 
by ISCOMS induced PEC, following stimulation in vitro with ylFN+LPS was found (Figure 
3.5a).
ii) IL-6
PEC from control animals produced moderate levels of IL-6 both spontaneously and 
after stimulation with ylFN+LPS in vitro (Figure 3.5b). Immediately after i.p. injection of 
ISCOMS both the spontaneous and ylFN+LPS induced production of IL-6 fell to 
undetectable levels, before increasing again after 24 hours, to levels more than double those 
of controls at 48 and 72 hours (Figure 3.5b).
iii) Immunoreactive IL-12
Control PEC cultures did not produce IL-12 spontaneously and only small amounts of 
ylFN+LPS induced IL-12 (Figure 3.5c). Spontaneous IL-12 production rose gradually from 
24 hours after administration of ISCOMS, plateauing after 48 hours at levels significantly 
above those of control PEC. The ylFN+LPS stimulated production of IL-12 declined to 
approximately 20% that of controls within 3.5 hours, but rose sharply to a peak at 72 hours, 
when levels were twice that of controls (Figure 3.5c).
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iv)yIFN
There was no spontaneous production of ylFN from control PEC, but low levels were 
detected after stimulation with Con A. Significant levels of spontaneous ylEN production 
were detected 24 hours after injection of ISCOMS but not thereafter. Con A stimulated PEC 
showed a small, but significant increase in ylEN production 3.5 hours after injection with 
ISCOMS. This fell back to control levels at 7 hours, but increased again to peak at 24 hours, 
when ylFN production was twice that of control PEC (Figure 3.5d).
V) TNFa
No TNFa production was found in the supernatants from any PEC preparation either 
spontaneously or after stimulation with ylFN+LPS (data not shown).
Thus, the local infiltration by macrophages, dendritic cells and T cells with activated 
phenotypes following injection of ISCOMS is accompanied by the production of 
inflammatory cytokines, indicating that recruited cells are not only phenotypically but also 
functionally activated by exposure to ISCOMS.
3.5 Stimulation of Nitric Oxide and Reactive Oxygen Intermediate Production After 
Parenteral Administration of ISCOMS
In view of the marked recruitment of activated phagocytic cells such as macrophages 
and neutrophils, I next examined the production of two other characteristic mediators of such 
cells, nitric oxide and reactive oxygen intermediates. The concentration of NO in PEC culture 
supernatants was determined from the concentration of its stable breakdown product nitrite, 
as assessed by the Griess Reaction. There was very little spontaneous NO production by
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control PEC, but this was increased by stimulation with ylFN+LPS (Figure 3.6). Spontaneous 
production of NO was detectable by 24 hours after injection of ISCOMS and substantial 
amounts were still present at 48 hours (Figure 3.6). Immediately after injection with 
ISCOMS, ylFN+LPS stimulated production of NO fell, but recovered from 7 hours onwards,
reaching a peak at 48 hours which was significantly above control levels (Figure 3.6).
PMA stimulated production of ROI was measured by chemiluminescence of Luminol.
Control PEC produced little or no ROI, but within 6 hours after injection of ISCOMS, ROI 
production was greatly increased (Figure 3,7). PEC taken 24 hours after ISCOMS produced 
even more ROI, with levels more than twenty times that of control cells. Thereafter, there 
was a decline in ROI production and by 72 hours after injection of ISCOMS, ROI production 
had returned to control levels (Figure 3.7).
Thus the recruitment of neutrophils and macrophages by ISCOMS is accompanied by 
increased production of ROI and NO respectively, underlining the possibility that these cells 
are activated following administration of ISCOMS.
3.6 Secretion of Inflammatory Mediators by ISCOMS Induced PEC is Dependent on 
the Presence of Adherent Cells
I next investigated the role of adherent cells in the production of inflammatory 
cytokines and nitric oxide, by depleting these cells from populations of PEC removed 48 
hours after administration of ISCOMS. As before, ISCOMS stimulated PEC produced small 
amounts of spontaneous IL-12, NO and IL -la  at this time, which were all increased by 
stimulation with ylFN+LPS (Figures 3.8a, b and c). There was no spontaneous production of 
IL-6 in this experiment, but marked amounts occurred after stimulation in vitro with 
ylFN+LPS (Figures 3.8d). In all cases, both the spontaneous and stimulated production of 
these mediators was reduced virtually to background levels when adherent cells were 
depleted (Figures 3.8a, b, c, d). Removal of adherent cells also abolished the spontaneous 
production of ylFN and significantly reduced the Con A stimulated production of ylFN by the 
same cells (Figure 3.8e). These results are consistent with the critical role of adherent cells,
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perhaps macrophages, in the production of inflammatory mediators after injection of 
ÏSCOMS.
3.7 Oral Administration of ISCOMS Induces Cellular Recruitment in the Gut 
Associated Lymphoid Tissues.
As one of the important features of ISCOMS is that they are active via mucosal 
routes, I went on to investigate whether oral administration of ISCOMS induced 
inflammatory responses in intestinal lymphoid tissues similar to those found in the 
peritoneum. Therefore I performed phenotypic and functional studies on PP and MLN cells at 
various times after a single feed of 200pg OVA ISCOMS. I was again unable to perform 
statistical analysis on these data, because I pooled the cells from each group of animals.
Oral administration of ISCOMS induced cellular recruitment in both PP and MLN as 
evidenced by total cell numbers in these tissues (Figures 3.9a and b). This was less marked in 
PP than in the MLN and was less pronounced compared with that found following an i.p. 
injection of ISCOMS (Figure 3.1). Nevertheless, a small increase in cell yield was found in 
both MLN and PP early after feeding ISCOMS, at 3.5 and 7 hours respectively, and after a 
subsequent fall, the numbers of MLN cells began to rise steadily, so that by 48 hours they 
were 2.5 times that of controls (Figure 3.9a). The total number of PP cells also increased from 
48 hours onwards, but when this peaked at 72 hours, it was only 50% above that of controls 
(Figure 3.9b).
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3.8 Phenotypic Analysis of GALT Ceils After Oral Administration of ISCOMS.
In order to assess the nature of the inflammatory infiltrate induced by ISCOMS, I 
analysed cell-specific surface markers and the expression of cellular activation molecules in 
PP and MLN cells .
i) Mesenteric Lymph Nodes
In contrast to the peritoneal cavity, there was no change in the numbers of neutrophils 
found in MLN at any time after oral administration of ISCOMS (Figure 3,10a). However, the 
numbers of F4/80+ macrophages increased steadily to a maximum 48 hours after feeding 
ISCOMS, at which time the numbers of F4/80+ macrophages were six times that of controls 
(Figure 3.10a). The numbers of F4/80 cells then began to decline towards control levels by 72 
hours. An early increase in the numbers of MLN derived CDllc+ dendritic cells occurred 3.5 
hours after feeding ISCOMS, but this was transient and the numbers quickly decreased to 
50% of controls by 24 hours after feeding ISCOMS. However, the numbers of dendritic cells 
then increased again, reaching a maximum by 48 hours after ISCOMS, at which time 
numbers were 2.5 times those in control mice, before returning to background levels by 72 
hours (Figure 3.9d). The majority of these CDllc+ cells were also MHC class II+, indicating 
that these cells were fully differentiated dendritic cells (Figure 3.10b)
The numbers of CD4+ T cells in MLN rose transiently immediately after feeding 
ISCOMS, fell thereafter and then increased steadily to a maximum at 48 hours, by which 
time numbers had increased to three times that of control animals (Figure 3 .10c). An identical 
pattern was obseiwed for CD8+ T cells (Figure 3 .10c). The numbers of both CD4+ and CD8+ 
T cells returned towards background levels by 72 hours. A similar trend was noted for the 
numbers of B lymphocytes, with a small spike in the numbers of B220+ cells occurring 3.5 
hours after feeding ISCOMS, followed by a more sustained recruitment after 24 hours, with 
peak numbers of B220+ B cells being noted at 48 hours, before decreasing towards control 
levels by 72 hours (Figure 3. lOd).
53
I used the coexpression of MHC class II on macrophages and CD25 on CD4 
lymphocytes to determine the degree of activation of these cells after oral administration of 
ISCOMS. After a small increase in the numbers of MHC class 11+ F4/80 macrophages at 7 
hours, however these numbers fell at 24 hours after feeding ISCOMS, when they were 50% 
that of control mice. This was despite the increase in total macrophages numbers at this time. 
However, the numbers of activated macrophages then quickly rose to a peak at 48 hours, by 
which time they were 3.5 times greater than controls (Figure 3.10e). There was a more 
gradual, but sustained, increase in the numbers of activated CD4 lymphocytes, as measured 
by coexpression of the CD25. These reached a maximum level at 72 hours after feeding 
ISCOMS, by which time the numbers of CD4+ CD25+ cells were twice that of controls 
(Figure 3.10e), It was not possible to measure the numbers of CD8+ CD25+ lymphocytes 
derived from the MLN, as the numbers were so low as to make accurate quantitation 
impossible.
ii) Peyer’s Patch
As in MLN, there was no increase in the numbers of neutrophils recovered from the 
PP at any time after feeding ISCOMS (Figure 3.11a). The numbers of F4/80+ macrophages, 
increased markedly at 3.5 and 7 hours, to levels nearly four times that of controls, but had 
returned to control levels by 24 hours (Figure 3.11a). The numbers of CD llc+ dendritic cells 
in PP changed very little throughout the experiment, and although there was some evidence 
of a transient increase at 3.5 hours, only 50% of these cells expressed MHC II in contrast to 
the dendritic cells in other tissues I examined (Figure 3.1 lb).
A small and transient increase in the numbers of CD4+ T cells was noted at 3.5 hours 
but this then declined before rising gradually to a peak at 72 hours when there was a 50% 
increase in the numbers of CD4+ lymphocytes compared with controls (Figure 3.11c). There 
were no differences in CD8+ T cell numbers at any time after feeding ISCOMS (Figure 
3.11c). There was a small increase in the numbers of B220+ B cells early after feeding
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ISCOMS, but by 24 hours B cells numbers had returned to control levels before rising again 
to reach a plateau from 48 hours onwards, when their numbers were increased by 45% above 
control levels (Figure 3.lid).
The numbers of activated MHC class 11+ macrophages paralleled those of total 
F4/80+ cells, with an early increase up to 7 hours, followed by a return to control levels by 24 
hours and thereafter (Figure 3.11e). There was no alteration in the numbers of CD25+ CD4+ 
lymphocytes at any time after feeding ISCOMS (Figure 3.10e).
Therefore, although oral administration of ISCOMS induces an inflammatory 
response in intestinal lymphoid tissues, this is less intense and more restricted in scope than 
that found after intraperitoneal injection. In addition, an inability to perform statistical 
analysis means that caution is required when interpreting the results.
3.9 Effects of Oral Administration of ISCOMS on the Production of Inflammatory 
Mediators by GALT Cells
After observing that there was some recruitment of inflammatory cells into the GALT, 
I went on to determine if these cells were functionally activated as I had found with PEC. 
Therefore, I isolated MLN and PP cells at different times after a single feed of ISCOMS and 
cultured them in vitro in the presence or absence of ylFN+LPS to examine for production of 
inflammatory mediators.
i) Mesenteric Lymph Node
Control MLN produced a relatively large level of IL-6 spontaneously and this was 
only slightly elevated after stimulation in vitro with ylFN+LPS (Figure 3.12a). Spontaneous
production of IL-6 was completely ablated after a single feed of ISCOMS and did not recover 
to control levels at any point thereafter (Figure 3.12a). The ylFN+LPS induced production of 
IL-6 from MLN was also severely reduced within 3.5 hours of feeding ISCOMS and never
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recovered to that of controls, despite a small rise after 24 hours (Figure 3 .12a). Control MLN 
produced some IL-12 spontaneously and this was more than doubled in the presence of 
ylFN+LPS (Figure 3.12b). Spontaneous IL-12 production was decreased within 3.5 hours of 
feeding ISCOMS to 40% of control levels and did not rise thereafter. ylFN+LPS induced IL- 
12 production was reduced by 50% immediately after a feed of ISCOMS and continued lower 
than normal throughout the time course (Figure 3.12b). Spontaneous production of ylFN by 
control MLN cells was very low, but after restimulation with Con A, ylFN secretion was 
more than 10 times greater (Figure 3.12c). Spontaneous production of ylFN did not vary from 
control levels at any time after feeding ISCOMS (Figure 3.12c). However within 7 hours, the 
Con A induced ylFN levels were reduced by 90%, before steadily returning to control levels 
by 72 hours (Figure 3.12c). No IL -la  or NO production from MLN cells was found at any 
time after feeding ISCOMS (Data not shown).
Thus despite the fact that ISCOMS induced recruitment of inflammatory cells into the 
MLN, these cells fail to produce inflammatory cytokines in this environment
ii) Peyer’s Patch
Control PP produced measurable levels of IL-12 which were not significantly 
elevated after stimulation in vitro with ylFN+LPS (Figure 3.13a). There was a decrease in the 
production of spontaneous IL-12 seven hours after feeding ISCOMS, but this was not 
maintained and levels returned to that of controls within 24 hours (Figure 3.13a). After 
feeding ISCOMS, a slow decrease in ylFN+LPS induced IL-12 production culminated in a 
60% reduction by 24 hours (Figure 3.12a). However, IL-12 levels then began to rise, and by 
48 hours, a very small but significant increase above controls was noted, before levels fell to 
that of controls once more (Figure 3.13a). Spontaneous production of ylFN was not 
detectable in control PP, but Con A induced ylFN could be measured (Figure 3 ,13b). There 
was a small increase in the level of spontaneous ylFN production early after feeding 
ISCOMS, but this returned to control levels by 24 and 48 hours, before evidence of a further 
increase by 72 hours (Figure 3.13b). In contrast, the Con A induced production of ylFN was 
significantly reduced below control levels immediately after feeding ISCOMS and remained
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so for the duration of the experiment (Figure 3,12b). There was no spontaneous or stimulated 
production of NO, IL -la  or IL-6 detectable in the PP cells at any time after feeding ISCOMS 
(Data not shown). These data reflected the small changes in PP cell populations as 
determined by flow cytometry. However, a small increase in activated F4/80 macrophages 
was noted at 7 hours and this may be responsible for the small increase in IL-12 secretion at 
later times. This cytokine production observed in the PP of ISCOMS fed mice was similar to 
that of the MLN, in that the majority of factors were either undetectable or unchanged after 
the administration of ISCOMS.
Summary and Conclusions
The results presented in this chapter indicate that ISCOMS induce intense local 
activation of the innate immune system with the recruitment of a wide variety of 
inflammatory cells including neutrophils, mast cells, dendritic cells, macrophages and 
lymphocytes. This inflammatory cascade is most evident when ISCOMS are administered 
parenterally, where many of the recruited cells were activated, as evidenced by expression of 
surface activation markers and the production of cytokines and other mediators. Oral 
administration of ISCOMS also induced an inflammatory cascade in the GALT, with 
recruitment of activated macrophages, dendritic cells, activated CD4+, CD8+ T cells and B 
cells. However there was no neutrophilia and although these recruited cells showed signs of 
phenotypic activation, very little or no increase in the production of inflammatory cytokines 
and mediators was measured after oral administration of ISCOMS.
In the next chapter, I will describe experiments conducted to determine which if any 
of the inflammatory mediators induced by ISCOMS were important in the induction of 
antigen-specific immunity.
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Figure 3.1 ISCOMS Recruit Inflammatory Cells Following Local Injection.
The graph shows PEC recmitment foUowmg an i.p. injection of 5pg OVA ISCOMS. PEC were removed by 
lavage and cell counts of PEC from the individual mice performed. Tlie results shown are mean PEC numbers 
for three mice + 1 SD (p<0.005 versus saline injected mice).
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Figure 3.2 Histological Examination of PEC after ISCOMS Injection
Cytospin appearances of pooled PEC removed from (a) saline injected mice or (b) 3.5 hours, (c) 7 hours after 
i.p. injection of 5pg OVA ISCOMS. Giemsa staine cytospins were examined by microscopy at x400 
magnification. (Key: RL - resting lymphocyte, MC - mast cell, M(|) - macrophage, N(j) - neutrophil, DMC - 
degranulating mast cell.)
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Figure 3.2 Histological Examination of PEC after ISCOMS Injection
Cytospin appearances of pooled PEC removed from (d) 24 hours, (e) 48 hours and (f) 72 hours alter i.p. 
injection of 5pg OVA ISCOMS. Giemsa stained cytospins were examined by microscopy at x400 
magnification. (Key: RBC - red blood ceil, AL - activated lymphocyte, MC - mast cell, N(j> - neutrophil, AM(|) - 
activated macrophage, RL - resting lymphocyte and E<J) - eosinophil).
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Figure 3.3 Induction of Mast Cell Recruitment and Degranulation by ISCOMS
Mast cells were counted on cytospins of PEC removed at various times after i.p. injection of 5[xg OVA 
ISCOMS. The results shown are the mean numbers of mast cells and degranulating mast cells in ten microscope 
fields at x400 maguilication + 1 SD p<0.01 versus saline injected mice).
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Figure 3.4 Phenotypic Analysis of ISCOMS Recruited PEC.
PEC were removed by lavage after an i.p. injection of 5[jg OVA ISCOMS and analysed by flow cytometry. The 
results shown are the numbers of (a) neutrophils and F4/80+ macrophages, (b) CD4 and CDS T cells, (c) B2201' 
B cells, (d) CDl lc+ dendritic cells, (e) MHC class 11+ F4/80 macrophages and CD25+ CD4 T cells. The results 
are expressed as the number of cells per mouse which were calculated from the percentage of cells positive for 
each marker in the PEC pooled from 5 animals per group. Control mice received saline alone.
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Figure 3.5 ISCOMS Induce Local Secretion of Inflammatory Cytokines by PEC.
Productiou of (a) IL-la , (b) IL-6, (c) immmioreactive IL-12 and (d) ylFN by PEC pooled from 5 mice given an 
i.p. injection of 5pg ISCOMS 3.5-72 hours before. Control mice received saline alone. The results shown are the 
mean concentration of cytokines measured in triplicate after 48 horns stimulation in the presence or absence of 
ylFN+LFS (a-c) or the presence or absence of Con A (d) + 1 SD (* p<0.05 versus sahne injected mice; ** 
p<0.005 versus saline injected mice).
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Figure 3.6 ISCOMS Induced Nitric Oxide Production from PEC
Production of nitric oxide from PEC pooled from 5 mice alter injection of 5|rg ISCOMS or saline. The results 
shown are the mean concentration of nitrite measured in triplicate after cnltuie for 48 hours in the presence or 
absence of ylFN+LPS + 1 SD (* p<0.01 versus saline injected mice).
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Figure 3.7 ISCOMS Induced Production of Reactive Oxygen Intermediates
Production of reactive oxygen intermediates from PEC pooled from 5 animals after injection with 5p,g ISCOMS 
or saline. The results show the release of ROl from 1x10^ PEC as measured by the PMA stimulated 
chemiluminescence of Luminol and are expressed in mV.
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Figure 3.8 Adherent Cells are Required for the Production of ISCOMS Induced Inflammatory Mediators
Production of (a) IL-12, (b) NO, (c) IL-la, (d) IL-6 and (e) ylFN by PEC pooled from 5 mice given an i.p. 
injection of 5pg ISCOMS 48 hours earlier. The results shown are the mean concentration of cytokines from 
supernatants of eitlier whole PEC cultures or of PEC depleted of adherent cells after 48 horns stimulation in the 
presence or absence of ylFN+LPS (a-d) or the presence or absence of Con A (e) + 1 SD ix0.05 versus whole 
PEC cultures; ** p<0.005 versus whole PEC cultures.
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Figure 3.9 Recruitmeut of Inflammatory Cells by a Single Feed of ISCOMS
The graph shows recmitment of (a) MLN and (b) PP cells after a single feed of 200pg OVA ISCOMS. MLN 
and PP tissues were removed from five mice at valions times after oral ISCOMS and cell coimts perfonned. The 
results shown are the mean cell numbers per MLN or PP, calculated from pooled samples. Control mice 
received sahne alone.
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Figure 3.10 Phenotypic Examination of MLN Cells Induced by Oral Administration of ISCOMS
MLN were removed at various times after a single feed of 200pg OVA ISCOMS, pooled and analysed by How 
cytometry. The results shown aie the numbers of (a) neutrophils and Fd/SO"*' macrophages, (b) CD4 and CDS T 
cells, (c) B22CF B cells, (d) CDllc+ dendritic cells and MHC class IH CDllc+ dendritic cells, (e) MHC class 
11+ F4/80 macrophages and CD25'*' CD4 T cells. The results are expressed as the number of cells per MLN, 
calculated from the percentage of cells positive for each marker. Control mice received saline alone.
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Figure 3.11 Phenotypic Examination of PP Cells Induced by Oral Administration of ISCOMS
PP were removed at various times after a single feed of 200jxg OVA ISCOMS, pooled and analysed by flow 
cytometry. The results shown are the numbers of (a) neutrophils and F4/80^ macrophages, (b) CD4 and CDS T 
cells, (c) B22fl+^  B cells, (d) CDl lc+ dendritic cells and MHC class IH CDl lc+ dendritic cells, (e) MHC class 
11+ F4/80 macrophages and CD25+ CD4 T cells. The results are expressed as the number of cells per MLN, 
calculated from the percentage of cells positive for each marker. Control mice received saline alone.
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Figure 3,12 Secretion of Inflanunatot^ Cytokines by MLN After Oral Administration of ISCOMS
Production of (a) IL-6, (b) IL-12 and (c) ylFN by MLN pooled from 5 mice given an i.p. injection of 5pg 
ISCOMS 3.5-72 hours before. Control mice received saline alone. The results shown are the mean concentration 
of cytokines measured in triplicate after 48 hours stimulation in the presence or absence of ylFN+LPS (a, b) or 
the presence or absence of Con A (c) + 1 SD (* p<0.05 versus saline injected mice; * *  p<0.005 versus saline 
injected mice; *** p<0.001 versus saline injected mice).
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Figure 3.13 Secretion of Inflammatoiy Cytokines by PP After Oral Administration of ISCOMS
Production of (a) IL-12 and (b) ylFN by PP pooled from 5 mice after a single feed of 200[rg ISCOMS 3.5-72 
hours before. Control mice received saline alone. The results shown are the mean concentration of cytokines 
measured in tiiphcate after 48 hours stimulation in the presence or absence of ylFN+LPS (a,) or the presence or 
absence of Con A (b) + 1 SD (* p<0.05 versus saline injected mice; p<0.01 versus saline iujected mice).
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Chapter 4
The Importance of ISCOMS Induced Inflammatory Mediators for the 
Generation of Antigen-Specific Immunity 
Introduction
It is currently believed that adjuvants act principally by stimulating different 
components of the innate immune system, with consequent upregulation of costimulatory 
molecules and production of accessory cytokines [Khortus and Jenkins, 1996]. In the 
previous chapter, I showed that ISCOMS are no exception to this theory, being capable of 
inducing a rapid and diverse range of inflammatory effects after parenteral or oral 
administration. In particular, there was a notable increase in the production of a number of 
proinflammatory mediators including “^ FN, IL-6, IL-12 and NO after an i.p. injection or 
feeding of ISCOMS. I felt that it was essential to determine if any of these mediators played a 
role in the generation of antigen-specific immune responses to ISCOMS associated antigen.
Vie had demonstrated previously that oral or parenteral immunisation with OVA- 
ISCOMS induced a wide range of antigen-specific responses, as measured by a number of in 
vitro and in vivo parameters, including delayed type hypersensitivity (DTH), MHC class I 
restricted cytotoxic T cells, as well as antigen-specific proliferation, cytokine and antibody 
production [Maloy et al., 1995, Mowat et al., 1993, Mowat et al., 1991b]. Therefore, in the 
experiments described in this chapter, I monitored these antigen-specific responses in gene- 
targeted knockout animals deficient in IL-6, ylFN, IL-12, iNOS, IL-18 and IL-4.
Experimental Protocol
Female KO mice and appropriate wild type mice all of 6-8 weeks of age, were 
immunised subcutaneously (s.c.) in the rear footpad with 5|ig of OVA ISCOMS in a volume 
of 50pl saline, intraperitoneally (i.p.) with 5p.g of OVA ISCOMS in a volume of 200fxl 
saline, or orally with six consecutive feeds of lOOpg OVA ISCOMS in 200 p,l saline on days
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1, 2,3, 8,9, and 10. Control mice were immunised with saline alone. OVA-specific DTH was 
measured in mice 24 hours after subcutaneous challenge of 100p,g heat aggregated OVA 
(HAO) given in the footpad, seven days after s.c. immunisation or the final feed of OVA 
ISCOMS. Antigen-specific proliferation and cytokine production in response to in vitro 
restimulation with OVA was measured in popliteal lymph nodes removed from animals 14 
days after s.c. immunisation or spleens taken at the same time after the final feed of OVA 
ISCOMS. OVA-specific CTL activity was measured in spleens of mice 7 days after i.p. 
immunisation or 14 days after oral administration of ISCOMS. Antigen-specific antibody 
production was assessed in serum taken 7 days after challenge with HAO. Antigen-specific 
secretory IgA production was measured in intestinal secretions collected 7 days after the final 
feed of ISCOMS.
Results
4.1 Immune Responses to ISCOMS in Interleukin 12 Deficient Mice
I have described earlier that production of IL-12 by ISCOMS recmited PEC was 
greatly enhanced immediately after injection with ISCOMS. IL-12 triggers the production of 
ylFN from NK cells jTrinchieri, 1995] and is responsible for driving the development of ylFN 
producing Thl CD4+ T cells, as well as the differentiation and activation of CTL[Abdi and 
Herrmann, 1997]. IL-12 also regulates the expression of the IL-2Ra and p subunits 
[Robertson et al., 1992, Nuame et al., 1993] on the surface of lymphocytes, meaning that it 
could potentially control T cell proliferation to an immune signal. IL-12 has also been 
implicated in the induction of cell surface IL-8 [Nuame et al., 1993] and so could also be 
involved in initiating the chemotactic compartments of an inflammatory cascade. For these 
reasons I was interested to investigate how IL-12 might regulate ISCOMS induced antigen- 
specific immune responses. To do this, IL-12KO mice on the BALB/c background were used 
for the assessment of antigen-specific DTH, antibody, proliferation and cytokine production
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and IL-12KO mice on the C57BL/6 background were used to measure antigen-specific CTL 
activity.
4.1.1 Antigen-Specific DTH Responses
As anticipated, wild type BALB/c mice showed a good level of OVA-specific DTH 
following s.c. immunisation with OVA ISCOMS (Figure 4.1a) and there was an even better 
response in orally immunised mice (Figure 4.1b). IL-12KO mice had dramatically decreased 
DTH responses after s.c. immunisation (Figure 4.1a) and these were also reduced by 50% in 
orally immunised IL-12KO mice (Figure 4.1b).
4.1.2. OVA-Specific Proliferative Responses
Lymph node cells from wild type BALB/c mice immunised with OVA ISCOMS s.c 
or orally generated good proliferative responses on restimulation with OVA in vitro. These 
were reduced by 40-60% in IL-12KO mice (Figure 4.2a and b).
4.1.3. Antigen-Specific Cytokine Production
OVA ISCOMS induced antigen specific production of ylFN from wild type BALB/c 
PLN after s.c. immunisation (Figure 4.3a), and from the spleen after oral immunisation 
(Figure 4.3b). Wild type mice also produced OVA-specific IL-5 after s.c. (Figure 4.3c) and 
oral immunisation (Figure 4.3d). As expected, IL-12KO mice produced virtually no OVA- 
specific ylFN in response to s.c. or oral immunisation (Figure 4.3a and b), but interestingly, 
these animals also had a 40% reduction in antigen-specific IL-5 production after s.c. 
immunisation (Figure 4.3c). However, orally immunised IL-12KO animals showed 
significantly increased levels of IL-5, which were twice that of wild types (Figure 4.3d).
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4.1.4 OVA-Specific CTL Activity
Wild type C57B1/6 mice generated good OVA-specific CTL responses after i.p. 
immunisation (Figure 4.4a). In IL-12KO animals, OVA-specific CTL activity was 
significantly reduced compared to that in wild type mice, with responses in the order of 50- 
60% that of normal animals (Figure 4.6.4a). There was no lysis of non OVA~expressing EL4 
cells by any cell population. Orally immunised wild type animals produced strong OVA- 
specific CTL responses (Figure 4.4b), with IL-12KO mice showing a slight reduction in the 
CTL activity at high effector : target cell ratios compared with wild type mice, but when less 
effector cells were used, this difference was not so obvious (Figure 4.4b).
4.1.5 Serum IgG Isotypes
Wild type BALB/c animals produced large amounts of OVA-specific IgG2a and IgGl 
antibodies after s.c. immunisation with ISCOMS (Figure 4.5a and b). IgG2a levels were 
significantly decreased in IL-12KO mice but the mice had normal production of IgGl 
antibodies, (Figure 4.5a and b). Orally immunised wild type animals produced OVA-specific 
IgGl antibodies in serum and these responses were significantly increased in IL-12KO 
animals (Figure 4.5c). Neither wild type nor IL-12KO mice produced any IgG2a antibodies 
after oral immunisation in this experiment.
4.1.6 Secretory Intestinal IgA Antibody Production
Wild type BALB/c and IL-12KO BALB/c mice produced equivalent amounts of 
secretory IgA antibodies in gut washes after oral immunisation (Figure 4.6).
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4.1.7 Summary
IL-12KO mice have a severely impaired antigen-specific immune response to OVA 
ISCOMS compared with wild type controls. The defect in OVA-specific immunity is more 
dramatic after s.c. immunisation, where IL-12KO mice generally produced less than half the 
level of immunity of their wild type counterparts for all the parameters measured in vivo and 
in vitro, including both Thl and Th2 type responses. A similar defect was seen in orally 
immunised IL-12KO mice, but in this case immune responses were generally only reduced by 
approximately 30-40%. In addition some responses, such as OVA-specific IgA, IL-5 and 
IgGl production, were either equivalent to, or increased compared with wild type controls 
after oral immunisation. Thus IL-12 plays an important role in the generation of ISCOMS 
induced OVA-specific immunity, but this is partly dependent on the route of immunisation 
used, apparently being important when ISCOMS are given subcutaneously than orally. The 
residual responses present in IL-12KO mice show that IL-12 is clearly not the sole factor 
required for the generation of antigen-specific immunity and so I went on to investigate other 
factors induced during an ISCOMS induced inflammatory cascade, which might replace or 
synergise with IL-12.
4.2 Immune Responses to ISCOMS in IL-18 Deficient Mice
IL-18 is a recently described cytokine which is part of the IL-1 family of proteins. It is 
secreted early in inflammation by a wide variety of cells including APC, kératinocytes and 
epithelial cells [Kohno and Kurimoto, 1998]. It is known to induce the activation of ylFN 
from NK cells and T cells, thus having similar properties to IL-12 [Okamura et al., 1998a, 
Okamura et al., 1995]. I had not been able to measure the presence of IL-18 after ISCOMS 
injection, because of the absence of a suitable ELISA, but the fact that IL-12KO mice had 
persistent responses to ISCOMS suggested that it would be useful to investigate whether IL- 
18 played a role. Mice deficient in IL-18 (IL-18KO) had been recently generated in this 
department by Dr. X-Q. Wei and I therefore performed a preliminary examination of antigen-
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specific immune responses to ISCOMS in wild type M Fl, heterozygous (IL-18+/") and ÏL- 
18KO animals.
4.2.1 Antigen-Specific DTH Responses
A single s.c. immunisation of OVA ISCOMS in the footpad induced a large DTH 
response in wild type MFl animals, but homozygous 1L-18KO animals showed almost 
complete ablation of the OVA-specific DTH response and IL~18+^“ heterozygous mice also 
had significantly reduced DTH responses compared with wild types (Figure 4.7a). Six feeds 
of OVA ISCOMS also induced a strong DTH response in wild type animals, but in contrast 
to s.c. immunised animals, orally immunised homozygous IL-18KO and IL-18+/- 
heterozygous mice bad normal DTH responses (Figure 4.7b).
4.2.2 Antigen-Specific Proliferative Responses
Wild type mice immunised with s.c. OVA ISCOMS produced a good level of antigen- 
specific proliferation on restimulation with OVA in vitro and identical responses were 
obtained in homozygous and heterozygous IL-18KO mice (Figure 4.8). Unfortunately, I 
obtained no results from the proliferation assays set up from spleen cells taken from orally 
immunised mice.
4.2.3. Antigen-Specific Cytokine Production
Wild type animals immunised s.c. with OVA ISCOMS produced large amounts of 
■ylFN when restimulated with OVA in vitro, as did heterozygous and homozygous IL-18KO 
mice (Figure 4.9a). Subcutaneously immunised wild type mice also produced a large amount 
of OVA-specific IL-5 and again there was no difference in the heterozygous or homozygous 
IL-IBKO mice (Figure 4.9b). Wild type animals immunised orally with ISCOMS produced a 
large amount of ylFN, but neither heterozygous nor homozygous IL-18KO mice produced
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significant levels of ylFN (Figure 4.9c). Wild type mice also produced OVA-specific IL-5 
and this was elevated to nearly three times that of wild type levels in both heterozygous and 
homozygous IL-18KO mice (Figure 4.9d).
4.2.4, Antigen-Specific CTL Activity
Wild type animals were primed for good antigen specific CTL activity after six feeds 
of OVA ISCOMS (Figure 4.10). There was no difference in the degree of cytotoxicity 
between either homozygous or heterozygous IL-18KO animals and wild types (Figure 4.10). 
Unfortunately there was not enough mice at this time to perform parallel experiments in 
parenterally immunised IL-18KO mice.
4.2.5, Serum IgG Antibody Production
Wild type animals were primed for IgGl and IgG2a antibody production after s.c. 
immunisation with OVA ISCOMS and equivalent secondary responses occurred in 
heterozygous and homozygous IL-18KO mice (Figures 4.11a and b). Wild type mice given 
six feeds of OVA ISCOMS were also primed for IgGl and IgG2a antibody production, as 
were heterozygous and homozygous IL-18KO mice (Figures 4.1 Ic and d).
4.2.6 Summary
Thus IL-18KO mice appear to have some defect in immune responses to ISCOMS. 
However, no consistent pattern was observed for either route of administration, or for 
individual components of the immune response, even those which IL-18 is thought to be 
important, such as ylFN production. Unfortunately, no further mice were available for these 
experiments to be repeated during the course of my project, but in view of the defects of IL- 
12KO mice and possibly IL-18KO mice, I went on to investigate the role of mediators 
downstream of these cytokines, beginning with ylFN, using ylFNRKO mice.
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4.3. Immune Responses to ISCOMS in ylnterferon-Receptor-DejRcient Mice
ylFN is essential for many aspects of effector immune responses, being central to the 
maintenance of the Thl polarised response [Maggi et af, 1992] and assisting the generation 
of class I MHC-restricted CTL[Scott and Kaufman, 1991]. As a result, it is often difficult to 
induce such responses or protective immunity to intracellular pathogens, in mice lacking 
ylFN or its receptor [Buchmeier and Schreiber, 1985, Scott, 1991, Schijns et al., 1994]. 
ISCOMS are potent inducers of Thl dependent responses in vivo, as well as CTL activity 
[Maloy et al., 1995, Mowat et al., 1991b, Mowat et al., 1993] and I showed in Chapter 3 that 
ylFN production was one of the components of early inflammatory response to ISCOMS. 
Therefore it seemed important to determine if ylFN was required for the induction of local 
and systemic immune responses by ISCOMS. To do this I used "^iFNRKO mice which lack 
functional ylFN.
4.3.1 OVA-SpecilRc DTH Responses
Subcutaneously immunised wild type mice produced low but significant antigen- 
specific DTH responses upon challenge with HAO and unexpectedly, s.c immunised 
ylFNRKO mice had a significantly increased DTH response compared with wild type mice 
which was four times greater than wild type mice (Figure 4.12a). Wild type animals fed OVA 
ISCOMS produced good DTH responses and there was no significant difference in the DTH 
responses in orally immunised ylFNRKO mice as compared to wild type mice (Figures 
4.12b).
4.3.2 OVA-Specific Proliferative Responses
Wild type mice immunised with OVA ISCOMS generated strong proliferative 
responses on restimulation with OVA in vitro after both subcutaneous or oral immunisation
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(Figure 4.13a and b). Proliferative responses were significantly enhanced in s.c. immunised 
ylFNRKO mice (Figure 4.13a), but these were significantly decreased in orally immunised 
ylFNRKO animals (Figure 4.13b).
4.3.3 OVA-Specific Cytokine Production
Subcutaneous immunisation with OVA ISCOMS induced a low but significant level 
of antigen specific ylFN from wild type mice and this was significantly enhanced in 
ylFNRKO mice (Figure 4.14a). Subcutaneous immunisation with OVA ISCOMS also primed 
antigen-specific IL-5 production in wild type mice and this was nearly twice as high in 
ylFNRKO mice (Figure 4.14b). In general, the antigen-specific cytokine production was 
much less in orally immunised mice than following s.c. immunisation with ISCOMS. Oral 
immunisation with OVA ISCOMS induced a low level of antigen-specific ylFN production 
from wild type mice and this was increased in ylFNRKO mice to three times that of wild type 
animals (Figure 4.14c). Six consecutive feeds of OVA ISCOMS also primed low levels of 
antigen-specific IL-5 production in wild type mice and ylFNRKO mice produced IL-5 
responses that were approximately 6 times greater than wild type animals (Figure 4.14d).
4.3.4. OVA-Specific CTL Responses
Wild type mice generated good OVA-specific CTL responses after i.p. immunisation, 
as did ylFNRKO mice, which showed normal levels of OVA-specific CTL activity (Figures 
4.15a). Wild type animals also produced good OVA-specific CTL responses after feeding 
OVA ISCOMS and these were somewhat elevated in ylFNRKO mice fed ISCOMS (Figure 
4.15b).
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4.3.5 Antigen-Specific Serum IgG Production
OVA ISCOMS primed for good secondary humoral immune responses in wild type 
mice when administered orally or as a s.c. immunisation. As expected, ylFNRKO mice 
showed increased production of IgGl and reduced IgG2a antibodies when ISCOMS were 
given subcutaneously (Figure 4 .16a and b),
4.3.6 OVA-Specific Intestinal IgA Production
Wild type mice had significant induction of IgA antibodies in gut washes following 
six consecutive feeds of OVA ISCOMS and these were greatly increased in the absence of 
functional ylFN (Figure 4.17).
4.3.7 Summary
Thus, immune responses to either oral or parenteral immunisation with OVA 
ISCOMS are essentially normal, or even increased, in the absence of functional ylFN. Despite 
the high level of inflammatory ylFN released immediately after exposure to ISCOMS, as well 
as some evidence for the role of the ylFN inducing cytokines IL-12 and IL-18, it appeared 
that ylFN did not directly promote the generation of the antigenic immunity induced by OVA 
ISCOMS. Therefore I carried out further investigations into the involvement of other 
cytokines that are known to direct the immune response.
4.4 Immune Responses to ISCOMS in Interleukin 6 Deficient Mice
In Chapter 3, I showed that ISCOMS induced a large non-specific increase in 
secretion of IL-6 after a parenteral injection. This is consistent with the role of this cytokine 
in the early acute inflammatory response [Baumann and Gauldie, 1994, Kopf et al., 1994] and 
also with reports that IL-6 is involved with the generation of protective antigen-specific
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immune responses in vivo against Candida albicans [Romani et aL, 1996], Listeria 
monocytogenes [Kopf et aL, 1994] and Mycobacterium avium [Appelberg et aL, 1994]. In 
addition, it has been suggested that lL-6 acts as an early inducer of Th2 responses [Rincon et 
aL, 1997] and there has been disputed evidence that mucosal IgA responses in IL-6KO mice 
may be defective [Ramsay e t  a l . ,  1994] [Ramsay et aL, 1994, Bromander et aL, 
1996]. Thus I investigated if IL-6 played any part in the development of acquired immune 
responses to OVA ISCOMS using IL-6 deficient (IL-6KO) mice. In these studies, I first 
performed preliminary experiments using the subcutaneous route and, in view of the results 
obtained and the difficulty in obtaining access to the mice, I carried out very few oral 
immunisation studies.
4.4.1 Antigen-Specific DTH Responses
Wild type 129/Sv animals produced good antigen-specific DTH responses seven days 
after a s.c. immunisation of OVA ISCOMS and there was no significant difference in the 
DTH response in IL-6KO mice (Figure 4.18).
4.4.2 Antigen-Specific Proliferative Responses
Wild type mice immunised with OVA ISCOMS subcutaneously generated good 
proliferative responses on restimulation with OVA in vitro and identical results were obtained 
in IL-6KO mice (Figure 4.19).
4.4.3 Antigen-Specific Cytokine Production
Subcutaneous immunisation with OVA ISCOMS primed very low antigen-specific 
ylFN (Figure 4.20a) and IL-5 (Figure 4.20b) production in wild type mice. Normal ylFN 
production was measured after s.c. immunisation in IL-6KO mice (Figure 4.20a), but OVA- 
specific IL-5 in IL-6KO mice was twice that of the wild type animals (Figure 4.20b).
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4.4.4 Antigen-Specific CTL Activity
Wild type SVJ mice generated good OVA-specific CTL responses after i.p. 
immunisation with OVA ISCOMS and identical responses were found with IL-6KO mice 
(Figure 4.21), There was no killing of the non-antigen expressing EL4 cells.
4.4.5 Antigen-Specific Serum IgG Antibody Production
Wild type mice produced OVA-specific IgGl and IgG2a when immunised 
subcutaneously with OVA ISCOMS (Figure 4.22a and b). There was no difference in the 
levels of either IgG isotype obtained in IL-6KO mice (Figure 4.22a and b).
4.4.6 Summary
Thus the absence of IL-6 does not impair the generation of antigen-specific immune 
responses after immunisation with OVA ISCOMS. In light of this information I went on to 
investigate the influence of another of the Th2 cytokines, IL-4.
4.5. Antigen-Specific Responses to ISCOMS in Interleukin 4 Deficient Mice
Previous results had shown that ISCOMS primed a number of Th2 responses, 
including antigen-specific cytokines as well as serum IgGl antibodies [Maloy et al., 1995] 
and recently, the oral adjuvant properties of cholera toxin (CT), another potent mucosal 
vaccine vector, were found to be entirely dependent on the presence of IL-4 in vivo [Vajdy et 
al., 1995]. Therefore it was important to investigate the role of this cytokine in ISCOMS 
induced immunogenicity.
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4.5.1. Antigen-Specific DTH Responses
As expected, wild type mice had significant DTH responses when challenged 7 days 
after subcutaneous immunisation with OVA ISCOMS. These were significantly greater in IL- 
4KO mice (Figure 4.23a). Wild type animals fed OVA ISCOMS also produced strong DTH 
responses when challenged with HAO seven days after the final feed, but there was no 
significant difference in the DTH results obtained in orally immunised IL-4KO mice (Figures 
4.23b).
4.5.2. Antigen-Specific Proliferative Responses
Wild type mice immunised with OVA ISCOMS subcutaneously generated good 
proliferative responses from PLN cells after restimulation with OVA in vitro and these were 
significantly enhanced in IL-4KO mice to 5 times of those in wild type animals (Figure 
4.24a). A similar pattern was observed in the spleens of orally immunised wild type mice and 
IL-4KO mice (Figure 4.24b).
4.5.3. Antigen-Specific Cytokine Production
Subcutaneous immunisation with OVA ISCOMS primed good antigen-specific 
production of ylFN from wild type splenocytes and, as expected, IL-4KO mice showed a 
dramatic increase in the level of antigen-specific ylFN production (Figure 4.25a). OVA- 
specific IL-5 production was also induced in wild type mice, and as expected, this was 
significantly reduced in IL-4KO mice (Figure 4.25b). Six feeds of OVA ISCOMS primed 
only low levels of antigen-specific ylFN production in wild type mice (Figure 4.25c) and no 
OVA-specific IL-5 production (Figure 4.25d). As before, orally immunised IL-4KO mice had 
significantly increased production of ylFN (Figure 4.25c), but unexpectedly, also showed 
some residual production of IL-5, although this was very low in comparison to that obtained 
in s.c. immunised animals (Figure 4.25d).
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4.5.4. Antigen-Specific CTL Activity
Wild type mice generated good OVA-specific CTL responses after i.p. immunisation 
with OVA ISCOMS (Figure 4.26a) and also significant CTL activity after oral immunisation 
(Figure 4.26b). IL-4KO mice were primed for identical levels of OVA-specific CTL activity 
after i.p. immunisation (Figure 4.26a), and also had CTL activity after oral immunisation, 
although the levels that were approximately 30% less than those in wild type animals (Figure 
4.26b). There was no killing of the non-OVA expressing EL4 cell line.
4.5.5 Antigen-Specific Serum IgG Antibody Production
Wild type animals produced antigen-specific IgGl and IgG2a antibodies after both 
subcutaneous and (Figures 4.27a, b). As expected, IL-4KO mice had decreased levels of IgGl 
and elevated IgG2a antibody in serum after either subcutaneous or oral immunisation with 
OVA ISCOMS (Figures 4.27a, b).
4.5.6. Increased Production of Intestinal Secretory IgA in IL-4KO Mice
Fourteen days after the last of six feeds of OVA ISCOMS, wild type mice had good 
OVA-specific secretory IgA production as measured in gut washes. This was significantly 
increased in orally immunised IL-4KO mice (Figure 4.28).
4.5,7 Summary
Thus, apart from the expected defects in Th2 activity, IL-4KO mice generate normal 
immune responses to either oral or parenteral immunisation with ISCOMS. I therefore went 
on to examine the last of the inflammatoiy mediators induced by injection of ISCOMS, 
namely NO.
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4.6 Immune Responses to ISCOMS in Inducible Nitric Oxide Synthase 
Deficient Mice
In the previous chapter, I showed that NO levels increased dramatically after an 
injection of ISCOMS into the peritoneum. During inflammation, NO is produced mainly via 
the action of inducible nitric oxide synthase (iNOS) and it plays an important part in 
regulating several aspects of inflammation, including blood supply [Moncada et a l, 1991], 
macrophage microbicidal activity [Nathan and Hibbs, 1991] and IL-12 production [Huang et 
a l, 1998]. There has recently been evidence that iNOS deficient mice are unable to control L. 
major infection [Wei et a l, 1995]. Therefore I investigated the role of inflammatory NO in 
the development of antigen-specific immune responses to OVA ISCOMS using iNOS 
deficient mice (iNOSKO), The experiments shown, only examined the responses to 
subcutaneous immunisation, as these mice were being bred onto an inbred background whilst 
my project was being concluded and before I could perform studies of oral immunisation.
4.6.1 Antigen-Specific DTH Responses
Wild type animals given a s.c. immunisation of OVA ISCOMS produced a good 
OVA-specific DTH response when challenged with HAO one week later and there was no 
significant difference in the DTH response obtained in iNOSKO mice (Figure 4.29).
4.6.2 Antigen-Specific Proliferative Responses
Wild type MFl mice immunised with OVA ISCOMS subcutaneously generated good 
proliferative responses upon restimulation with OVA in vitro (Figure 4.30). Although, there 
was a slightly reduced proliferative response in iNOSKO mice, this was not statistically 
significant (Figure 4,30).
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4.6.3 Antigen-Specific Cytokine Production
Subcutaneous immunisation with OVA ISCOMS induced antigen-specific production 
of ylFN from wild type mice and this was significantly reduced in iNOSKO mice (Figure 
4.31a). Subcutaneous immunisation also primed antigen-specific IL-5 production in wild type 
mice, although this was low compared with that found in other experiments. iNOSKO mice 
showed reduced levels of OVA-specific IL-5 production which were four times lower than 
those in wild type animals (Figure 4.31b).
4.6.4 Antigen-Specific Serum IgG Antibody Production
Wild type and iNOSKO mice produced low, but similar levels of both IgGl and 
IgG2a antibodies after challenge with HAO (Figure 4.32a and b).
4.6.5 Summary
The absence of functional iNOS and thus a reduction in the production of 
inflammatory NO did not affect many of the antigen-specific immune responses generated by 
subcutaneous immunisation with OVA ISCOMS. The only alteration in OVA-specific 
immunity in iNOS mice was the reduction in cytokine production which affected IL-5 and 
ylFN equally. Therefore, there is a possible defect in these mice but, given that these were 
preliminary experiments, it is a priority to repeat studies with the iNOSKO mice with 
measurement of a full range of immune parameters after both parenteral and oral 
immunisation.
Summary and Conclusions
The results presented in this chapter show that even though ISCOMS induce a wide 
range of non-specific inflammatory mediators in vivo, their mucosal and systemic adjuvant
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effects are expressed normally in mice lacking the function of most of these factors, including 
IL-4, IL-6 and ylFN- Systemic DTH, class I MHC-restricted CTL responses and humoral 
immunity in vivo, as well as antigen-specific proliferation and cytokine production in vitro, 
together with intestinal secretory antibody responses where measured, were induced normally 
after either oral or parenteral immunisation of mice deficient in these factors.
However, the adaptive immune response to ISCOMS was at least partly dependent on 
the presence of IL-12, as mice deficient in IL-12 appeared to have significantly decreased 
immune responses when immunised with OVA ISCOMS parenterally. The majority of 
responses were also significantly reduced in orally immunised IL-12KO mice, but the 
reduction under these circumstances was not as dramatic as with s.c. immunised animals and 
some responses such as intestinal IgA secretion were entirely normal. Preliminary studies in 
IL-18KO mice suggested that some immune responses may also have been dependent on the 
complimentary cytokine IL-18, although the pattern was less clear and the experiments need 
repeated and extended. The study in iNOSKO mice also suggests that some aspects of the 
OVA-specific response may be altered in these animals, but these experiments were also 
preliminary and need to be repeated and extended.
Together, these findings emphasise ; that the scope of action of ISCOMS may
not be limited by the absence of many individual regulatory cytokines, perhaps because they 
have an ability to exploit redundant cytokines. To try and explore in more detail how these 
inflammatory mediators help to regulate the induction adaptive immune responses to 
ISCOMS, in the next chapter I will describe the innate immune responses which were 
induced in the different knockout mice and will indicate how these correlate with antigen- 
specific immunity in the same animals.
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Figure 4.1 Antigen-Specific DTH in OVA ISCOMS Immunised IL-12 KO mice.
The graph shows OVA specific DTH responses measured 24 hours after subcutaneous challenge into the 
footpad with lOOpg HAO. Mice were immunised with either (a) 5pg OVA ISCOMS in 50|d saline 
subcutaneously into the rear footpad or (b) six feeds of lOOpg OVA ISCOMS in 200p,l saline. The results 
shown are the mean specific increments in footpad thickness of 5 animals per group ± 1 SD, measured 7 days 
after the last immunisation (^=*p<0.005, * p<0.05 verses wild type BALB/c mice). The background footpad 
increment obtained in imimmiinised animals has been subtracted.
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Figure 4.2 Antigen-Specific in vitro Proliferation in OV A-ISCOMS Immunised BL-12KO Mice.
OVA specific proliferative responses were measured in PLN removed (a) 14 days after a single subcutaneous 
immunisation in the rear footpad wiüi 5pg OVA ISCOMS in 50pl saline or (b) 14 days after the last of 6 feeds 
of lOOpg OVA ISCOMS in 200pl sahne. The graph shows the mean OVA-specific proliferation following a 96 
hour culture with Img/ral OVA as determined by incorporation of thymidine into DNA after 16 hours 
incubation. Results are shown as mean counts of quadruplicate cultures of cells pooled from 5 animals ± 1 SD 
(*p<0.05 verses wild type BALB/c mice). Background proliferation from control animals has been subtracted.
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Figure 4.3 Antigen-Specific T Cell Cytokine Production in OVA ISCOMS Innxiunised IL-12KO Mice.
OVA-specific ylFN (a) and IL-5 (b) production after s.c. immunisation with 5[xg OVA ISCOMS. OVA-specific 
ylFN (c) and IL-5 (d) production following six feeds of lOOpg OVA ISCOMS. The results are shown as means 
± 1 SD of tiiplicate cultures using cells pooled from 5 mice per group, 14 days after tire last immunisation. 
Background cytokine production from control animals has been subtracted. (*p<0.05, p<0.001 verses wild
type BALB/c mice).
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Figure 4.4 Antigen-SpeciClc MHC Class I -Restricted CTL Activity in OVA ISCOMS immunised XL* 
12KO Mice.
OVA-specific CTL activity in spleens of IL-12K0 or C57B1/6 wild type mice, seven days after tlie last 
immunisation with either (a) a single i.p. immunisation of 5pg OVA ISCOMS in 200pl sahne or (b) 14 days 
after the final of 6 feeds of lOOpg OVA ISCOMS in 200[xl saline. Spleens from. 5 animals were pooled and 3 x 
10^ cells restimulated with 1.5 x 10^ mitomycin c treated OVA expressing EG7.0VA cells. Tlie results show 
tlie % cytotoxicity calculated from quadmphcate samples, Antigen-specificity was deteimined by the degiee of 
lysis of non-OVA expressing EL4 cells.
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Figure 4.5 Antigen-Specibc Serum IgG Isotype in OV A-ISCOMS Immunised IL-12KO Mice.
OVA-specific IgGl (a and c) and IgG2a (b) antibody levels in sen\m, 7 days after s.c, challenge of HAO in mice 
immunised s.c. (a and b) or orally (c) with OVA ISCOMS. The results show the reciprocal dilutions of serum 
from individual mice which produced the equivalent O.D. 630nm to a 5% dilution of a standard anti-OVA 
senim (*p<0.05 verses wild type mice). The control levels are from mice that received HAO only.
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Figure 4.6 Antigen-Specific Intestinal IgA Production in OVA ISCOMS Immunised BL-12KO Mice.
IgA secretion from the small intestine was assessed in gut washes by ELISA seven days after the last six feeds 
of lOOpg OVA ISCOMS. The results shown are the mean OD 405nm of triplicate samples from 5 mice ± ISD. 
Background IgA production from contr ol animals has been subtracted.
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Figure 4.7 Antigen-Specific DTH in OVA ISCOMS Immunised ÏL-1SKO mice.
The graph shows OVA specific DTH responses measured 24 horns after subcutaneous challenge into tlie 
footpad with lOOpg HAO. Heterozygous (Ih-18KO‘ '^ '), homozygous (IL-18KO''^") or wild type mice were 
immunised with either (a) 5pg OVA ISCOMS in 50pl saline subcutaneously into the rear footpad or (b) six 
feeds of lOOpg OVA ISCOMS in 200pl saline. The results shown are the mean specific increments in footpad 
thickness of 5 animals per group ± 1 SD, measured 7 days after tlie last immunisation (**p<0.001, * p<0.01 
verses wild type mice). The background footpad increment obtained in unimmunised animals has been 
subtracted.
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Figure 4.8 Antigen-Specific in vitro Proliferation in OV A-ISCOMS Inununised IL-I8KO Mice.
OVA specific proliferative responses were measured in PLN removed from heterozygous (IL-18K0'^^"), 
homozygous (ILT8KO"/) or wild type mice 14 days after s.c. immunisation with 5pg OVA ISCOMS in 50pl 
saline. The graph shows the mean OVA-specific proliferation following a 96 hour cultuie with Img/ml OVA as 
determined by incorporation of thymidine into DNA after 16 horns incubation. Results are shown as mean 
counts of quadruplicate cultures of cells pooled from 5 animals ± 1 SD (*p<0.05 verses wild type mice). 
Background proliferation from control animals has been subtracted.
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Figure 4.9 Antigen-Specific T Cell Cytokine Production in OVA ISCOMS Immunised IL-ISKO Mice.
OVA-specific ylFN (a) and IL-5 (b) production after s.c. immunisation with 5pg OVA ISCOMS. OVA-specific 
ylFN (c) and IL-5 (d) production following six feeds of lOOpg OVA ISCOMS. The results are shown as means 
+ 1 SD of tiiplicate cultures using cells pooled from 5 mice per group, 14 days after the last immunisation. 
Background cytokine production from control animals has been subtracted. (*p<0.05, ** p<0.001 verses wild 
type mice).
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Figure 4.10 Antigen-Specific MHC Class I -Restricted CTL Activity in OVA ISCOMS immunised IL- 
18KO Mice.
OVA-specific CTL activity in spleens 14 days alter the final of 6 feeds of lOOpg OVA ISCOMS in 200pl saline. 
Spleens from 5 animals were pooled and 3 x 10^ cells restimulated with 1.5 x 10^ mitomycin c treated OVA 
expressing EG7.0VA cells. The results show the % cytotoxicity calculated from quadruplicate samples.
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Figure 4.11 Antigen-Specific Serum IgG Isotype in OV A-ISCOMS Immunised IL-18KO Mice.
OVA-specific IgGl (a and c) and IgG2a (b and d) antibody levels in serum, 7 days after s.c. challenge of HAO 
in mice immunised s.c. (a and b) or orally (c and d) with OVA ISCOMS. The results show the reciprocal 
dilutions of serum from individual mice which produced the equivalent O.D. 630nm to a 5% dilution of a 
standard anti-OVA serum. The control levels are from mice that received H /\0 only.
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Figure 4.12 Antîgen-Speciflc DTH in OVA ISCOMS Inununised ylFNRKO mice.
The graph shows OVA specific DTH responses measured 24 hours after subcutaneous challenge into the 
footpad with lOOpg HAO. Mice were immunised with either (a) 5pg OVA ISCOMS in 50pl sahne 
subcutaneously into the rear footpad or (b) six feeds of lOOpg OVA ISCOMS in 200pl sahne. The results 
shown aie the mean specific increments in footpad thickness of 5 animals per group ± 1 SD, measmed 7 days 
after the last immunisation (*p<0.01 verses wild type C57B1/6 mice). The background footpad increment 
obtained in unimmunised animals has been subtracted.
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Figure 4.13 Ântigen-Specific in vitro Proliferation in OV A-ISCOMS Immunised ylFNRKO Mice.
OVA specific proliferative responses were measured in PLN removed (a) 14 days after a single subcutaneous 
immunisation in the rear- footpad with 5pg OVA ISCOMS in 50pl sahne or (b) 14 days after the last of 6 feeds 
of lOOpg OVA ISCOMS in 200pl saline. The graph shows the mean OVA-specific proliferation following a 96 
hour cultme with Img/ml OVA as determined by incorporation of thymidine into DNA after 16 hours 
incubation. Results are shown as mean counts of quadruplicate cultmes of cells pooled from 5 animals ± 1 SD 
('■"p<0.05, *p<0.001 verses wild type C57B1/6 mice). Background proliferation from control animals has been 
subtracted.
1 0 1
Io
2 -
1 -
*
I
g
td
laI
b
100-1
80
60
40
20 -
Wild Type IFNRKO WildTyiJe IFNRKO
1
I
3 -
1 -
8n
Wüd Type IFNRKO
IV)
dIi 2 -
Wild Type IFNRKO
Figure 4.14 Antigen-Specific T Cell Cytokine Production in OVA ISCOMS Immunised ylFNRKO Mice.
OVA-specific ylFN (a) and IL~5 (b) production from PLN after s.c. immunisation witli OVA ISCOMS, and 
OVA-specific ylFN (c) and IL-5 (d) production from spleen following six feeds of 100p.g OVA ISCOMS. The 
results are shown as means ± 1 SD of triplicate cultures using cells pooled from 5 mice per group, 14 days after 
the last immunisation. Backgioimd cytokine production from control animals has been subtracted. (*pc0.05, ** 
p<0.005 verses wild type C57B1/6 mice).
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Figure 4.15 Autîgen-Specifîc MHC Class I-Restrieted CTL Activity in OVA ISCOMS immunised 
ylFNRKO Mice,
OVA-specific CTL activity in spleens seven days after the last immunisation with either (a) a single i.p. 
immunisation of 5[rg OVA ISCOMS in 200p,l saline or (b) 14 days after the final of 6 feeds of lOOpg OVA 
ISCOMS in 200pl saline. Spleens from 5 animals were pooled and 3 x 10  ^cells restimulated with 1.5 x 10^ 
mitomycin c treated OVA expressing EG7.0VA cells. The results show tlie % cytotoxicity calculated from 
quadruplicate samples. Antigen-specificity was determined by the degree of lysis of non-OVA expressing EL4 
cells.
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Figure 4,16 Antigen-Specific Serum IgG Isoiype in OVA-ISCOMS Immunised ylFNRKO Mice.
OVA-specific IgGl (a) and XgG2a (b) antibody levels in serum, 7 days after s.c. challenge of HAO in mice 
immunised s.c with OVA ISCOMS. The results show the reciprocal dilutions of serum from individual mice 
which produced the equivalent O.D. 630mn to a 5% dilution of a standard anti-OVA serum (p<0.005 versus 
wild type mice). The control levels are from mice that received FIAO only.
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Figure 4.17 Antigen-Specific Intestinal IgA Production in OVA ISCOMS Immunised ylFNRKO Mice.
IgA secretion from the small intestine was assessed in gut washes by ELISA seven days after the last six feeds 
of 100[xg OVA ISCOMS. The results shown are the mean OD 405nm of triplicate samples from 5 mice ± ISD 
(*p<0.01 versus wild type C57B1/6 mice). Backgroimd IgA production from control animals has been 
subtracted.
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Figure 4.18 Antigen-Specific DTH în OVA ISCOMS Immunised IL-6KO mice.
The graph shows OVA specific DTH responses measured 24 hours after subcutaneous challenge into the 
footpad with lOOpg HAO. Mice were immunised with %g OVA ISCOMS in 50pl saline subcutaneously into 
the rear footpad. The results shown are tlie mean specific increments in footpad tliickness of 5 animals per group 
± 1 SD, measured 7 days after the last immunisation. The backgroimd footpad increment obtained in 
unimmunised annuals has been subtracted.
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Figure 4.19 Antigen-Specific in vitro Proiifemtion in OV A-ISCOMS Immunised IL-6KO Mice.
OVA specific proliferative responses were measured in PLN removed 14 days after a single subcutaneous 
immunisation in the rear footpad with 5{xg OVA ISCOMS in 50pl saline. The graph shows the mean OVA- 
specific proliferation following a 96 hour culture with Img/ml OVA as determined by incorporation of 
t^ PT) thymidine into DNA after 16 horn's incubation. Results are shown as mean counts of quadmplicate cultures 
of cells pooled from 5 animals ± 1 SD. Background proliferation from control animals has been subtracted.
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Figure 4.20 Antigen-Specific T Cell Cytokine Production in OVA ISCOMS Immunised EL-6KO Mice.
OVA-specific ylFN (a) and IL-5 (b) production after s.c. immunisation with 5pg OVA ISCOMS. The results are 
shown as means ± 1 SD of triplicate cultiues using cells pooled from 5 mice per group, 14 days after the last 
immunisation. Backgiound cytokine production from control animals has been subtracted. ("'p<0.05 verses wild 
type 129/S V mice).
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Figure 4.21 Antigen-Specific MHC Class I-Restricted CTL Activity in OVA ISCOMS immunised EL- 
6KO Mice.
OVA-specific CTL activity in spleens of IL-12KO or C57B1/6 wild type mice, seven days after the last 
immunisation with a single i.p. immunisation of 5|jig OVA ISCOMS in 200pil saline. Spleens from 5 animals 
were pooled and 3 x 10^ cells restimulated with 1.5 x 10^ mitomycin c treated OVA expressing EG7.0VA 
cells. The results show tlie % cytotoxicity calculated from quadruphcate samples. Antigen-specificity was 
determined by the degree of lysis of non-OVA expressing EL4 cells.
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Figure 4.22 Antigen-Specific Serum IgG Isotype in OV A-ISCOMS Immunised IL-6KO Mice.
OVA-specific IgGl (a) and IgG2a (b) antibody levels in sennn, 7 days after s.c. challenge of HAO in mice 
immunised s.c. with OVA ISCOMS. The results show the reciprocal dilutions of serum from individual mice 
which produced the equivalent O.D. 630nm to a 5% dilution of a standard anti-OVA serum. The control levels 
are from mice that received HAO only.
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Figure 4.23 Antigen-Specific DTH in OVA ISCOMS Immunised IL-4KO mice.
The giaph shows OVA specific DTH responses measured 24 horns after subcutaneous challenge into the 
footpad wiüi lOOpg HAO. Mice were immunised with either (a) 5pg OVA ISCOMS in 50pl saline 
subcutaneously into the rear footpad or (b) six feeds of 100p,g OVA ISCOMS in 200pl sahne. The results 
shown are the mean specific increments in footpad thickness of 5 animals per group ± 1 SD, measured 7 days 
after the last immunisation (*p<0.05 verses wild type C57B1/6 mice). The baekground footpad increment 
obtained in unimmunised animals has been subtracted.
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Figure 4.24 Aiitigen-Specific in vitro Prolifération in OV A-ISCOMS Immunised IL-4KO Mice.
OVA specific proliferative responses were measured in PLN removed (a) 14 days after a single subcutaneous 
immunisation in the rear footpad with 5|xg OVA ISCOMS in 50pl saline or (b) 14 days after the last of 6 feeds 
of 100[rg OVA ISCOMS in 200pl sahne. The graph shows the mean OVA-specific prohferation following a 96 
hour culture with Img/ml OVA as determined by incorporation of [^H|tliymidine into DNA after 16 hours 
incubation. Results are shown as mean counts of quadruplicate cultures of cells pooled from 5 animals ± 1 SD 
(*p<0.005 verses wild type C57B1/6 mice). Background proliferation from control animals has been subtracted.
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Figure 4.25 Antigen-Specific T Cell Cytokine Production in OVA ISCOMS Immunised DL-4KO Mice.
OVA-specific ylFN (a) and lL-5 (b) production after s.c. immunisation with 5pg OVA ISCOMS. OVA-specific 
ylFN (c) and IL-5 (d) production following six feeds of lOOpg OVA ISCOMS. The results are shown as means 
± 1 SD of triphcate cultures using cells pooled from 5 mice per group, 14 days after the last immunisation. 
Background cytokine production from control animals has been subtracted. (*p<0.05, ** p<0.005 verses wild 
type C57B1/6 mice).
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Figure 4.26 Antigen-Specific MHC Class I-Restricted CTL Activity in OVA ISCOMS immunised IL- 
4KO Mice.
OVA-specific CTL activity in spleens of IL-14KO or C57B1/6 wild type mice, seven days after the last 
immunisation with either (a) a single i.p. immunisation of 5[xg OVA ISCOMS in 200pl sahne or (b) 14 days 
after the final of 6 feeds of lOOpg OVA ISCOMS in 200pl saline. Spleens from 5 animals were pooled and 3 x 
lo"^  cells restimulated with 1.5 x 10^ mitomycin c treated OVA expressing EG7.0VA cells. The results show 
the % cytotoxicity calculated from quadruplicate samples. Antigen-specificity was determined by the degree of 
lysis of non-OVA expressing EL4 cells.
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Figure 4.27 Antigen-SpeciOc Serum IgG Isotype in OV A-ISCOMS Immunised IL-4KO Mice.
OVA-specific IgGl (a) and IgG2a (b) antibody levels in serum, 7 days after s.c. challenge of HAO in mice 
immunised s.c, with OVA ISCOMS. The results show tlie reciprocal düutions of serum from individual mice 
winch produced the equivalent O.D. 630nm to a 5% dilution of a standard anti-OVA serum (*p<0.05 versus 
wild type mice). The control levels are from mice that received HAO only.
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Figure 4.28 Antigen-Specinc Intestinal IgA Production in OVA ISCOMS Immunised IL-4KO Mice.
IgA secretion from the small intestine was assessed in gut washes by ELISA seven days after the last six feeds 
of lOOjxg OVA ISCOMS. The results shown are the mean OD 405nm of tiiplicate samples from 5 mice ± ISD 
(*p<0.01 versus C57B1/6 wild type mice). Background IgA production from control animals has been 
subtracted.
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Figure 4.29 Antigen-Specific DTH in OVA ISCOMS Immunised iNOSKO mic^.
The graph shows OVA specific DTH responses measured 24 houis after subcutaneous challenge into the 
footpad with lOOpg HAO. Mice were immunised with 5pg OVA ISCOMS in 50{d sahne subcutaneously into 
the real' footpad. The results shown are the mean specific increments in footpad thickness of 5 animals per group 
± I SD, measured 7 days after the last immunisation. The background footpad increment obtained in 
unimmunised animals has been subtracted.
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Figure 4.30 Antigen-Specifîc in vitro Prolifération in OVA-ISCOMS Immunised iNOSKO Mice.
OVA specific proliferative responses were measured in PLN removed 14 days after a single subcutaneous 
immunisation in the rear footpad with 5pg OVA ISCOMS in 50pl saline The graph shows the mean OVA- 
spedfic proliferation following a 96 hour culture witli Img/ml OVA as determined by incorporation of 
thymidine into DNA after 16 hours incubation. Results are shown as mean counts of quadruplicate cultures 
of cells pooled from 5 animals ± 1 SD. Background prohferation from control animals has been subtracted.
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Figure 4.31 Autigen-Specifîc T Cell Cytokine Production in OVA ISCOMS Immunised INOSKO Mice. 
OVA-specific ylFN (a) and IL-5 (b) production after s.c. immunisation with 5p.g OVA ISCOMS. The results are 
shown as means ± 1 SD of triphcate cultures using cells pooled from 5 mice per group, 14 days after the last 
immunisation. Background cytokine production from control animals has been subtracted. (*p<0.005 verses 
wild type MFl mice).
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Figure 4.32 Antigen-Specifîc Serum IgG Isotype in OVA-ISCOMS Immupiised iNOSKO Mice.
OVA-specific IgGl (a) and IgG2a (b) antibody levels in serum, 7 days after s.c. challenge of HAO in mice 
immunised s.c. with OVA ISCOMS. The results show the reciprocal dilutions of serum from individual mice 
which produced the equivalent O.D. 630nm to a 5% dilution of a standaid anti-OVA semm. The contiol levels 
are from mice that received HAO only.
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Chapter 5
Role of Inflammatory Mediators Induced by ISCOMS in Regulating Innate 
_________________________ Immune Responses._________________________
Introduction
As I have already described in Chapter 3, parenteral or oral administration of 
ISCOMS induces a wide range of innate immune responses, including the recruitment and 
activation of inflammatory cells and the production of several inflammatory mediators. In 
Chapter 4 I determined, by utilising gene-targeted knockout mice, which of these mediators 
were important for the generation of an antigen-specific immune response to OVA ISCOMS. 
I found that although most of these factors were not essential for antigen-specific immunity to 
OVA ISCOMS, mice lacking functional IL-12 had abnormal immune responses when 
immunised with OVA ISCOMS. It is now generally accepted that the development of an 
acquired response is influenced by the initiation of innate cascades, and so in this chapter I 
have attempted to investigate if these defects in adaptive immunity were related to 
abnormalities in the activation of the different components of the early inflammatory 
response. To do this, I explored the inflammatory responses induced in cytokine deficient 
mice, using the model of PEC recruitment I described in Chapter 3.
Experimental Protocol
Gene targeted IL-12KO, IL-18KO, ylFNRKO, IL-6KO and IL-4KO mice, together 
with wild type controls, were injected i.p. with a single dose of 5pg OVA ISCOMS in 200pl 
saline. At various times after injection of ISCOMS, PEC were removed from the animals by 
peritoneal lavage, and examined phenotypical!y by FACS. The production of cytokines and 
nitric oxide was measured after 48 hour culture in vitro in the presence or absence of various 
stimuli. In all experiments control mice were injected with saline.
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Results
5.1 Innate Responses to ISCOMS in Interleukin 12 Deficient Mice
In Chapters 3 and 4, I have shown that IL-12 was not only induced as part of the 
inflammatory cascade, but was also vital for the generation of antigen-specific immunity to 
OVA-ISCOMS. As IL-12 is an early inflammatory factor which has been linked to the 
initiation of cellular recruitment through its regulation of the chemokine IL-8 [Nuame et 
al., 1993], I was interested to examine if the absence of this cytokine affected the innate 
inflammatory cascade, and if so, whether this could account for the importance of IL-12 in 
the generation of antigen-specific immunity.
5.1.1. ISCOMS Induced Inflammatory Infiltrate.
Wild type B6 mice produced the usual pattern of PEC recruitment following i.p. 
injection of ISCOMS. Initially, PEC numbers were reduced, with the minimum occurring at 7 
hours after administration of ISCOMS. However PEC numbers then began to increase to a 
peak at 48 hours by which time they were 1.5 times greater than in uninjected mice. PEC 
numbers were beginning to return to background levels by 72 hours (Figure 5.4.1). In 
contrast, IL-12KO mice showed an early spike in the numbers of PEC after administration of 
ISCOMS, which then rapidly declined below that of the control saline injected animals and 
remained so until 72 hours, when PEC numbers returned to noimal (Figure 5.1).
5.1.2. Phenotypic Analysis of PEC
As I found in earlier experiments, the number of neutrophils in PEC increased 
dramatically in wild type B6 mice soon after injection of ISCOMS, with peak levels being 
seen at 3,5 hours. Neutrophil numbers then returned to control levels (Figure 5.2a). IL-12KO 
mice also showed an immediate increase in the numbers of neutrophils after injection of
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ISCOMS, but the increase was only 20% of that in wild type mice and the peak numbers 
were recorded later, at 7 hours. At all other times, no neutrophils could be found in IL-12KO 
mice (Figure 5.2a),
The number of F4/80+ macrophages also increased after an injection of ISCOMS into 
wild type mice, with maximal levels being seen at 48 hours, returning towards control levels 
by 72 hours (Figure 5.2b). In contrast, IL-12KO mice had higher baseline numbers of F4/80+ 
macrophages before injection and these cells were almost completely lost within 3.5 hours of 
administration of ISCOMS. Thereafter, the levels of F4/80+ cells remained very much lower 
than in control mice for the duration of the experiment (Figure 5.2b).
Wild type animals showed a steady increase in the numbers of activated F4/80~*" 
macrophages from a baseline of zero, as indicated by the expression of the MHC class II 
molecule. Peak levels of activated macrophages were observed at 48 hours, when 25% of all 
macrophages were MHC class 11+ (Figure 5.2c). In addition to the failure to recruit 
macrophages, IL-12KO mice also did not show this pattern of activation. Class II MHC+ 
macrophages were present in uninjected mice, but then there was a marked drop in their 
numbers with no recovery thereafter (Figure 5.2c).
The numbers of dendritic cells in wild type B6 mice as determined by expression of 
CD He, were low in control PEC, but after a further drop at early timepoints after injection of 
ISCOMS, these made a gradual return to baseline levels by 72 hours (Figure 5,2d). IL-12KO 
mice had a much higher level of baseline CDllc+ dendritic cells compared with wild type 
mice and these increased numbers were present throughout the experiment. However, the 
numbers of CDllc+ dendritic cells from IL-12KO mice fell dramatically within 3.5 hours 
after injection of ISCOMS and although their numbers began to increase at 48 hours, they 
were still below baseline numbers and even fell again slightly at 72 hours (Figure 5.2d).
Wild type mice showed an immediate reduction in the number of CD4+ lymphocytes 
in PEC after injection of ISCOMS, before returning towards control levels by 48 hours. IL- 
12KO mice had slightly higher numbers of CD4+ T cells before injection of ISCOMS, but 
these fell rapidly after injection of ISCOMS and there was no subsequent recovery in their 
numbers at later times (Figure 5,3a).
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Although there was no dramatic increase in CD4+ T cells in wild type B6 mice after 
injection of ISCOMS, these cells were becoming activated as shown by their expression of 
CD25 and by 48 hours, 26% of CD4+ T cells were CD25+ (Figure 5.3b). In contrast, IL- 
12KO mice did not show any increase in the expression of this activation marker and in fact, 
the levels of CD25+ CD4 cells were lower than those in the uninjected controls throughout 
the experiment (Figure 5.3b).
A small decrease in the number of CD8+ lymphocytes was also noted immediately 
after administration of ISCOMS to wild type animals, but these began to recover rapidly and 
by 72 hours, CD8 cell numbers were more than twice those of uninjected controls (Figure 
5.3c). IL-12KO mice showed the same immediate loss of CD8+ cell numbers, but these did 
not recover above baseline levels during the experiment (Figure 5.3c). It was not possible to 
deteimine the activation state of these cells, as numbers were so low.
The numbers of B220+ B cells in wild type B6 mice showed a rapid early decrease, 
followed by recovery to levels which were eventually double that of control values at 48 
hours after administration of ISCOMS (Figure 5,3d). Although IL-12 KG mice had baseline 
numbers of B cells that were greater than those in wild type mice, these fell constantly after 
injection of ISCOMS and remained suppressed below that of the control animals throughout 
the experiment (Figure 5.3d).
5.1.3. Inflammatory Cytokine Production
In parallel with the numbers of activated macrophages, PEC from saline injected wild 
type mice produced little or no ylFN+LPS stimulated IL -la  and this remained the case until 
48 hours after administration of ISCOMS, when IL-lct secretion was nearly eight times 
greater than baseline levels, before falling back to zero (Figure 5.4a). Consistent with the 
presence of class II MHC+ macrophages, IL-12KO mice had a slightly higher basal level of 
IL -la production, but this was quickly reduced to below control levels after injection of 
ISCOMS and remained so until 72 hours (Figure 5.4a).
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There was some basal ylFN+LPS stimulated ÏL-6 production by PEC removed from 
saline injected wild type mice. However, this was reduced almost to zero within 3.5 hours of 
injection of ISCOMS, remaining very low until 48 hours, when IL-6 production was nearly 
double that of control mice and then returned towards normal levels by 72 hours (Figure 
5.4b). PEC from IL-12KO mice produced nearly double the background IL-6 levels 
compared with wild type PEC, but this too was reduced to extremely low levels within 3.5 
hours of injection of ISCOMS. Unlike wild type mice, this low level of IL-6 production then 
persisted throughout the experiment (Figure 5.4b).
PEC from wild type B6 mice injected with ISCOMS produced two peaks of ylFN 
production when restimulated with Con A in vitro, both of which were approximately 6 times 
greater than that in uninjected mice. The first peak was at 3.5 hours and the second at 48 
hours, but ylFN production had returned to control levels by 72 hours (Figure 5.4c). PEC 
taken from IL-12KO mice and cultured in vitro with Con A showed a similar level of basal 
ylFN production, but immediately after administration of ISCOMS, this was reduced by half, 
before returning to control levels by 24 hours. ylFN production then remained at this level 
until 72 hours (Figure 5.4c).
As anticipated, no IL-12 was measurable in IL-12KO mice, although wild type B 6 
mice showed the characteristic early decrease followed by an increase to a peak in IL-12 
production by 72 hours (data not shown).
5.1.4. Secretion of Nitric Oxide
PEC from saline injected wild type mice secreted high levels of NO after stimulation 
in vitro with ylFN+LPS. This was reduced by 80% within 3.5 hours of injection of ISCOMS. 
The depressed level of NO production was maintained until 48 hours, when levels rose to 1.5 
times of those in control mice, before returning to normal by 72 hours (Figure 5.5). PEC from 
ÎL-12KO mice produced a similar level of baseline NO production as wild types. This also 
decreased soon after administration of ISCOMS, but this suppressed level persisted for most 
of the experiment, only returning to normal levels by 72 hours (Figure 5.5).
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5.1,5. Summary
Thus, the absence of IL-12 severely inhibits the generation of the inflammatory 
cascade induced by injection of ISCOMS. Apart from some neutrophilia and a higher than 
normal level of macrophages present before injection of ISCOMS, IL-12KO mice were 
unable to recruit inflammatory cells into the peritoneum and the production of inflammatory 
mediators was also abolished.
5,2 Innate Responses to ISCOMS in ylnterferon-Receptor Deficient Mice
ylFN is another of the inflammatory cytokines that I showed in Chapter 3 to be 
upregulated after injection of ISCOMS. However, I showed in Chapter 4 that unlike IL-12, 
ylFN appeared not to be required for the generation of antigen-specific immunity to OVA- 
ISCOMS. Therefore I decided to explore the innate cascade induced by ISCOMS in 
ylFNRKO mice to determine if this might shed light on the different patterns of antigen- 
specific immune responses to ISCOMS found in these two strains.
5.2.1 ISCOMS Induced Inflammatory Infiltrate.
Wild type B6 mice showed the characteristic profile of cellular recruitment after i.p. 
injection of ISCOMS, with an early decrease in PEC numbers, followed by an increase at 
later times, peaking at 48 hours when numbers had increased by approximately two fold 
(Figure 5.6). Control ylFNRKO mice had similar numbers of PEC and showed the same early 
loss of PEC numbers after injection of ISCOMS. However, PEC remained low in these 
animals and did not return to control levels throughout the timecourse of the experiment 
(Figure 5.6).
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5.2.2. Phenotypic Analysis PEC
The detailed phenotypic analysis of the inflammatory infiltrates induced by ISCOMS 
in ylFNRKO mice was performed at the same time as that in IL-12KO mice, using the same 
group of wild type B6 mice as controls. These data are shown again for comparison in the 
relevant figures. ylFNRKO mice showed the early neutrophilia soon after injection of 
ISCOMS, but the numbers were much reduced compared with those in controls and they 
peaked later than in wild type mice (Figure 5.7a).
Saline injected ylFNRKG mice had a larger baseline number of F4/80+ macrophages 
than wild type mice, but this decreased rapidly to very low levels within 3.5 hours of an 
injection of ISCOMS and remained low for the duration of the experiment (Figure 5.7b). In 
parallel with the failure to recruit macrophages to the same extent as in wild type mice, 
F4/80+ macrophages in ISCOMS injected ylFNRKO mice did not express MHC class II at 
any time during the experiment (Figure 5.7c).
ylFNRKO mice showed a similar reduction of dendritic cell numbeis seen in the first 
7 hours after injection of ISCOMS as that seen in wild type mice. However some CD llc+ 
cells remained and the numbers were actually greater than baseline by 24 hours, before 
decreasing again at later times, when numbers were steadily increasing in wild type animals 
(Figure 5.7d).
Despite the numbers of CD4+ PEC in saline injected ylFNRKO mice being much 
lower than in wild types, ylFNRKO CD4 numbers began a steady increase immediately after 
administration of ISCOMS, peaking after 48 hours, when there was over twice the number of 
CD4+ cells than in control animals and then began to decline back to control levels by 72 
hours (Figure 5.8a). Although the numbers of CD4+ T cells were much lower, this 
recruitment was different to that seen in wild types, as no increase in CD4+ T cell numbers 
was observed.
Whereas wild type mice injected with ISCOMS showed a dramatic increase in the 
level of activated CD4+ T cells expressing the IL-2Rct chain CD25, the level of CD25 
expression on CD4+ T cells removed from ylFNRKO mice remained at baseline levels
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throughout the experiment (Figure 5.8b). CD8^ lymphocytes in ylFNRKO mice increased
steadily from very low levels in control mice to a maximum by 48 hours when their numbers
were nearly 6 times greater than baseline. However these numbers were still much reduced
compared with those in injected wild type mice (Figure 5.8c).
The numbers of B cells in control ylFNRKO mice were approximately 50% lower
than in wild type mice and fell further immediately after injection of ISCOMS, remaining
below the baseline level for a further 24 hours and then returning to normal levels by 48
\hours. However, unlike the subsequent recruitment seen in wild type mice, there was no 
increase in B cell numbers above baseline levels in ylFNRKO mice at any time and the 
numbers were always lower than those in wild type animals (Figure 5.8d).
5.2.3. Inflammatory Cytokine Production
As described earlier in Chapter 3, PEC from uninjected wild type mice produced a 
low but significant level of IL-Ia in response to stimulation with ylFN+LPS, and this was 
increased to more than 5 times greater than uninjected levels at 48 hours after injection of 
ISCOMS, before decreasing quickly to baseline levels (Figure 5.9a). ylFNRKO mice did not 
produce any IE-lot at any time before or after administration of ISCOMS (Figure 5.9a).
PEC from saline injected wild type mice produced a large amount of IL-6 after 
stimulation with ylFN+LPS, which was reduced by 75% within 3.5 hours of injection with 
ISCOMS (Figure 5.9b). IL-6 production then returned to normal and, in this experiment, 
continued at control levels for the remainder of the study. PEC from saline injected 
ylFNRKO mice produced significantly higher levels of IL-6 compared with PEC from wild 
type mice, but IL-6 levels then fell rapidly to 50% of baseline within 3.5 hours and continued 
at low levels thereafter (Figure 5.9b).
PEC from saline injected wild type mice produced IL-12 after stimulation in vitro 
with ylFN+LPS and this declined soon after injection of ISCOMS, so that by 7 hours, it was 
half that of unimmunised mice. However, the levels of IL-12 production began to rise at later 
times and by 72 hours, ISCOMS stimulated PEC produced more than twice the amount of IL-
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12 compared with uninjected animals (Figure 5.9c). PEC from saline injected ylFNRKO mice 
secreted very small amounts of IL-12 and although this increased slightly by 3.5 hours after 
injection of ISCOMS, the levels of IL-12 from ylFNRKO mice did not change thereafter and 
remained significantly lower than those of wild type mice until the duration of the experiment 
(Figure 5.9c).
As I found in Chapter 3, PEC from saline injected wild type mice produced two peaks 
of Con A stimulated ylFN production, both of which were approximately 6 times greater than 
those of uninjected control mice. The first peak was at 3.5 hours, and the second peak 
occurred at 48 hours (Figure 5.9d). ylFNRKO mice on the other hand, did not produce any 
ylFN in response to Con A at any time either before or after injection of ISCOMS (Figure 
5.9d).
5.2.4 Nitric Oxide Release
As I observed in Chapter 3, PEC from saline injected wild type animals produced 
substantial amounts of NO in response to ylFN+LPS stimulation in vitro before injection of 
ISCOMS and this was reduced to zero immediately after administration of ISCOMS. NO 
production returned to control levels by 24 hours and by 48 hours was increased significantly 
by approximately 20% above baseline levels, before declining to below control levels by 72 
hours (Figure 5.10). There was no measurable production of NO from ylFNRKO PEC either 
before or after administration of ISCOMS (Figure 5.10).
5.2.5. Sumntiary
Thus ylFNRKO mice showed a major defect in the inflammatory response induced by 
ISCOMS. There was a dramatic yet selective failure to recruit cells into the peritoneum after 
injection of ISCOMS, as seen by reduced numbers of neutrophils, macrophages and 
activation of CD4+ T cells and macrophages. However, normal levels of B cells, CD4+ T 
cells and dendritic cells were observed in PEC from ylFNRKO mice. However, a major
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defect in inflammatory mediator production from ISCOMS injected ylFNRKO PEC was 
noted as cells were not activated nor secreting inflammatory mediators.
5.3 Innate Responses to ISCOMS in Interlenkin 18 Deficient Mice
As I showed in Chapter 4, antigen-specific immune responses were not completely 
defective after immunisation of 1L-12KO mice with OVA ISCOMS and some antigen- 
specific responses were also defective in mice lacking the functionally related cytokine IL-18. 
Therefore I thought that it was important to determine if IL-18KO mice shared the defective 
innate immune response seen in IL-12KO mice. Only a small number of IL-18KO mice were 
available for these studies and no wild type or heterozygous littermate animals at all were 
available. However, in view of the potential importance of the cytokine and because I had 
found relatively consistent inflammatory responses to ISCOMS in the wild type animals used 
in other experiments, I decided to proceed with a preliminary experiment.
5.3.1. ISCOMS Induced Inflammatory Inflltrates
Immediately after injection of ISCOMS into IL-18KO mice, the number of PEC fell 
by half and remained below baseline levels until 72 hours, by which time the numbers 
returned to baseline levels (Figure 5.11). However, the numbers did not rise above the 
background, in contrast to what I had observed earlier in wild type mice.
5.3.2. Phenotypic Analysis of PEC
The numbers of neutrophils decreased to zero immediately after injection of ISCOMS 
into IL-18KO mice and these reduced levels of neutrophils continued until 72 hours, when 
neutrophil numbers had returned to normal (Figure 5.12a). The numbers of F4/80+ 
macrophages also dropped to zero within 3.5 hours after injection of ISCOMS and remained 
so for the duration of the experiment (Figure 5.12b). This contrasts with the increase in
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neutrophils I had observed previously using wild type mice injected with ISCOMS. In 
addition, there was also no evidence of the usual macrophage activation in IL-18KO mice 
(Figure 5.12c).
The numbers of CDllc+ dendritic cells were also reduced to background numbers in 
ÏL-18KO mice immediately after injection with ISCOMS and this suppressed level was 
maintained until 72 hours (Figure 5.12d), in contrast to the increased recruitment of CD llc+ 
dendritic cells I observed previously in wild type animals.
The numbers of CD4+ lymphocytes in IL-18KO PEC also decreased soon after 
administration of ISCOMS and failed to recover at any time thereafter and ISCOMS also 
failed to activate these T cells in IL-18KO mice as identified by expression of CD25 (Figure 
5.13a). The numbers of CD8+ T lymphocytes followed the same pattern as CD4+ T 
lymphocytes, with an immediate decrease which was sustained until the end of the 
experiment (Figure 5.13b). Such a pattern contrasts with the profile of CD4 and CD8 
recruitment I had found in wild type mice injected with ISCOMS.
The numbers of B cells from IL-18KO mice dropped by 50% immediately after 
injection of ISCOMS, but as previously observed in wild type mice, this then returned to 
normal before increasing to five times the baseline numbers at 72 hours (Figure 5.13d).
5.3.3. Inflammatory Cytokine Production
PEC from saline injected IL~18KO mice did not produce any IL-lcx after in vitro 
stimulation with ylFN+LPS and this was the case until 72 hours after injection of ISCOMS, 
when IL -la production was significantly increased above background levels (Figure 5.14a).
Saline injected IL-18KO PEC secreted significant amounts of IL-6 after in vitro 
stimulation with ylFN+LPS, but in contrast to what I had found previously with wild type 
mice, there was no significant change in the production of IL-6 from PEC removed from 
ISCOMS injected IL-18KO mice at any time during the experiment (Figure 5.14b).
Saline injected IL-18KO PEC produced very little IL-12 when stimulated in vitro 
with ylFN+LPS, but within 6 hours of administration of ISCOMS, IL-12 production was
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significantly increased. By 24 hours, levels were more than twenty times greater than in 
uninjected mice and continued to a peak at 72 hours, when IL-12 production was 25 times 
greater than background (Figure 5.14c). Although the early increase contrasts with the normal 
decrease in IL-12 after injection of ISCOMS in wild type animals, maximal production of IL- 
12 from IL-18KO PEC coincided with that normally seen with wild type animals.
PEC from saline injected IL-18KO mice produced a small amount of ylFN after in 
vitro stimulation with Con A, and within 6 hours of administration of ISCOMS, ylFN 
production more than doubled, reaching a peak at 24 hours when ylFN levels were nearly 
five times greater than control animals and remained high until 72 hours (Figure 5.14d). This 
pattern of sustained increase in ylFN production is in contrast to the biphasic pattern normally 
seen in wild type animals.
5,3.4 Summary
Thus, in the absence of IL-18, no recruitment of PEC occurred in response to 
ISCOMS, but there appeared to be normal or even increased production of ylFN and IL-12 as 
well as an abnormal pattern of IL -la  secretion, with the only defective cytokine measured 
being IL-6 as the levels were unchanged after injection with ISCOMS.
5.4. Innate Responses to ISCOMS in Interleukin 4 Deficient Mice
As I had observed normal antigen-specific immune responses in IL-4KO mice 
immunised with OVA-ISCOMS, I wished to see if innate immune responses were also 
normal in these mice and if correlating these responses in the different mice would provide 
information on how the innate response regulates adaptive immunity. Again, because I found 
that these mice retained normal antigen-specific responses to ISCOMS, I decided to use 
representative timepoints only.
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5.4.1. Recruitment of PEC
PEC numbers from wild type B6 mice were normal 24 hours after injection of 
ISCOMS in this study. Thereafter PEC numbers increased by approximately two fold at 72 
hours and remained at an elevated level at 168 hours (Figure 5.15). An identical pattern of 
PEC recruitment was seen in IL-4KO mice at all times after injection of ISCOMS (Figure 
5.15).
As there were no gross differences in the pattern of ISCOMS recruited PEC in IL- 
4KO mice and their antigen-specific responses were entirely normal, phenotypic studies were 
not performed on PEC in this study and only selected functional studies were undertaken.
5.4.2. Inflammatory Cytokine Production
No detectable levels of IL -la  were measured in ISCOMS injected wild type or IL- 
4KO mice, but this was not unexpected, given that this timecourse did not include the times 
when I found IL-la to be maximal (data not shown).
As with other wild type mice, PEC from saline injected animals produced detectable 
IL-6 production in response to ylFN-t-LPS and this fell markedly by 24 hours after injection of 
ISCOMS, remaining depressed throughout the remainder of the experiment. (Figure 5.16a). 
Again this may be because the usual peak of IL-6 production was missed. PEC from IL-4KO 
mice show a decrease in ylFN+LPS stimulated IL-6 production at 24 hours, but in these mice, 
there was an increase in IL-6 production at 72 hours, when levels were significantly greater 
than in wild type animals. IL-6 levels then decreased below background levels by 168 hours 
(Figure 5.16a).
As before, wild type B6 mice produced low levels of IL-12 which initially decreased 
at early timepoints, but then increased markedly to a peak at 72 hours after injection of 
ISCOMS, when levels of IL-12 secretion were 20 times greater than the saline injected 
controls. IL-12 production then returned to background levels by 168 hours (Figure 5.16b). 
IL-4KO mice showed a similar pattern of ylFN+LPS stimulated IL-12 secretion, which also
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peaked by 72 hours, when it was significantly greater than that in wild type mice, before 
returning to control levels by 168 hours (Figure 5.16b).
PEC from saline injected wild type B6 mice produced a significant amount of Con A 
stimulated ylFN and after an initial decrease in ylFN secretion 24 hours after injection of 
ISCOMS, this increased steadily to a peak at 72 hours at a level more than twice that of 
controls (Figure 5.16c). ÏL-4KO mice showed an identical pattern of ylFN production, with 
an early decrease compared with background levels, followed by a peak at 72 hours which 
returned to control levels by 168 hours. There were no significant differences between Con A 
induced ylFN production from IL-4KO and wild type mice at any time (Figure 5.16c).
5.4.3. Secretion of Nitric Oxide
NO production in wild type mice fell soon after injection of ISCOMS to zero, before 
levels returned to those of saline injected control mice by 72 hours. (Figure 5.20). An 
identical pattern was found in ISCOMS injected IL-4KO mice, although a significant 
decrease was noted at 168 hours compared with wild types (Figure 5.20).
5.4.4 Summary
Together these results indicate that the absence of IL-4 has no effect on the ability of 
ISCOMS to induce an inflammatory cascade.
5.5 Innate Responses to ISCOMS in Interleukin 6 Deficient Mice
I had shown in Chapters 3 and 4 that large amounts of IL-6 were induced by an 
injection of ISCOMS, but IL-6 was not important for the induction of antigen-specific 
immune responses to ISCOMS. As I found discrepancies between the innate and adaptive 
immune responses induced by ISCOMS in ylFNRKO mice, I was interested to see if a similar 
dichotomy occurred in IL-6KO mice. In these experiments I only assessed two representative
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timepoints, 24 hours and 72 hours, as well as an extended timepoint at 168 hours in order to 
assess if there might be a more delayed response in these animals.
5.5.1 Recruitment of PEC
The recruitment of PEC in wild type 129/Sv mice after injection of ISCOMS induced 
a steady increase in cell numbers which reached a peak at 72 hours when PEC numbers had 
nearly doubled before returning towards control levels by 168 hours. The recruitment of PEC 
in IL-6KO mice followed an almost identical pattern to that found in wild type mice (Figure 
5.18). Because of this and because I found that the IL-6KO mice had normal antigen-specific 
responses, I did not conduct further experiments to assess individual populations of PEC 
phenotypically.
5.5.2. Inflammatory Cytokine Production
There was no measurable production of ylFN+LPS stimulated IL -la  in either 129/Sv 
or IL-6KO mice, but this is not unexpected given the lack of a 48 hour timepoint when IL -la  
has been shown previously to be maximal (Data not shown). No ylFN+LPS stimulated IL-6 
production was measured in IL-6KO mice, although SV/129 wild types produced a normal 
profile of IL-6 with decreased levels detected at 24 hours which then returned to control 
levels by 72 and 168 hours (Data not shown).
Wild type 129/Sv mice produced increased levels of ylFN+LPS stimulated IL-12 at 
24 hours after injection of ISCOMS, which were approximately 4 times greater than in saline 
injected control 129/Sv mice. However as in my previous experiments, the maximal 
production of IL-12 occurred at 72 hours, by which time IL-12 production was 5 times that of 
control levels (Figure 5.19a). IL-12 production was also increased in ISCOMS injected ÏL- 
6KO mice, but this peaked at the earlier time of 24 hours and remained high at 72 hours. The 
peak of IL-12 production in IL-6KO mice was twice that in wild type mice. At later times.
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IL-12 production from both 129/Sv and IL-6KO mice returned to control levels (Figure 
5.19a).
In these experiments, uninjected wild type 129/Sv mice had high baseline levels of 
Con A stimulated ylFN production, but this decreased rapidly after injection of ISCOMS and 
remained depressed until 168 hours (Figure 5.19b). Saline injected ÏL-6KO mice produced 
very low amounts of ylFN and this was not increased after injection of ISCOMS. (Figure 
5.19b).
5.5.3 Secretion of Nitric Oxide
PEC from wild type 129/Sv mice stimulated with ylFN+LPS produced a large amount 
of NO before injection with ISCOMS and this decreased rapidly by 90% within 24 hours of 
administration of ISCOMS. NO production then gradually returned to background levels by 
168 hours (Figure 5.20). IL-6KO mice had significantly lower levels of NO production then 
wild type controls and these remained very low until 168 hours, when there was a dramatic 
increase in NO production which was now significantly greater than wild types (Figure 5.20).
5.5.4. Summary
IL-6KO mice did not show any defect in cellular recruitment after injection of 
ISCOMS and were capable of sustaining inflammatory responses after an injection of 
ISCOMS, but there were some differences in the ability to produce inflammatory mediators 
in particular ylFN.
Summary and Conclusions
The experiments in this chapter were designed to investigate how the absence of 
individual inflammatory mediators influenced the induction of innate immune responses by
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ISCOMS and to explore how these correlated with the generation of antigen-specific 
immunity in these mice.
My previous results had shown that antigen-specific immune responses to ISCOMS 
were dependent on the presence of IL-12 and here I found that IL-12KO mice had severely 
crippled innate responses to ISCOMS, lacking recruitment or activation of an inflammatory 
infiltrate and with little or no inflammatory mediator production. Thus, this cytokine plays a 
crucial role in the initiation of the inflammatory cascade by ISCOMS.
ylFNRKO mice proved to be the most interesting of the knockout animals. Although I 
had previously found that these mice had intact antigen-specific immune responses to OVA 
ISCOMS, the innate immune response was unexpectedly and severely deficient in ylFNRKO 
mice. The most dramatic abnormality in these mice was the complete absence of cellular 
recruitment or activation especially of macrophages or CD4+ lymphocytes, but numbers of B 
cells and dendritic cells were unaltered. However, these mice had severely defective 
inflammatory mediator production following injection with ISCOMS.
In Chapter 4 I found that certain antigen-specific responses to ISCOMS were 
defective in IL-18KO mice and in this chapter, I found that IL-18KO mice also appeared to 
have defective cellular recruitment into the peritoneum, with B cells being the only cell type 
which seemed to be recruited in the same way as in wild type mice. However, IL-18KO mice 
actually retained the ability to produce high levels of IL-12, ylFN and IL-la, occasionally at 
levels somewhat higher than I had found previously with wild type animals. However, IL-1 
responses were delayed and there was no induction of IL-6. The interpretation of these 
experiments was limited by the unavailability of appropriate controls.
IL-6 is a member of the inflammatory cascade and was increased after administration 
of ISCOMS in wild type animals. However IL-6 was shown not to be involved in the 
generation of OVA-specific immunity to ISCOMS and in this chapter I found that this 
cytokine is not important for the innate immune response, as IL-6KO mice had normal 
cellular recruitment and there was no gross defect in the inflammatory mediator production. 
A similar pattern was seen in IL-4KO mice which had normal antigen-specific immune 
responses to OVA ISCOMS and an intact inflammatory response. One problem with these
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experiments was that they were conducted before I had determined the optimal time courses 
for the induction of inflammatory cytokine production and therefore some of the responses I 
observed were variable or suboptimal. Nevertheless, as there was no gross defect in the 
inflammatory cascade and because specific immune responses were normal for both ÎL-4KO 
and IL-6KO, I decided that it was inappropriate to perform further work in these animals.
In conclusion, individual components of the immune system showed different patterns 
of involvement in antigen-specific and innate immunity. Whereas IL-4 and IL-6 appear not to 
be required for either aspect of the immune response, IL-12 is important for both. In contrast, 
the absence of ylFN had dramatic effects on the induction of innate inflammatory cascade, 
but was not required for antigen-specific immunity, whereas IL-18 appeared to have variable 
effects on both aspects of the immune response. Therefore, these experiments show that the 
links between the innate and adaptive immune system are regulated by a highly complex and 
delicately balanced system.
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Figure.5.1 ISCOMS Induced Recruitment of PEC in IL- 12KO Mice.
The graph shows PEC recruitment following an i.p. injection of 5pg OVA ISCOMS. PEC were removed from 
five mice by lavage, pooled and ceU counts performed. The results shown are mean PEC numbers for wild type 
mice (closed squares) and IL-12K0 mice (open squares). Saline injected mice from each strain were used as 
controls.
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Figure 5,2 Phenotypic Analysis of ISCOMS Recruited PEC from IL-12KO Mice.
PEC were removed by lavage after an i.p. injection of 5pg OVA ISCOMS and analysed by flow cytometry. The 
results shown are the numbers of (a) neutrophils, (b) F4/80+ macrophages, (c) MHC class 11+ F4/80 
macrophages and (d) CDllc+ dendritic cells. The results are expressed as tire uiunber of cells per peritoneum 
wliich were calculated from the percentage of cells positive for each marker in the PEC pooled from 5 animals 
per group for wild type mice (closed squares) and IL-12KO mice (open squares). Saline injected animals of each 
strain were controls.
140
a CD4 b
2000 Wild Type IL-12KO
§
a 1000
0
0 12 24 36 48 60 72
Time After ISCOMS IHoms')
CD4+CD25+
120
100
80 
IS  60 
1'S 40
0 12 24 36 48 60 72
Time After ISCOMS fHoiirsl
CDS B220
§
I
1000
800
600
400-g
200
0
0 12 24 36 48 60 72
5000
S '4000
8
3000
U 1000
e
0 12 24 36 48 60 72
Time After ISCOMS tflomsl Time After ISCOMS rHoursl
Figure 5.3 Phenotypic Analysis of ISCOMS Recruited PEC from IL- 12KO Mice,
PEC were removed by lavage after an i.p. injection of 5pg OVA ISCOMS and analysed by flow cytometry. The 
results shown are the numbers of (a) CD4"  ^ lymphocytes, (b) CD4+ lymphocytes, (c) CD8+ lymphocytes and 
(d) B220+ B cells. The results are expressed as the number of cells per peritoneum which were calculated from 
the percentage of cells positive for each marker in the PEC pooled from 5 animals per group for wild type mice 
(closed squares) and IL-12KO mice (open squares). Control mice were saline injected animal s of each strain.
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Figure 5.4 ISCOMS Induced Inflammatory Cytokine Production by PEC from IL- 12KO Mice 
Productioii of (a) IL-1 a  , (b) IL-6, (c)ylFN by PEC pooled from 5 mice given an i.p. injection of 5p.g ISCOMS 
3.5-72 hours before. The results shown aie the mean concentiation of cytokines from wild type mice (closed 
squares) or IL-12KO mice (open squaies), measured in tiiplicate after 48 hours stimulation in the presence or 
absence of ylFN+LPS (a and b) or the presence or absence of Con A (c) ± 1 SD (^ ’p<0.05 versus wild type 
mice; p<0.005; *** p<0.001 versus wild type mice). Control mice were uninjected animals of each stiain.
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Figure 5,5 ISCOMS Induced Nitric Oxide Production from IL-12KO PEC
Production of nitric oxide from PEC pooled from 5 mice following injection of 5(Ag ISCOMS. The results 
shown are the mean concentration of nitrite measured in triplicate from wild type mice (closed squares) or IL- 
12KO mice (open squares), after culture for 48 hours in the presence or absence of ylFN+LPS ± 1 SD (* p<0.05 
versus wild type mice; ** p<0.005 versus wild type mice). Control mice were uninjected animals of each strain.
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Figure 5.6 ISCOMS Induced Recruitment of PEC in ylFNRKO Mice.
The graph shows PEC recruitment following an i.p. injection of 5p,g OVA ISCOMS. PEC were removed from 
five mice by lavage, pooled and cell counts performed. The results shown are mean PEC numbers for wild type 
mice (closed squares) and IFNRECO mice (open squares). Saline injected mice from each strain were used as 
controls.
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Figure_5,7 Phenotypic Analysis of PEC from ylFNRKO mice after Injection of ISCOMS.
PEC were removed by lavage after an i.p. injection of 5pg OVA ISCOMS and analysed by flow cytometry. The 
results shown are the numbers of (a) neutrophils, (b) F4/80+ macrophages, (c) MHC class IH F4/80 
macrophages and (d) CDllc+ dendritic cells. The results are expressed as the nmiiber of ceUs per peritoneum 
which were calculated from the percentage of cells positive for each marker in the PEC pooled from 5 animals 
per group for wild type mice (closed squaies) and ylFNRKO mice (open squares). Control mice were 
uninjected.
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Figure 5.8 Phenotypic Analysis of ISCOMS Recruited PEC from ylFNRKO Mice.
PEC were removed by lavage after an i.p. injection of 5pg OVA ISCOMS and analysed by flow cytometry. The 
results shown are the numbers of (a) CD4'*' lymphocytes, (b) CD25+ CD4 lymphocytes, (c) CD8+ lymphocytes 
and (d) B220^ B cells. The results are expressed as the number of cells per peritoneum which were calculated 
from the percentage of cells positive for each marker in the PEC pooled from 5 animals per group for wild type 
mice (closed squares) and ylFNRKO mice (open squares). Control mice were injected wiûi saline.
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Figure 5>9 ISCOMS Induced Inflammatory Cytokine Production by PEC from ylFNRKO Mice.
Production of (a) IL-la , (b) IL-6, (c) immunoreactive IL-12 and (d) ylFN by PEC pooled from 5 mice given an 
i.p. injection of 5pg ISCOMS 3.5-72 hours before. The results shown are the mean concentration of cytokines 
from wild type mice (closed squares) or ylFNRKO mice (open squares), measured in tiiplicate after 48 hours 
stimulation in the presence or absence of ylFN+LPS (a-c) or the presence or absence of Con A (d) + 1 SD 
('“p<0.001 versus wild type mice; =^^ p<0.05 versus wild type mice). Control mice were saline injected animals 
of each strain.
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Figure 5.10 ISCOMS Induced Nitric Oxide Production by PEC fi-om ylFNRKO M ice.
Production of nitric oxide from PEC pooled from 5 mice following injection of 5[xg ISCOMS. The results 
shown are the mean concentration of nitrite measured in triplicate from wild type mice (closed squares) or 
YIFNRJCO mice (open squares), after culture for 48 hours in the presence or absence of ylFN+LPS ± 1 SD 
Control mice were saline injected animals of each strain.
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Figure 5.11 ISCOMS Induced Recruitment of PEC from IL-18KO Mice,
Tlie graph shows PEC recruitment following an i.p. injection of 5pg OVA ISCOMS. PEC were removed from 
five mice by lavage, pooled and cell counts performed. The results shown are mean PEC numbers for IL-18K0 
mice (open squares). Sahne injected mice were used as controls.
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Figure 5.12 Phenotypic Analysis of ISCOMS Recruited PEC from IL- 18KO Mice.
PEC were removed by lavage after au i.p. injection of 5pg OVA ISCOMS and analysed by flow cytometry. The 
results shown are the numbers of (a) neutrophils, (b) F4/80+ macrophages, (c) MHC class 11+ F4/80 
macrophages and (d) CDllc+ dendritic cells. The results are expressed as the number of cells per peritoneiun 
which were calculated from the percentage of cells positive for each marker in the PEC pooled from 5 animals 
per group for IL-18KO mice (open squares). Control mice were saline injected animals.
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Figure 5.13 Phenotypic Analysis of ISCOMS Recruited PEC from ILr ISKO Mice.
PEC were removed by lavage after an i.p. injection of 5pg OVA ISCOMS and analysed by flow cytometry. The 
results shown are tlie numbers of (a) CD4+ lymphocytes, (b) CD25+ CD4 lymphocytes, (c) CD8^ lymphocytes 
and (d) B220^ B cells. The results are expressed as the number of cells per peritoneum which were calculated 
from the percentage of cells positive for each marker in the PEC pooled from 5 animals per group for IL-18KO 
mice (open squaies). Control mice were saline injected animals.
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Figure 5.14 ISCOMS Induced Inflammatory Cytokine Production by PEC from IL- ISKOMice.
Productioa of (a) IL-1 a, (b) IL-6, (c) immunoreactive IL-12 and (d) ylFN by PEC pooled from 5 mice given an 
i.p. injection of 5pg ISCOMS 3.5-72 horns before. The results shown are the mean concentration of cytokines 
from IL-18KO mice, measured in triplicate after 48 hours stimulation in the presence or absence of ylFN+LPS 
(a-c) or the presence or absence of Con A (d) ± 1 SD(^ p<0.05 versus wild type mice; ** p<0.001 versus wild 
type mice). Control mice were saline injected animals of each strain.
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Figure 5.15 ISCOMS Induced Recruitment of PEC in IL-4KO Mice.
The graph shows PEC recniitment following an i.p. injection of 5pg OVA ISCOMS. PEC were removed from 
five mice by lavage, pooled and cell counts performed The results shown are mean PEC numbers for wild type 
mice (closed squares) and IL-4KO mice {open squares). Saline injected mice from each strain were used as 
controls.
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Figure 5.16 ISCOMS Induced Inflammatory Cytokine Production by PEC from IL-4KO Mice.
Production of (a) IL-6 , (b) immunoreactive IL-12 and (c) ylFN by PEC pooled from 5 mice given an i.p. 
injection of 5pg ISCOMS. The results shown are the mean concentration of cytokines from wild type mice 
(closed squares) or IL-4KO mice (open squaies), measured in triplicate after 48 hours stimulation in the 
presence or absence of ylFN+LPS (a-b) or the presence or absence of Con A (c) ± 1 SD (* p<0.05 versus wild 
type mice; p<0.005 versus wild type mice; p<0.001 versus wild type mice). Control mice were saline 
injected animals of each strain.
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Figure 5.17 ISCOMS Induced Nitric Oxide Production by PEC from IL-4KO Mice
Production of nitric oxide from PEC pooled from 5 mice following injection of 5|xg ISCOMS. The results 
shown are the mean concentration of nitrite measured in triplicate from wild type mice (closed squares) or IL~ 
4KO mice (open squares), after culture for 48 hours in the presence or absence of ylFN+LPS ± 1 SD (* p<0.01 
versus wild type mice). Control mice were saline injected animals of each strain.
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Figure 5.18 ISCOMS Induced Recruitment of PEC from BL-6KO Mice.
The graph shows PEC recruitment following an i.p. injection of 5pg OVA ISCOMS. PEC were removed from 
five mice by lavage, pooled and cell counts performed The results shown are mean PEC numbers for wild type 
mice (closed squaies) and IL-6KO mice (open squares). Saline injected mice from each strain were used as 
controls.
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FigHi^e5.19 ISCOMS Induced Inflammatory Cytokine Production by PEC from 1L-6KO Mice.
Production of (a) immimoreactive IL-12 and (b) ylPN by PEC pooled from 5 mice given an i.p. injection of 5p,g 
ISCOMS 3,5-72 hours before. The results shown are the mean concentration of cytokines from wild type mice 
(closed squares) or IL-6KO mice (open squares), measured in triphcate after 48 hours stimulation in the 
presence or absence of ylFN+LFS (a) or the presence or absence of Con A (b) ± 1 SD (* p<0.05 versus wild 
type mice; * p<0.01 versus wild type mice; p<0,001 versus wild type mice). Control mice were saline 
injected animals of each strain.
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Figure 5.20 ISCOMS Induced Nitric Oxide Production by PEC from DL-fiKO Mice
Production of nitric oxide from PEC pooled from 5 mice following injection of 5pg ISCOMS. The results 
shown are the mean concentration of nitrite measured in triplicate from wild type mice (closed squares) or IL- 
6KO mice (open squaies), after cultme for 48 hours in die presence or absence of ylPN+LPS ± 1 SD (* p<0.05 
versus wild type mice; p<0.005 versus wild type mice). Control mice were saline injected animals of each 
strain.
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Chapter 6
Discussion
Although ISCOMS have been used to stimulate antigen-specific immune responses by 
parenteral and mucosal routes, the mechanisms that underlie these adjuvant effects have not 
been elucidated. The results presented in this thesis have demonstrated that the adjuvant 
properties of ISCOMS are associated with an ability to stimulate an innate inflammatory 
cascade, and that only certain components of this response are essential for the antigen- 
specific effects of ISCOMS. My work therefore extends previous investigations into the non­
specific properties of ISCOMS [Watson et al., 1989, Vilîacres-Eriksson et al., 1993, 
Behboudi et al., 1996, Behboudi et al., 1997, Villacres-Eriksson et al., 1997] and showed that 
IL-12 played a particularly important role in the immimogenicity of ISCOMS. A clearer 
understanding of how adjuvants like ISCOMS exert their effects may lead to more efficiently 
designed and effective vaccines that are active parenterally and orally.
My initial experiments examined which, if any, inflammatory effects were induced 
after an injection of ISCOMS. I decided to focus primarily on following the response after a 
parenteral injection of ISCOMS into the peritoneum, which provided an easily accessible and 
discrete site to collect and assess the functional activity of any cellular infiltrate. Once this 
protocol had been established, I then extended the work to include an assessment of the 
inflammatory responses occurring at mucosal sites after oral administration of ISCOMS. 
These experiments showed that ISCOMS induced a cascade of inflammatory events 
characterised by recruitment and activation of cells to the injection site and release of several 
inflammatory mediators. To assess the role of these factors in the generation of antigen- 
specific immune responses to immunisation of ISCOMS, I immunised gene-targeted 
knockout mice and monitored their specific immune responses as determined by parameters 
already established in the laboratory. These studies identified 11-12 as the only mediator of all 
of the factors induced by ISCOMS which was necessary for specific immune responses to 
ISCOMS. Responses were either completely normal or only partially defective in the absence 
of the other mediators.
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Once this had been established, I then went on to determine how the same 
inflammatory cytokines influenced the inflammatory cascade induced by ISCOMS. In this 
case the innate cascade was lacking in both IL-12KO and ylFNRKO mice, despite the fact 
that antigen-specific immune responses were lacking only in the IL-12KO animals. This 
apparent dichotomy indicated that the role of the ISCOMS induced innate immune response 
in the generation of antigen-specific immunity is as complex as it is important and must be 
better understood if efficacious and potent vaccines are to be developed.
ISCOMS Induce an Inflammatory Cascade
Over the past few years, the view that the innate immune response was merely a 
retention of an immune mechanism utilised by primitive evolutionary ancestors, has been 
redefined. As a result, it has been realised that these non-specific inflammatory processes 
both initiate and co-ordinate the antigen-specific immune respons by recruiting and activating 
immune cells, as well as providing appropriate cytokines and costimulatory molecules 
necessary for promoting adaptive immunity. The innate immune response therefore plays a 
number of crucial roles in the induction and shaping of protective immunity [Medzhitov and 
Janeway Jr, 1997a, Fearon and Locksley, 1996].
In Chapter 3 ,1 showed that intraperitoneal injection of ISCOMS induced intense local 
activation of the innate immune response, which consisted of recruitment of a wide variety of 
inflammatory cells including neutrophils, mast cells, dendritic cells, macrophages and 
lymphocytes. Many of these cells were activated as evidenced by expression of surface 
activation markers and the production of cytokines and other mediators.
The first effect of injecting ISCOMS was a pronounced decrease in the numbers of 
PEC which was retained up to 48 hours after administration of ISCOMS, The saponin 
derivative Quil A has long been known to have haemolytic properties which are due to its 
ability to disrupt membranes by binding to cholesterol and inducing pore formation [Kensil, 
1996, Ronnberg et al., 1997]. As ISCOMS have some of the haemolytic nature of Quil A 
[Gupta et al., 1993], the sudden decrease in total PEC cell numbers that occurred immediately
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after administration of ISCOMS could be due to cell death because of the toxic effects of 
Quil A. However I found no evidence of cell death in PEC at any time after injection of 
ISCOMS as determined by histological examination. As this may have been because I did not 
examine PEC removed from mice at an early enough time after administration of ISCOMS, it 
would be important to assess PEC isolated at earlier timepoints. However, at present I did 
not find any evidence that cell death is responsible for the loss in numbers. An alternative 
mechanism which may explain this observed phenomenon was that ISCOMS induced some 
cells to leave the peritoneum and migrate to draning lymph nodes. Experiments to confirm 
this possibility should be part of any future work and could be performed by labelled PEC 
prior to injection of ISCOMS and then monitoring where these cells travel to after injection.
In the next 48 hours after injection of ISCOMS there was a large increase in the 
numbers of cells recovered from the peritoneum. This local inflammatory infiltrate consisted 
of an initial emigration of neutrophils, followed by macrophages and dendritic cells, and 
eventually lymphoid cells. Neutrophils are not normally present in the peritoneum, but at 3.5 
and 7 hours after administration of ISCOMS, I observed a large increase in the numbers of 
polymorphonuclear cells. Histological and phenotypic studies identified that these were 
mostly neutrophils, confirming previous observations that neutrophils are recruited to the site 
of injection with ISCOMS [Watson et al., 1989, Watson et al., 1992]. In other models of 
inflammation, neutrophils are recruited by chemokines such as IL-8, neutrophil chemotactic 
factor (NCF), the C5a fragment of complement, prostaglandin D% (PGD2) and leukotriene B4 
(LTB4) [Baggiolini, 1995]. None of these factors were examined after injection of ISCOMS 
and this would be an important aspect of furure studies.
The neutrophilia was accompanied by the recmitment of mast cells 6 hours after 
administration of ISCOMS, when there was morphological evidence of mast cell 
degranulation. A second, larger recruitment of mast cells was observed at 48 hours. It would 
be important to establish the functional implications of these findings by determining the 
production of mast cell products such as histamine, or mouse mast cell protease-1 (MCP-1). 
Together with their ability to produce araFv donic acid metabolites and prefonned cytokines 
such as TNFa, mast cells could play an important role in initiating the early phase of the
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inflammatory response. Mast cell products have been implicated as being important for the 
induction of several cell mediated immune responses in vivo such as DTH and contact 
sensitivity [Church and LeviSchaffer, 1997], and also act as sources of chemotactic agents for 
other leukocytes. For example TNFa and LTB4 are important for the recruitment of 
macrophages and monocytes [Wershil et al., 1991]. It is not clear how ISCOMS could recruit 
and activate mast cells, although mast cells do accpmulate early in other forms of acute 
inflammation, and are known to be recruited by chemotactic signals such as C3 complement 
fragments [Prodeus et al., 1997]. Although the most usual way that mast cells are activated is 
by crosslinking of IgE bound to FceR by multivalent antigen [Galli et al., 1999], this could 
not occur so quickly after administration of ISCOMS. Therefore, an alternative mechanism 
must be initiating the activation of these cells and one possibility is that a secretory factor 
produced by neutrophils or another cell type may induce degranulation. This is consistent 
with other findings that TNFa [Brzezinska-BIaszczyk and Pietrzak, 1997] and stem cell 
factor (SCF) [Wershil et al., 1992] were able to induce mast cell degranulation and may 
implicate neutrophils as the cells from which mast cell stimulators are released. However, the 
role of mast cells in the induction of specific immunity by ISCOMS remains to be clarified, 
although this could be achieved using mast cell deficient W/W^ mice.
Macrophages were next population to appear in the recruited PEC, reaching maximal 
numbers 48 hours after injection of ISCOMS. Macrophages were identified histologically on 
cytospins by their characteristic kidney-shaped nuclear morphology, and phenotypically by 
the expression of the pan metalophillic tissue macrophage marker F4/80. The macrophages 
may have been recruited to the injection site by neutrophil derived chemotactic factors such 
as macrophage chemotactic factor-1 (MCP-1) and TNFa. The ISCOMS recruited 
macrophages were shown to be activated both by their large and foamy morphological 
appearance and by their increased expression of MHC class II. These observation were 
consistent with other laboratories’ findings of increased MHC class II expression after 
ISCOMS treatment [Watson et al., 1992, Bergstrom et al., 1990]. Despite this and in contrast 
to earlier findings of elevated CD86 on APC removed from ISCOMS vaccinated mice 
[Sambhara et al., 1998], in preliminary studies I found little or no alteration in CD40, CD80
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or CD86 expression on ISCOMS recruited macrophages. This suggests that these cells may 
play an inflammatory role, rather that being directly involved in presenting antigen to T cells. 
This is consistent with evidence from this and other laboratories using silica or the liposomal 
toxin dichloromethylene diphosphate (CI2MDP) to block macrophage function, that 
macrophages are not important for the priming of most specific immune responses by 
ISCOMS [Maloy, 1996, Claassen et al., 1995]. Nevertheless, ISCOMS appear to be taken up 
efficiently by macrophages, presumably reflecting their particulate nature [Claassen et al., 
1995, Claasen et al., 1995] and it has been shown that eliminating macrophages markedly 
inhibits the induction of OVA-specific CD8+ CTL responses in vivo [Maloy, 1996] as well as 
a reduction in viral specific CTL activity in other systems [Wijburg et al., 1997]. Thus the 
role of macrophages in the uptake and preservation of ISCOMS associated antigen needs to 
be examined directly.
Increased numbers of dendritic cells, determined as cells expressing CD 11c were also 
observed in the recruited PEC population. Dendritic cells were present in low numbers in 
control PEC populations and disappeared soon after injection of ISCOMS. The loss of 
dendritic cells at early timepoints may be a result of cell death, or that dendritic cells are 
migrating away from the peritoneum after ISCOMS injection, which would be consistent 
with their proposed immune surveillance role. The number of dendritic cells then increased to 
a maximum at 72 hours, and these cells were mature as determined by their co-expression of 
MHC class II [Cella et al., 1997]. It is now considered that dendritic cells are the principle 
APC that can prime naive T cells, due to their efficient ability to take up and process antigen, 
as well as their expression of high levels of MHC class II and of costimulatory molecules 
such as CD40, CD80 and CD86 in conditions of inflammation [Gallucci et al., 1999]. I did 
perfonn preliminary experiments to explore the expression of CD80 and CD86 costimulatory 
molecules on ISCOMS recruited dendritic cells, but I did not detect any expression either 
before or after administration of ISCOMS at any timepoint. This could reflect that I looked at 
the wrong time and that the relevant dendritic cells were either recruited at later timepoints or 
had already left the injection area, and those I examined were recently recruited, immature 
cells. Recent studies conducted in the laboratory since I left support this latter possibility, as
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they show that there is a very early increase in dendritic cell numbers at times before I 
looked, 1-2 hours after injection of ISCOMS and that PEC contain antigen-loaded APC at 
this time (Allan Mowat personal communication). In addition, other work using the cytokine 
fits ligand (FLt3L) to recruit dendritic cells, has shown that OVA-specific responses are 
enhanced in FLt3L treated mice immunised with ISCOMS (Allan Mowat personal 
communication). More work is clearly wananted to investigate fully the role of dendritic 
cells in the establishment of immune responses to ISCOMS.
At the same time that activated macrophages and dendritic cells were obseiwed in 
PEC populations, lymphocyte numbers were also increasing. A small number of CD4+ T 
cells were identified in PEC from control mice, but within a few hours of administration of 
ISCOMS, this population decreased before steadily returning towards background levels by 
48-72 hours. At this time a large percentage of CD4+ T cells were activated, as determined 
by their co-expression of the IL-2 receptor a  chain (CD25). A similar pattern of CD8+ T cell 
recruitment was also observed, although the low numbers of these cells present, meant that it 
was not possible to assess their expression of CD25. As ISCOMS are strong inducers of 
CD8-restricted CTL activity [Mowat et al., 1991a, Heeg et al., 1991, Smith et al., 1998], it 
would have been useful to have examined this in more detail. The fact that lymphocytes were 
the last cell types to be recruited into the PEC suggested that these cells might include 
antigen-specific T cells destined to respond to the OVA incorporated in the ISCOMS. To 
examine this, I undertook preliminary experiments in which OVA-specific TcR transgenic 
CD4+ and CD8+ lymphocytes were transferred into syngeneic recipients, before i.p. injection 
with ISCOMS. These studies indicated that OVA-specific CD4+ and CD8+ T cells were part 
of the lymphocyte recruitment and that these cells showed signs of activation such as an 
increase in size (data not shown). More detailed timecourse studies of the appearance and 
functions of these transgenic T cells would provide information on the relationships between 
ISCOMS induced inflammation and the priming of specific T cells.
Although ISCOMS can prime antigen-specific antibody responses [Lovgren et al., 
1988, Morein, 1991, Sjolander et al., 1996], little is known about how ISCOMS promote 
these responses. I found that ISCOMS also recruited B cells into the peritoneum, although
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whether these cells were activated or producing OVA-specific antibody was not determined. 
It would also have been interesting to examine if the recruited B cells played any part in the 
induction of primary immune responses to ISCOMS, but pMT KO mice lacking B cells were 
not available to examine this.
Oral administration of ISCOMS also induced an inflammatory infiltrate in the 
lymphoid tissues of the gut. However alterations of the cell populations in these tissues was 
less marked than in the peritoneum, perhaps indicating tighter regulation of potentially 
dangerous inflammation in this vulnerable organ, as well as the fact that the gut is not a 
closed compartment like the peritoneum. A single feed of ISCOMS did not induce the 
decrease in cell numbers in either PP or MLN that I had observed in PEC. Instead, cell 
numbers increased steadily in both tissues to peak at 48-72 hours. In addition there was no 
recruitment of neutrophils in either MLN or PP at any time after feeding ISCOMS, perhaps 
reflecting the fact that neutrophils are rare in these tissues. It may be important to control 
rigorously the recruitment of these potent inflammatory cells to such delicate tissues.
Despite the absence of neutrophilia in the gut, recruitment and activation of 
macrophages was still noted in both MLN and PP. The numbers of F4/80+ macrophages in 
MLN resembled the pattern of recruitment observed in PEC, with numbers increasing 
gradually to a peak almost 4 times that of controls at 48 hours. These cells were almost all 
activated as indicated by their co-expression of MHC class II. The profile of F4/80+ 
macrophage recruitment in PP was completely different, as it was characterised by an 
immediate increase at 7 hours and levels above background for the duration of the 
experiment. Again nearly all these macrophages expressed MHC class II. Thus neutrophils 
are not essential for the recruitment of macrophages into tissues in response to ISCOMS. 
MHC class II expressing mature dendritic cell numbers were increased in MLN, with the 
peak seeming at 48 hours after feeding ISCOMS. However, there was no increase in dendritic 
cell numbers in the PP and it would be interesting to determine whether this reflected 
emigration to the MLN by the time I examined the cells. Afferent lymph draining from the 
gut mucosa and PP contains many dendritic cells [Lui and MacPherson, 1995] which are
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known to constantly migrate to the MLN, especially after exposure to inflammatory stimuli 
[MacPherson et al., 1995]. This could have accounted for the increase in dendritic cells 
numbers I found in the MLN after feeding ISCOMS.
MLN tissue showed an almost identical pattern of T cell recruitment as that found in 
PEC. CD8+ lymphocytes increased to a peak at 48 hours and CD4+ lymphocytes also 
increased gradually until a maximum at 72 hours, and by this time 15% were CD25+. In PP 
there was no real change in CD8 numbers after feeding ISCOMS, but a small increase in 
CD4+ T cells was observed at 3.5 hours and again at 72 hours, although these cells did not 
express CD25. B cell numbers were also increased in MLN after feeding ISCOMS, peaking 
by 48 hours. This pattern although smaller was also present in PP.
Together these results suggest that there is more recruitment of cells after feeds of 
ISCOMS in the MLN and they are consistent with the idea that the increased numbers of 
dendritic cells, lymphocytes and macrophages in MLN are derived from cells emigrating 
from the PP and the intestinal mucosa. However, this needs to be confirmed in more detailed 
timecourse studies using OVA-specific TcR transgenic T cells to define where and when 
ISCOMS first initiates inflammation and then activation of specific T cells. I did undertake 
preliminary studies to investigate the localisation of orally administered ISCOMS and these 
suggested that the ISCOMS could be detected rapidly in cells both in the PP and the intestinal 
LP. This partly which confirms other studies showing localisation of ISCOMS to the PP after 
feeding [Claasen et al., 1995], but I was unable to establish the identity op the cells involved. 
It would be of interest to determine the nature of these cells and their subsequent migration 
pathways in vivo.
Together, these results show that ISCOMS recruit many components of the innate and 
adaptive immune responses. This recruitment is not restricted to the periphery and although 
cellular changes are less pronounced in the GALT, the same pattern of recruitment is present 
at least in the MLN. I then went on to examine the functional significance of this 
inflammatory infiltrate, by exploring the pattern of inflammatory mediator secretion after 
administration of ISCOMS.
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The Importance of ISCOMS Induced Inflammatory Mediator Production
The cytokines and other inflammatory mediators, produced during the early 
inflammatory response are critical for initiating and shaping the primary antigen-specific 
immune response [Fearon and Locksley, 1996b, Medzhitov and Janeway Jr, 1997a]. I 
therefore examined the pattern of inflammatory cytokine recruitment after administration of 
ISCOMS and also, how the absence of some of these affected antigen-specific and innate 
immune responses, using gene-targeted knockout mice.
Although previous studies had demonstrated that in vitro administration of ISCOMS 
induced IL-1 secretion from spleen cells [Villacres-Eriksson et a l, 1993], other reports had 
suggested that no IL-1 was detected in vivo after administration of ISCOMS [Behboudi et 
al., 1996]. PEC from control mice did not secrete IL-1 a, but 48 hours after injection of 
ISCOMS, large quantities of IL -la were present in PEC supernatants. Interestingly, the 
amount of IL-1 produced by ISCOMS induced PEC was the same irrespective whether the 
PEC were stimulated with ylFN+LPS or not, suggesting ISCOMS may have primed maximal 
amounts of IL-1 production. This IL-1 was dependent on the presence of adherent cells, 
consistent with the source being activated macrophages whose recruitment was also maximal 
at this time. I was unable to determine the role of IL-1 in ISCOMS mediated antigen-specific 
immunity, because no viable IL-1 deficient mice or depleting antibodies were available. 
However, this cytokine is an important component of the acute phase, regulating the 
recruitment and activation of a number of inflammatoiy cells, as well as increasing the 
expression of adhesion molecules on vascular endothelium and assisting in the activation of T 
cells. Thus a role for IL-1 in the induction of antigen-specific immune responses to ISCOMS 
cannot be excluded without direct investigation.
IL-6 production was also enhanced in ISCOMS stimulated PEC and again this 
correlated with maximal numbers of activated macrophages and was dependent on the 
presence of adherent cells. This observation confirms earlier findings that ISCOMS induced 
elevated serum IL-6 levels [Behboudi et a l, 1997]. IL-6 is an important mediator for effector 
immune responses, having a role in the promotion of T cell proliferation in synergy with IL-1
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[Houssiau and Van Snick, 1992] and also differentiation to Th2 CD4+ T cells [Rincon et a l,
1997], as well as promoting B cell differentiation and antibody responses [Takatsuki et al., 
1988]. Therefore I investigated the ability of ISCOMS to induce antigen-specific immune 
responses in ÎL-6KO mice. Previous studies in these mice showed them to have defective 
protective immune responses to intracellular infections such as vaccinia virus [Kopf et al., 
1994], L. major [Kopf et al., 1994] and C. albicans [Romani et ai., 1996], as well as defects 
in mucosal IgA secretion [Ramsay et al., 1994], IgG production and CTL activity [Kopf et 
al., 1994]. However, I found that IL-6KO mice developed entirely normal antigen-specific 
immune responses to parenteral immunisation with OVA ISCOMS, as detennined by DTH, 
proliferation, CTL activity, cytokine and antibody profiles. The retention of antigen-specific 
immune responses in IL-6KO mice is consistent with other studies in these animals which 
showed normal responses to CT + KLH given orally or nasally and normal IgA responses to 
an infection of Helicobacter fells [Bromander et al., 1996]. I was unable to examine the status 
of secretory immunity in IL-6KO mice immunised orally with OVA ISCOMS due to the fact 
that these mice were no longer available to me. However, I can conclude that IL-6 is not 
required for the majority of responses induced by ISCOMS.
The innate immune cascade induced by ISCOMS was also normal in IL-6KO mice as 
far as I examined. 1L-6KO mice had normal recruitment of total PEC and production of 
inflammatory mediators. However, in light of the previous reports of the defects in neutrophil 
recruitment that these mice exhibit [Kopf et al., 1994], it would have been interesting to 
undertake a phenotypic study of the PEC recruited after injection of ISCOMS, so as to clarify 
the importance of this cytokine for the recruitment and activation of individual inflammatory 
cells after injection of ISCOMS.
An i.p. injection of ISCOMS led increased production of ylEN by Con A stimulated 
PEC. This showed a biphasic pattern, with an early but transient increase first occumng at 3.5 
hours. After a subsequent fall, ylFN production rose again to levels four times greater than 
baseline by 24 hours. As ylFN activates transcription of the genes that encode the enzymes of 
the NADPH oxidase system [Cassatella et al., 1990], the early spike in ylEN production may 
have been responsible for the production of H2O2 by neutrophils recruited to the peritoneum
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after injection with ISCOMS. I did not determine the source of the ISCOMS induced ylFN at 
either timepoint. Although the production of ylFN required the presence of adherent cells, it 
is unlikely that these cells themselves are producing ylFN. CD4‘^  T cells, CD8+ T cells and 
NK cells can all produce ylFN [Heinzel et ai., 1994]. However, NK cell derived ylFN 
requires accessory cell derived cytokines such as IL-12 and TNFa [Tripp et al., 1993], which 
are both produced by among other cell types, adherent macrophages. CD4+ and CD8+ T cells 
were rare at the time of I found maximal levels of ylFN. Thus it may be that NK cells were 
involved, an idea that is consistent with evidence from other systems in which NK cells 
producing ylFN early in the immune response [Billiau, 1995]. One other possibility is the 
small subset of NK1.1+ CD4+ T cells which recognise lipid antigens derived from microbes 
in association with non-classical restriction elements such as GDI, and produce large 
amounts of IL-4 together with other cytokines such as ylFN [Vicari and Zlotnik, 1996]. GDI 
is capable of presenting non-peptidic antigens such as lipids and glycolipids [Porcelli et al.,
1998], and as ISCOMS contain many lipid elements, it is feasible that these could be capable 
of binding to GDI. It would be interesting to define the cells producing ylFN early after 
administration of ISCOMS, for example by intracellular cytokine staining.
ylFN has a number of properties which could influence immune responses and 
inflammation induced by ISCOMS, including activation of phagocytic activity and increasing 
MHC class II expression on APC, the development of Thl responses, the establishment of 
CTL activity [Roth et al., 1991] and switching to an IgG2a antibody isotype [Finkelman et 
al., 1988]. I therefore examined the requirement for ylFN in immunity to parenterally and 
orally administered ISCOMS using ylFNRKO mice. Surprisingly, I found that ylFNRKO 
mice had normal or even increased DTH responses after immunisation with OVA ISCOMS. 
This is in contrast to other observations in the laboratory which had shown that ylFNRKO 
mice had impaired responses to OVA and CFA [Mowat et al., 1999]. As I measured a 
classical DTH response which peaked at 24-48 hours after challenge, the reasons for this 
retention of DTH to OVA ISCOMS in the absence of functional gIFN are unclear. However, 
it could reflect the ability of ISCOMS or Quil A to induce mediators which may compensate 
for the usual requirement of ylFN. Thus it would be of interest to examine whether the DTH
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response in ylFNRKO mice is identical in all respects to that in normal animals and if it is 
affected by neutralisation of other cytokines. Overall, there was no evidence for a defect in 
antigen-specific immunity to OVA ISCOMS in ylFNRKO mice. Although I found a decrease 
in OVA-specific proliferative responses after oral immunisation of these mice and others 
have reported defective mucosal immune responses to orally administered CT [Kjerrulf et al., 
1997] and Salmonella in ylFNRKO mice [Hess et al., 1996], other responses to oral OVA 
ISCOMS, were normal or increased, including sIgA production. In addition, all responses to 
OVA ISCOMS were normal after parenteral immunisation. Antigen specific proliferative 
responses were actually increased after subcutaneous immunisation with OVA-ISCOMS, a 
finding that may be due to the known cytostatic properties of this cytokine [Jeong, 1995, 
Hansson et al,, 1989]. The cytokine profiles of both s.c. and orally immunised ylFNRKO 
mice showed a greatly increased level of anti gen-specific IL-5 production, consistent with the 
known ability of ylFN to suppress Th2 dependent responses [Wange et al., 1994]. Similar 
findings were seen with the IgGl and IgG2a antibody isotypes, as ylFNRKO mice had 
suppressed IgG2a and elevated IgGl antibodies. I also found that ylFNRKO mice produced 
levels of ylFN which were above that of the wild type mice, confirming earlier findings have 
been reported by others [Dalton et a l, 1993]. This indicates that the production of ylFN in 
vivo does not require ylFN signalling and suggests that ylFN may nonnaily down-regulate its 
own production. As ylFN has been identified as a potential cofactor for the generation of CD8 
restricted CTL activity [Roth et a l, 1991], it was somewhat surprising that CTL responses 
were normal in OVA ISCOMS immunised ylFNRKO mice, or even increased. These results 
indicate that other factors must be involved in the generation of OVA-specific CTL by 
immunisation with ISCOMS.
Despite the mostly normal specific responses in ylFNRKO mice, the development of a 
full innate inflammatory cascade was dependent on the presence of functional ylFN, as 
ylFNRKO mice failed to generate normal cellular recruitment after injection of ISCOMS. 
These mice showed reduced recruitment of neutrophils, lowered recruitment of B220+ 
lymphocytes and CD4+ lymphocytes and no recruitment of macrophages. However, 
relatively normal CD8 recruitment was noted and an increase in dendritic cell numbers was
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also observed. In addition to the defective inflammatory responses seen in ylFNRKO mice, 
the inflammatory cells that were recruited showed virtually no evidence of activation as 
assessed by expression of cell surface markers, or the secretion of inflammatory cytokines 
and mediators. As antigen-specific immune responses to ISCOMS were normal after both 
parenteral and oral immunisation of IFNRKO mice, the remaining innate responses in these 
animals may provide enough of an innate trigger to induce adaptive immunity. Alternatively 
other factors whose activity I did not measure in ylFNRKO mice given ISCOMS, may have 
been important, such as mast cells. It is possible that a relatively normal range of innate 
responses did occur in these mice, but that these were delayed beyond the 72 hour timecourse 
that I examined. Thus a longer time course measuring more innate factors is warranted in 
these animals to attempt to understand the dichotomy between the innate and adaptive 
responses to ISCOMS in the absence of functional ylFN.
The cytokine for which I obtained the most conclusive evidence as being involved in 
the immunogenicity of ISCOMS was IL-12. PEC from ISCOMS injected mice showed 
elevated IL-12 production at 72 hours, extending recent findings of elevated serum IL-12 
levels after injection of ISCOMS [Villacres-Eriksson et al., 1997]. The increased levels of IL- 
12 in PEC and PP coincided with the appearance of cells such as macrophages, dendritic cells 
and B cells, all of which can secrete IL-12 [Trinchieri, 1995]. The production of IL-12 in 
vitro required the presence of adherent cells and recent studies have indicated that ISCOMS 
can directly stimulate production of IL-12 mRNA from PEC adherent cells [Grdic et al., 
1999], suggesting an involvement of macrophages in this process. It would be interesting to 
determine the source of this IL-12 more directly, for example by observing coexpression of 
internal IL-12 in phenotypically labelled cells either by flow cytometry or 
immunohistochemistry in vivo [Reis e Sousa et al., 1997]. Although ISCOMS may indeed 
induce IL-12 production directly from macrophages, recent studies suggest that a substantial 
proportion of IL-12 in vivo is derived from dendritic cells, often requiring activation by 
CD40-CD40 ligand (CD40L) interactions with antigen-specific T cells [Stuber et al., 1996, 
Kennedy et al., 1996]. This could be explored by a combination of the approaches described 
above, together with the use of CD40LKO mice.
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When I examined the requirement of IL-12 in antigen-specific immune responses to 
ISCOMS, I found that IL-12KO mice had substantial defects in these responses. This defect 
was more pronounced in parenterally immunised mice, but was also present after oral 
immunisation. In contrast to the published evidence that IL-12KO mice have only selective 
defects in Thl and CDS T cell activity [Trinchieri, 1995], I found that virtually all 
immunological parameters were decreased in IL-12KO mice immunised with OVA ISCOMS. 
In addition to the expected defects in DTH, ylFN production and CTL activity, I also found 
that there was a 40% reduction in OVA-specific proliferation in IL-12KO mice. This may 
reflect the role of IL-12 in inducing the expression of the IL-2Ra and p subunits [Robertson 
et al., 1992, Nuame et al., 1992], an idea supported by the my observation that IL-12KO mice 
failed to increase expression of CD25 on peritoneal CD4+ T cells following administration of 
ISCOMS. More surprisingly, s.c. immunised ÏL-12KO mice also had defective IL-5 
production, supporting further the possibility that IL-12 plays an imporant role in the priming 
of all T cells, rather than just Thl cells. Nevertheless, it should be noted that IL-12KO mice 
had a selective defect in IgG2a responses, whereas the Th2 dependent IgGl response was 
normal or even enhanced. This supports other studies which have revealed that IL-12 
regulates the production of IgG isotypes after immunisation [McKnight et a l, 1994, German 
et al, 1995, Buchanan et a l, 1995] IL-12KO mice also had a 50% reduction in CTL activity 
compared with wild types after i.p. immunisation, extending previous studies on the role of 
IL-12 in the generation of antigen-specific CTL [Abdi and Herrmann, 1997] and the 
increased susceptibility of these animals to intracellular pathogens such as Leishmania major 
[Mattner et a l, 1996], Mycobacterium tuberculosis [Cooper et a l, 1997] and Listeria 
monocytogenes [Gateley et a l, 1998]. Thus IL-12 plays an important and wide ranging role 
in the induction of systemic immune responses by parenterally administered ISCOMS. 
However, its influence on the mucosal immune responses seemed less, with entirely normal 
secretion of intestinal IgA antibodies in IL-12KO mice. This may indicate that the GALT 
may use alternative mechanisms for generating inflammation, to compensate for the lack of 
IL-12.
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In addition to the defective antigen-specific systemic immune response to ISCOMS in 
IL-12KO mice, these animals also had a severely impaired innate response to ISCOMS, with 
low levels of recruitment of neutrophils, macrophages, CD4+ or CD8+ T cells and B cells, 
being the only changes observed. The macrophages and CD4+ T cells which were recruited 
also failed to show evidence of activation, such as production of inflammatory mediators and 
expression of MHC class II or CD25 respectively. Interestingly, the baseline numbers of 
dendritic cells were increased in these mice, although no additional recruitment of these cells 
was observed, indicating that IL-12 may in some way regulate proliferation of dendritic cells. 
The marked lack of an inflammatory cascade in IL-12KO mice could reflect an absence of 
chemotactic factors such as IL-8 whose production may be dependent on IL-12 [Nuame et al.,
1993]. The lack of MHC class II on macrophages presumably reflects the expected absence 
of ylFN, while the absence of CD25 on T cells supports the suppressed proliferative 
responses in ISCOMS immunised IL-12KO mice. Despite the severely altered innate immune 
responses to ISCOMS, it is important to note that antigen-specific responses were not 
completely lost in IL-12KO mice, indicating that there are other factors which govern the 
generation of adaptive immunity in the absence of IL-12, These may be factors which I did 
not measure, such as mast cells and other inflammatory mediators and chemokines, which 
can replace in part, the function of IL-12. One candidate for this is IL-18, which has many 
properties that are similar to IL-12, including the generation of NK activity and ylFN 
secretion [Kohno and Kurimoto, 1998], and is also secreted from activated macrophages 
[Okamura et al., 1998b].
As a suitable ELISA did not become available until the end of my project and I was 
unable to establish PCR methods for assessing IL-18 mRNA levels, I could not determine 
whether ISCOMS stimulated the production of IL-18 in vitro. However, during the course of 
my work, IL-18KO mice were developed in the department and I was able to perform a 
preliminary experiment in which specific immune responses were examined in the absence of 
IL-18. However, conflicting results were obtained. Although, homozygous IL-18“F mice had 
dramatically reduced antigen-specific DTH responses after subcutaneous immunisation and a 
partial decrease was also noted in heterozygous IL-18+^“ mice, other responses were normal.
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s.c immunised IL-18KO mice had noimal OVA-specific IL-5 and more surprisingly, normal 
ylFN responses, contrasting with earlier findings that IL-18 is closely implicated in the 
induction of ylFN production [Okamura et al., 1998a, Kohno and Kurimoto, 1998]. Similarly 
all of the IL-18KO mice also had normal IgGl and Ig02a antibody responses. When these 
mice were immunised orally, conflicting data were also obtained. In contrast to s.c. 
immunised mice, homozygous and heterozygous IL-18KO mice had normal DTH and 
antigen-specific proliferative responses, but had severely defective OVA-specific ylFN 
secretion and enhanced IL-5 production. This pattern supports the role of this cytokine in the 
establishment of Thl cell activity but contrasts with my earlier observations in s.c. 
immunised animals. Orally immunised IL-18KO mice also developed normal OVA-specific 
cytotoxicity, as well as IgGl and IgG2a antibody responses. These results need confirmation 
in a larger series of studies in IL-18KO mice.
I also undertook a preliminary experiment to explore the ISCOMS induced 
inflammatory cascade in IL-18KO animals. Although no wild type animals of the appropriate 
strain were available at the time I carried out this experiment and the results must be 
interpreted with caution, but i.p. injection of IL-I8KO mice with ISCOMS did not induce the 
usual pattern of cellular recruitment that I found in previous experiments in wild type mice. 
There was no increase in total PEC numbers and there was a failure to recruit neutrophils, 
CD4+ T cells and macrophages. There was also no evidence of increased MHC class II 
expression on macrophages, or of CD25 expression on CD4+ T cells. However there were 
elevated numbers of CD8+ T cells, B cells and mature dendritic cells. These features were 
somewhat similar to those I found in IL-12KO and ylFNRKO mice. Nevertheless, PEC from 
ISCOMS injected IL-18KO mice had some evidence of functional activity, as they produced 
increased amounts of IL-la, IL-12 and ylFN, although IL-6 did not increase above control 
levels. Again it would be important to repeat these studies using more IL-18KO and wild type 
mice in parallel. However, my preliminary results suggest that the role of IL-18 in the innate 
and adaptive responses to ISCOMS warrants further study, both by more extensive 
confirmation of my findings, as well as by determining if IL-18 is induced by ISCOMS as
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part of an early innate cascade. It would also be useful to determine if IL-12 and IL-18 play 
overlapping roles using IL-12 x IL-18 double knockout mice.
IL-4 has potent immunomodulatory properties, including the activation or inhibition 
of APC activity, as well as promoting the differentiation of Th2 cells [Noble et al., 1993, 
Nabors and Farrell, 1994]. As my results confirmed, previous work in the laboratory had 
shown that ISCOMS were capable of inducing antigen-specific Th2 responses [Maloy et al., 
1995, Maloy, 1996] and others had shown that mucosal adjuvant properties of CT were 
dependent on IL-4 [Vajdy et al., 1995]. Therefore I attempted to assess whether IL-4 was 
important for the induction of immune responses by ISCOMS, first by measuring the 
secretion of IL-4 immediately after injection of ISCOMS. However, I could not detect any 
IL-4 protein in supernatants from PEC taken from ISCOMS injected mice by ELISA. 
Therefore I rested the ability of ISCOMS to induce specific immune responses by oral and 
paienteral routes in IL-4KO mice.
IL-4KO mice immunised s.c. with OVA ISCOMS produced antigen-specific DTH 
responses above that of wild type mice, and orally immunised IL-4KO mice retained normal 
DTH responses. OVA-specific proliferation was increased both in s.c and orally immunised 
IL-4KO mice, and this normal or enhanced response may be consistent with the ability of IL- 
4 dependent Th2 cells to suppress Thl dependent immune responses normally [Maggi et al., 
1992]. As expected, both s.c and orally immunised ISCOMS immunised IL-4KO mice had 
elevated production of OVA-specific ylEN, and s.c. immunised IL-4KO mice produced 
significantly less IL-5 than wild types. Although orally immunised IL-4KO mice also 
produced low levels of IL-5, surprisingly these were higher than those in wild type animals. 
This may be consistent with early reports that IL-5 production could be partially preserved in 
IL-4KO mice [Kuhn et al., 1991, Kopf et al., 1993]. I found that antigen-specific CTL 
responses were also retained in IL-4KO mice after both oral and parenteral immunisation at 
levels similar to or greater than those in the wild type mice, despite evidence that IL-4 may be 
a growth factor for CTL in vitro [Liang et al., 1992, Horvat et al., 1991]. However, this is the 
first study to examine antigen-specific CTL induction in IL-4KO animals in vivo and the 
preserved activity may reflect the ability of other cytokines such as IL-2 [Horvat et al., 1991,
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Ley et al., 1991], ylFN [Roth et al., 1991] and IL-15 [Ye et al., 1996] to compensate as CTL 
growth factors in vivo. Th2 cells and, in particular IL-4, have also been associated with 
regulating the production of sIgA in the intestine [Murray et al., 1987, Harriman et al., 1988], 
but I found that the total si g A antibody production was actually enhanced in IL-4KO mice 
compared with controls. These results contrast with the defective IgA responses found in IL- 
4KO mice immunised orally with antigen and cholera toxin (CT) [Vajdy et al., 1995], but 
similar findings of normal mucosal responses in the absence of IL-4 have been made using 
Salmonella as a mucosal adjuvant [Okahashi et al., 1996]. The local immune response to CT 
itself is also intact in IL-4KO mice [Vajdy et al., 1995]. The innate immune responses I 
measured in ÎL-4KO mice were also normal atfer injection of ISCOMS indicating that IL-4 is 
not essential for either specific or innate immune responses induced by ISCOMS. However, 
this may be due to the activity of compensatory cytokines such as IL-6, IL-10 or TGFp 
[Okahashi et al., 1996]. As described previously, I investigated the role of IL-6 in the 
generation of antigen-specific immune responses to ISCOMS and found it not to be required. 
Therefore it would be important to establish the role of IL-10 and TGPp, in compensating for 
the absence of IL-4. IL-13 would be a further important molecule to examine shares many of 
the biological functions of IL-4 [Chomarat and Banchereau, 1998]. Its role could be 
determined using IL-4 x IL-13 double knockout mice or in IL-4RaKO mice [Mohrs et al.,
1999].
An i.p. injection of ISCOMS produced large increases in the respiratory burst, as 
measured by H2O2 and also increased NO production. The production of oxygen radicals and 
H2O2 are crucial innate mechanisms for the control of intracellular microbes [Clark, 1999] 
and are properties of activated macrophages and neutrophils. After injection of ISCOMS, the 
peak production of ROI coincided with the maximal neutrophilia and occurred at a time when 
other potential ROI producing cells were virtually absent from the PEC population. In 
parallel, there was no neutrophil recmitment or ROI production in tissues of the GALT after 
feeding ISCOMS. These results suggest that neutrophils are the source of ROI after injection 
of ISCOMS and confirm that these cells are activated.
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Although it is unlikely that these ROI could contribute to the induction of specific 
immunity to ISCOMS, nitric oxide was also increased after injection of ISCOMS. This 
corresponded with the maximum recruitment of activated macrophages and the production of 
NO was totally dependent on the presence of adherent cells, supporting other evidence that 
activated macrophagqs are the major source of iNOS derived NO [Nathan and Hibbs, 1991]. 
The peak production of NO also coincided with the maximum secretion of ylFN which is a 
known promoter of iNOS activity [Xie et al., 1992] and its rapid loss may reflect the fact that 
NO can regulate its own production [Huang et al., 1998]. There was no NO production was 
observed in the gut after feeding ISCOMS, perhaps because the repeated exposure to low 
doses of LPS, which occurs in the gut may cause a state of unresponsiveness of iNOS 
induction which has been demonstrated in macrophages pre-incubated with small 
concentrations of LPS in vitro [Severn et al., 1993]. Mice deficient in iNOS have been shown 
previously to be susceptible to a range of intracellular and extracellular infections such as L. 
major, herpes simplex virus [McClean et al., 1998], as well as having decreased susceptibility 
to endotoxic shock [Wei et al., 1995]. In addition to this critical role as a microbicidal factor, 
other reports have suggested that NO may also influence the outcome of antigen-specific 
immune responses. First, NO can decrease the expression of MHC class II [Sicher et al.,
1994] as well as the proliferation of T lymphocytes [Wei et ai., 1995]. In addition, it can 
down regulate the production of ylFN in vitro and promote a more Th2 like T cell phenotype 
[Huang et al., 1998]. Thus I attempted to examine specific immune responses to ISCOMS in 
a small cohort of iNOSKO mice that had been generated in the department. In these 
preliminary studies, OVA-specific DTH responses were normal after s.c. immunisation, as 
was antigen-specific proliferation as well as IgGl and IgG2a antibody production. However, 
iNOSKO mice had markedly reduced levels of both OVA-specific ylFN and IL-5 production. 
Thus it appeared that the loss of functional NO may have had some minor effects on the 
induction of antigen-specific immunity by ISCOMS, but no clear pattern was observed and it 
would be important to extend these studies when additional mice become available.
When I examined the inflammatory cytokine secretion in GALT after oral 
administrtion of ISCOMS a markedly different pattern was observed that compared with that
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seen in PEC cells removed after an i.p. injection of ISCOMS. I was unable to detect IL -la  
production in either MLN or PP tissues at any time, IL-6 production was reduced in MLN 
and absent in PP cells, IL-12 production was reduced in MLN after administration of oral 
ISCOMS but a small but not significant increase in IL-12 was seen in PP, ylFN production 
was also reduced in MLN and also PP. Apart from the elevated levels of IL-12 in ylFN-i-LPS 
induced PP cells, I did not observe any increase in inflammatory mediator secretion. This is 
surprising given that there are populations of activated macrophages recruited into both 
tissues after feeding ISCOMS, although at a lower level that was observed in PEC. The lack 
of cytokine production may reflect a more tightly regulated iiiflammatoiy response in the 
GALT, or that there are different populations of macrophages secreting different cytokines in 
different tissues. Therefore, it would be important to assess if feeding ISCOMS induce 
inflammatory mediator secretion from other GALT tissues such as LP or epithelium, and this 
could be performed quickly by RT-PCR.
The dichotomy between the specific and innate immune responses induced by 
ISCOMS in IL-12KO mice and ylFNRKO mice may provide some clues to how 
inflammatory mediators regulate the establishment of antigen-specific immunity. Although 
the defective antigen-specific immunity to OVA ISCOMS in IL-12KO mice was 
accompanied by a decrease in innate immunity, ylFNRKO mice had normal or even enhanced 
antigen-specific immune response to OVA ISCOMS, but almost completly absent innate 
immunity. The only difference in the innate immune responses found in the two strains was 
that ylFNRKO mice retained some recruitment of B cells and an early increase in CD llc+ 
dendritic cells, suggesting that one of these cell types could be involved in the induction of 
immunity to ISCOMS. Although both can produce IL-12, this appears to be a function mostly 
of dendritic cells in vivo [Trinchieri, 1995]. In addition, dendritic cells are generally 
considered to be the predominant APC able to prime T cells [Gallucci et al., 1999]. 
Nevertheless, B cells are also capable of acting as APC, under some conditions [Yang and 
Brunham, 1998, Evans et al,, 2000] and it has been shown previously that splenic B cells can 
present ISCOMS associated antigen to T cells in vitro, almost to the same extent as dendritic
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cells [Villacres-Eriksson, 1995], As noted earlier, the adjuvant effects of another mucosal 
adjuvant, CT and its derivatives, appear to be dependent on B cells [Vajdy et al., 1995]. In 
most cases, no role for B cells in priming T cells has been identified but this needs to be 
tested directly in the case of ISCOMS associated antigen using B cell KO mice. There are no 
specific models of dendritic cell deficiency in vivo available, but an alternative approach is to 
expand the dendritic cell numbers using the selective growth factor Flt3L. Preliminary 
experiments suggest that Ht3L does enhance immune responses and the activation of antigen- 
specific T cells after immunisation with ISCOMS (Allan Mowat personal communication). 
Therefore dendritic cells may be important in the establishment of ISCOMS immunity.
One cell that my studies seems to exclude in being central to the induction of immune 
responses to ISCOMS is the macrophage, as both IL-12KO and ylFNRKO mice had equally 
deficient activated macrophages in PEC after injection of ISCOMS, although ylFNRKO mice 
had nonnal antigen-specific immunity despite this. In other studies, ISCOMS have been seen 
to accumulate within marginal metalophillic macrophages (MMM) in the spleen after i.v. 
injection [Claassen et al., 1995]. Depletion of these macrophages in vivo ablated T cell 
proliferative responses in the spleen, but did not significantly alter humoral immunity to 
ISCOMS [Claassen et al., 1995]. Macrophages are known to preferentially take up particulate 
antigens and have exeellent antigen-presenting properties. Therefore the particulate nature of 
ISCOMS may target them to macrophages and also in the process of phagocytosis, activate 
them. In the presence of ISCOMS, macrophages have been shown to increase expression of 
MHC class II in vitro [Watson et al., 1992, Bergstrom et al., 1990], and I observed this 
phenomenon in vivo. However, in this laboratory, ablation of macrophages either by silica or 
toxin loaded liposomes did not significantly alter the generation of cell mediated responses 
[Maloy, 1996] which parallels my findings in the ylFNRKO mice.
In order to address the mechanism by which ISCOMS exert their adjuvant effect 
several questions need to be addressed. Firstly, how do ISCOMS gain access to APC? One 
possibility is that ISCOMS directly associate with APC by binding to and stimulating 
receptors on the cell surface. As ISCOMS are very rich in carbohydrates because of the fact
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that Quil A contains a mixture of triterpenoids [Higuchi et al., 1988], it is feasible that these 
may bind to receptors such as the mannose receptor found on macrophages and dendritic cells 
and thus be internalised [Aderem and Underhill, 1999]. Alternatively, because of their 
lipophilic nature, it is also possible that ISCOMS may simply diffuse through the plasma
membrane and into cells.
The second important question is how do ISCOMS establish the early inflammatory
response? Although, at the times I examined PEC histologically, there was no evidence of 
cell debris or dead cells, it is possible that the haemolytic nature of ISCOMS causes cell lysis, 
with release of inflammatory cytoplasmic contents into the local micro-environment, as well 
as ISCOMS particles themselves. This could recruit inflammatory cells, as well as dendritic 
cells, which have been shown recently to be able to phagocytose necrotic cells including 
macrophages followed by the priming of specific immune responses [Gallucci et al., 1999], 
may then be attracted to this site and phagocytose cell debris and ISCOMS. This possibility 
has recently been emphasised by observations of increased numbers of dendritic cells within 
1 hour of administration of ISCOMS (Allan Mowat personal communication), which may 
reflect the recruitment of these cells very early to clear cell debris.
Thus I propose that ISCOMS are internalised by macrophages in vivo and that these 
cells are lysed due to the haemolytic nature of Quil A. The subsequent release of 
inflammatory cytoplasmic material, together with intact ISCOMS induces the release of 
chemoattractants and chemokines, and consequently the recruitment and de granulation of 
local mast cells followed by the release of other inflammatory molecules such as histamine. 
This process recruits further inflammatory cells which include dendritic cells and 
macrophages, which process nd present the ISCOMS associated antigen and are induced to 
secrete large quantities of IL-12. The resulting release of ylFN then positively feeds back to 
increase the activation of macrophages and elevate still further the expression of surface 
MHC class II. IL-12 is also a direct stimulus to T cells and can induce the activity of CD8+ T 
cells. As a result, I predict that IL-12 derived possibly from dendritic cells may be the central 
factor in the ability of ISCOMS to prime such a wide mge of specific immune responses in 
mice.
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In conclusion, my results confirm and extend previous reports that ISCOMS generate 
wide ranging inflammatory cascade^ comprising recruitment of cells and release of 
inflammatory mediators. In addition, the mucosal and systemic immunogenicity of ISCOMS 
encompasses a wide range of immune effector responses, including both Thl and Th2 
dependent responses. However, the antigen-specific responses to ISCOMS are not limited by 
the absence of the majority of thes innate factors thought to be critical for initiating these 
responses, ylHN, IL-4, IL-6 and iNOS respectively, but these results do indicate that there is a 
role for ISCOMS induced IL-12 and to a lesser extent IL-18 in the development of antigen- 
specific immune responses following ISCOMS immunisation. These findings distinguish 
ISCOMS from other mucosal adjuvant vectors such as Salmonella or CT and underline the 
complexity of the factors which may determine the induction of immune responses via 
mucosal surfaces. My results have identified key components of the innate immune response, 
namely IL-12, whose presence may crucial for the establishment of protective immunity by 
ISCOMS. The identification of such components has led to a better understanding of the 
mechanism by which ISCOMS exert their adjuvanticity, and hopefully may allow for their 
better exploitation in practical vaccine studies in the future.
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